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Abstract
Multiple myeloma (MM) is an incurable neoplastic plasma cell (PC) disorder characterized by
proliferation of clonal/aberrant PCs in bone marrow, usually preceded by a premalignant stage
known as monoclonal gammopathy of undetermined significance (MGUS). Diagnosis of MGUS
and MM, and minimal residual disease assessment rely on multiparameter flow cytometry (MFC),
which allows immunophenotypic characterization of clonal vs normal/reactive PCs, elaboration of
prognostic considerations and study of the other cellular populations of the sample. Some critical
points remain to be solved: i) exact definition of normal PC immunophenotype; ii) evaluation of
relationship between depth of response/presence of relapsing disease and both clonal and normal
PC immunophenotype; iii) introduction of new PC detection markers; iv) wider understanding of
connection among relapse/response-PC immunophenotype-alterations in bone marrow
microenvironment. In my PhD research I provided some new insights in these directions. My
original contribution to knowledge is the dissection of the relation existing between the influence
that malignancy exerts on other cells, including normal PCs, and the characteristics of the disease,
in terms of clonal PC immunophenotype and achieved response. I demonstrated that normal and
clonal PCs are not equal among different categories of patients, so I proposed the adoption of
response/relapse related MFC panels and the introduction of normal PC analysis to follow the
various phases of disease. I recognized CD229 as a new identification marker suitable for test in
clinical routine, especially in patients undergoing to therapies which may compromise efficient PC
staining using classical CD38 and CD138 markers. Studying distribution of bone marrow
naïve/transitional and memory B cells, I detected significant differences among stringent complete
responders and other treated patients. Thus, I suggested a possible role of naïve/transitional and
double negative B cells in prediction of depth of response. I explored the influence of CD117
clonal PC positivity on CD34+ hematopoietic progenitor cell (HPC) distribution, and I
demonstrated that response to treatment takes place through different forms in CD117- and
CD117+ subjects, involving a diverse partition of CD34+ HPCs into CD34+CD19- and
CD34+CD19+ subsets, which becomes evident comparing untreated and treated CD117- patients,
but is impossible to detect in CD117+ cases.
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21. Introduction
3Multiple myeloma is an incurable neoplastic plasma cell disorder characterized by proliferation of
clonal malignant plasma cells in bone marrow, and presence of monoclonal immunoglobulin (M-
protein) in blood and/or urine, associated with immunodeficiency and related organ or tissue
impairment (end-organ damage) usually manifested through CRAB signs (hypercalcemia,
osteolytic bone lesions, renal insufficiency, anemia) [1-4]. Median age at diagnosis is between 65
and 70 years [4]. As indicated by Moreau et al. [4] the disease represents 1% of all cancers and
~10% of all haematological malignancies. The incidence in Europe is 4.5–6.0/100,000/year, with a
mortality of 4.1/100,000/year [4]. Multiple myeloma is usually preceded by a premalignant plasma
cell proliferative stage characterized by asymptomatic M-protein production known as monoclonal
gammopathy of undetermined significance (MGUS) [3, 5]. MGUS has a prevalence of 3.2% in the
white general population ≥50 years of age [5]; in some of these patients, MGUS progresses to 
smoldering (asymptomatic) multiple myeloma (SMM) and to multiple myeloma, with a risk of
around 1% per year for patients with MGUS [2-3, 6].
Progression from MGUS to multiple myeloma is associated with a variety of genetic alterations
and changes in the bone marrow microenvironment involving cytokines and growth factors as
mediators, but also direct cellular interaction, influencing clonal plasma cell expansion, immune
suppression, and augmented angiogenesis and bone resorption [2-3].
In the last years, the introduction of novel antimyeloma agents bortezomib (proteasome inhibitor),
and thalidomide and lenalidomde (immunomodulatory drugs), flanking autologous stem cell
transplantation (ASCT), has improved survival significantly [3, 7], both in post-ASCT relapse and
in new diagnosis scenarios [8]. The adoption of these new approaches has produced a 50%
improvement in median survival [8-9]. As revealed in a study by Brenner et al. [10] related to
2002-2004 period, the most prominent progresses were observed in younger patients (<50 years),
leading to 5- and 10-year relative survival of 56.7% and 41.3%, and in subjects whose age is
comprised between 50 and 59 years, with a 5- and 10-year relative survival of 48.2% and 28.6%. In
turn, only modest improvement was achieved in patients with 60–69 years of age, and no
significant amelioration was reached in older patients [10]. Despite these improvements in
survival, the course of multiple myeloma is still characterized by a pattern of remission and relapse,
with decrease in durability of response and increase in frequency of salvage therapies, and the final
developing of a refractory stage. This pattern reflects the persistance of residual tumour cells even
after ASCT or the reaching of a complete response to treatment [3, 11-13].
In multiple myeloma diagnosis, monitoring, transplant settling and elaboration of prognosis,
clinicians may take advantage from many technical interventions, like protein and imaging studies,
bone marrow morphologic evaluation, allele-specific oligonucleotide polymerase chain reaction
(ASO-PCR), deep-sequencing and multiparameter flow cytometry (MFC) [2, 14-15]. Every cited
approach clearly offers a panel of advantages, but only MFC allows a rapid enumeration and
characterization of clonal plasma cells, providing immunophenotypic data which may be used for
4minimal residual disease (MRD) assessment and prognostic purposes. Moreover, while molecular
approaches may be centered on the detection of specific genetic markers in whole marrow
populations, or associated with high technical complexity, and are time consuming and relatively
expensive (and therefore less applicable in routine clinical practice), MFC permits to perform
single cell focused studies, demonstrates a large applicability, requires shorter time to
prepare/analyze the sample, is associated with good levels of sensitivity (higher than 10-4-10-5 with
new instruments and analysis of up to 2x106 cells) and offers a high level of concordance in MRD
detection with deep sequencing [14-15]. In addition, MFC renders possible simultaneous
exploration of immunophenotype and characterization of other cellular populations present in the
same sample. Nowadays, from a practical point of view, some aspects of myeloma management
relies only on MFC in clinical routine, like for example assessment of immunophenotypic complete
response in treated patients (as I discuss in the following paragraph). MFC was regarded as highly
dependent on expertise and poorly reproducible in multicenter studies, mostly because of the lack
of standardization in data analysis, interpretation, and presentation, and limited evaluation of “new”
vs “classical” markers [16]. However many efforts have been made in order to ensure
standardization of procedures and instrument settings [15, 17-18], and MFC has been proved to be
considerably useful in diagnosis and prognostic stratification of multiple myeloma, as well as other
hematological malignancies [15, 18]. In the following sections, I briefly discuss the state of art for
multiple myeloma and related condition MGUS as regards diagnosis, definition of prognosis and
monitoring, in order to provide the conceptual basis to critical interpret and to understand the
research lines deepened in this thesis. For each aspect, I focus on the role of MFC and the most
critical unsolved questions.
51.1 Defining the variants.
As indicated in WHO classification [2], ~97% of patients with multiple myeloma present an M-
protein in the serum or urine (lgG 50%; IgA 20%; light chain 20%; IgD, IgE, IgM and biclonal <
10%). The remaining ~3% of cases are non-secretory subjects. In this last category, 85% of patients
shows defects in immunoglobulin secretion, since cytoplasmic M-protein may be detected. In turn,
15% of patients are true non-producer myeloma cases. In up to two-thirds of non-secretory
myeloma cases, increased serum free light chains and/or an abnormal free light chain (FLC) ratio
may be detected [2]. As regards MGUS, 3 distinct clinical subtypes (non-IgM MGUS, IgM MGUS,
and light-chain MGUS) have been distinguished [2, 19-20]. IgM MGUS tends to progress to other
disease entities (such as Waldenström macroglobulinemia) and only sporadically to the extremely
rare entity IgM multiple myeloma. Instead non-IgM MGUS and light chain MGUS are
premalignant condition of non-IgM multiple myeloma and light chain multiple myeloma,
respectively [2, 19-20]. In the following chapters, “multiple myeloma”, “MGUS” and “SMM” are
used to indicate all the variants of the respective category without distinctions, unless otherwise
specified.
61.2 Diagnosis, definition of prognosis and monitoring: still looking for the light.
Each aspect of diagnosis and management of MGUS and multiple myeloma are described
synthetically in specific paragraphs. A more profound dissertation about these topics may be found
in bibliographical references reported in the paragraphs.
1.2.1 Diagnosis.
Diagnosis of MGUS and multiple myeloma is a multistep process resorting to clinical chemical,
serological and immunological laboratory analysis, morphological evaluation, imaging, cytogenetic
and MFC investigation. As MGUS is an asymptomatic condition, a crucial parameter for a
differential diagnosis vs multiple myeloma is the absence of end organ damage, mostly defined as
CRAB signs [19-23].
CRAB stands for hypercalcemia (serum calcium ≥11.5 mg/dL), renal insufficiency (serum
creatinine >2 mg/dL), anemia (normochromic, normocytic with a hemoglobin >2 g/dL below the
lower limit or hemoglobin <10 g/dL) and bone lesions (lytic lesions or osteoporosis with
pathologic fractures) [2, 20, 22-25]. Other recognized signs of organ or tissue impairment are
symptomatic hyperviscosity, amyloidosis, recurrent bacterial infections (>2 episodes in 12 months)
[20, 24-25]. Specifically in case of IgM MGUS, criteria are slightly different, and include no
evidence of anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or
hepatosplenomegaly that can be attributed to the underlying disorder [19, 21-22]. To complete a
diagnosis of MGUS, serum M-protein must be <3 g/dL, and clonal bone marrow plasma cells (or
lymphoplasmacytic cells in case of IgM MGUS) must be <10%. In case of light chain MGUS,
criteria for percentage of bone marrow plasma cells and absence of end organ damage do not
change. However, some additional requirements are necessary: abnormal FLC ratio (<0.26 or
>1.65), increased level of the appropriate involved light chain (increased kappa FLC -in subjects
with ratio >1.65- and increased lambda FLC -in patients with ratio<0.26-), and no immunoglobulin
heavy chain detection on immunofixation [19-22]. As reported by Engelhardt et al. [26], MGUS
with renal impairment (RI) has been recognized as an independent entity and thus called
‘monoclonal gammopathy of renal significance’ (MGRS) [26]. SMM is also an asymptomatic
condition. It may be distinguished from MGUS because it requires serum M-protein ≥3 g/dL and/or 
clonal bone marrow plasma cells ≥10%. Presence of end organ damage, with clonal bone marrow 
plasma cells ≥10% or biopsy proven plasmacytoma (i.e. masses of monoclonal plasma cells), and 
presence of serum and/or urinary M-protein (except in patients with true nonsecretory disease) are
criteria to set a diagnosis of multiple myeloma [2, 19-20, 22-25]. Even in absence of end organ
damage, presence of 60% of clonal plasma cells is a valid requisite to establish a diagnosis of
multiple myeloma [21]. In IgM multiple myeloma, diagnostic criteria include clonal bone marrow
plasma cells  ≥10%, detection of serum IgM monoclonal protein, and presence of lytic bone lesions 
and/or translocation t(11;14) detected on fluorescence in situ hybridization [19-20].
7Other clinical manifestations of multiple myeloma include appearance of focal tumoural masses of
plasma cells. Extramedullary manifestations generally develop in advanced phases of the disease.
In turn, plasma cell leukemia (in which the number of clonal plasma cells in peripheral blood is >
2x109/L or is 20% of the leukocyte differential count) may be present at the time of diagnosis
(primary) or appear lately (secondary) [2].
1.2.2 Definition of prognosis and its influence on the choice of therapy.
MGUS patients are generally not treated, but only monitored in order to detect progression of
disease [26]. The risk of progression is estimated on the basis of two models as indicated in Korde
et al. [20]. The Mayo Clinic risk stratification model recognizes as risk factors non-IgG isotype,
serum M-protein levels >1.5 g/dL and abnormal FLC ratio (<0.26 or >1.65) [20]. Instead the so
called Spanish study group has specified as risk factors MFC aberrant plasma cell/total bone
marrow plasma cell ratio (aberrant plasma cells within the bone marrow plasmacellular
compartment) ≥95% and DNA aneuploidy (further data are provided in the following paragraphs) 
[20]. Also for SMM patients risk progression factors were determined. The Mayo Clinic risk
stratification scheme uses bone marrow plasma cells ≥10%, serum M-protein levels ≥3 g/dL and 
abnormal FLC (<0.125 or >8) to evaluate the risk of progression [20]. In turn, the Spanish study
group reported aberrant plasma cell/total bone marrow plasma cell ratio ≥95% and immunoparesis 
as risk factors for progression [20]. As regards treatment of SMM cases, conflicting reports has not
brought to a final agreement; following the Mayo Clinic updates included in the Mayo
Stratification for Myeloma and Risk-adapted Therapy (mSMART) reports [21,27], treatment may
be indicated exclusively in a small subset of subjects considered at risk of imminent progression
(including patients with serum FLC ratio ≥100), although the ESMO (European Society for 
Medical Oncology) Clinical Practice Guidelines and the European Myeloma Network
recommendations do not adopt automatically these criteria [4, 21, 26-27]. Symptomatic myeloma
patients are always treated, though the type of treatment depends on a series of factors. There is an
unsolved “cure versus control” debate about whether myeloma should be treated with an aggressive
multi-drug strategy with the objective of achieving complete response, or through a sequential
disease control approach that puts the accent on quality of life, including toxicity avoidance, and
overall survival [21, 26]. This debate makes multiple myeloma a “multiple approach” disease, as
expresses itself through multiple possible treatment related guidelines. Briefly, the following
classes of agents are available: novel agents, i.e. immunomodulatory drugs thalidomide,
lenalidomide and pomalidomide and proteasome inhibitors bortezomib and -recently- carfilzomib,
alkylating agents melphalan and cyclophosphamide, anthracyclines adriamycin and liposomal
doxorubicin, and corticosteroids dexamethasone and prednisone. Other agents include platinum,
vincristine, and etoposide, employed in aggressive combinations [4, 21, 27-28]. More molecules
are expected to be introduced in treatment protocols, for example antibodies (anti-CD38
8daratumumab and SAR650984, anti-CD319 elotuzumab, anti-IL6 siltuximab, anti-BAFF
tabalumab, anti-RANKL denosumab, anti-sclerostin romosozumab) and heat shock protein
inhibitors [26]. The most immediate classification of myeloma subjects is based on age and clinical
conditions. Multiple myeloma cases are usually divided into two big classes: transplant eligible
(<65 years or fit patients in good clinical condition) and transplant ineligible patients [4, 21, 26]. In
the ESMO clinical practice guidelines [4], this distribution of myeloma patients is sufficient to
elaborate a therapeutic strategy: in transplant ineligible patients oral combinations of melphalan
and prednisone plus novel agents, in transplant eligible patients induction (3 drugs regimens based
on bortezomib in combination or not with lenalidomide and thalidomide) followed by high-dose
therapy (melphalan) before ASCT [4, 29]. In both types of approach, consolidation and
maintenance therapy after induction or ASCT are not systematically indicated [4]. In addition to
simple distinction of transplant eligible and ineligible patients, more sophisticated risk stratification
systems based on host, tumor burden and tumor biology related factors have been elaborated.
Patients with active disease may be categorized through the use of Durie-Salmon [30] and ISS [31]
staging systems.
Table1 . ISS staging system from Greipp PR et al.
International staging system for multiple myeloma. J Clin
Oncol 23(15), 2005:3412-20. Erratum in: J Clin Oncol
23(25) 2005:6281. Harousseau, Jean-Luc [corrected to
Avet-Loiseau, Herve]. [31]
Reprinted with permission.© 2005 American Society of
Clinical Oncology. All rights reserved.
Stage Criteria
Median
Survival
(months)
I Serum β2-microglobulin <3.5 mg/L
Serum albumin  ≥3.5 g/dL 
62
II Neither stage l nor stage lll* 44
III Serum β2-microglobulin ≥5.5 mg/L 29
* There are two categories for stage II: serum β2-microglobulin < 3.5
mg/L but serum albumin < 3.5 g/dL; or serum β2-microglobulin 3.5 to
< 5.5 mg/L irrespective of the serum albumin level.
As indicated in Durie and Salmon [30], classification of myeloma cases at diagnosis may be
performed analyzing hemoglobin, calcium and M-protein levels. In Durie-Salmon staging system
three stages are distinguished: I, characterized by hemoglobin >10 g/dL, serum calcium normal
(≤12 mg/dL), normal bone structure or solitary bone plasmacytoma only, and low M-component 
production rate (IgG <5 g/dL, IgA <3 g/dL, urine light chain M-component on electrophoresis <4
g/24 h); III, associated with one or more parameters among hemoglobin <8.5 g/dL, serum calcium
>12 mg/dL, advanced lytic bone lesions, and high M-component production rate (IgG >7 g/dL, IgA
>5 g/dL, , urine light chain M-component on electrophoresis >12 g/24 h); II, fitting neither stage I
nor stage III [30]. A subclassification was defined depending on renal function: A, normal renal
9function (serum creatinine <2.0 mg/dL); B, abnormal renal function (serum creatinine level ≥2.0 
mg/dL) [30]. In a subsequent study by Greipp et al. [31], median survival according to Durie-
Salmon staging system was: 62 months for IA, 22 months for IB, 58 months for II A, 34 months
for IIB, 45 months for IIIA and 24 months for III B [31]. ISS staging system and median survivals
are reproduced in Table 1 [31]. In a further investigation, none of the two systems was recognized
as strongly predictive of outcomes [32]. A complementary approach consist in the evaluation of
cytogenetic, karyotypic and molecular abnormalities. Nearly half of MGUS and myeloma cases are
hyperdiploid (HRD), characterized by 48–75 (mostly 49–56) chromosomes, usually with extra
copies of three or more specific chromosomes (trisomies of 3, 5, 7, 9, 11, 15, 19 and 21
chromosomes). In turn, non-hyperdiploid (NHRD) tumors have <48 and/or >75 chromosomes.
HRD tumours rarely (~10%) have a primary immunoglobulin heavy-chain (IgH) translocation;
NHRD tumours usually (~70%) have an IgH translocation. HRD patients have a better prognosis
than NHRD patients [33-35]. A total of 7 recurrent chromosomal partners and oncogenes involved
in primary IgH translocations in MGUS and myeloma cases has been described. These alterations
are divided into 3 translocation groups -chromosomal site, involved oncogenes, and prevalence in
multiple myeloma are reported as described by Chesi and Bergsagel [33] and subsequent records
[34-35]-: (1) CYCLIN Ds: 11q13 (CCND1) 15%; 12p13 (CCND2) < 1%; 6p21 (CCND3) 2%; (2)
MAFs: 16q23 (MAF) 5%; 20q12 (MAFB) 2%; 8q24.3 (MAFA) < 1%; and (3) MMSET/FGFR3
4p16 (WHSC1/MMSET, and in 80% of cases also FGFR3) 15%. Secondary oncogenic events
driving MGUS and multiple myeloma progression include: MYC dysregulation; chromosome 13
deletion; activating mutations of RAS, BRAF and NF-κB pathway; chromosome 17p loss and
abnormalities of TP53; secondary Ig translocations; gain of chromosome 1q and loss of
chromosome 1p [33-35]. The interest in patterns of expression of deregulated genes has led to
analysis of gene-expression profiling (GEP) by different research groups. This was put into practice
through the elaboration of various GEP models [36], the most known being GEP70 (developed by
researchers at University of Arkansas)[37] and GEP15 (proposed by the Intergroupe Francophone
du Myélome) [38], and GEP-based risk stratification systems [36-39]. Although GEP analysis is
included in the algorithms for prognostic factors and risk stratification, the consensus guidelines do
not openly recommend performing GEP analysis in a non-research or routine setting [27]. On these
basis, the European Myeloma Network [26] presented a risk stratification system based on two
categories, standard-risk and high-risk, and three types of determinants: host factors, tumor burden
and tumor biology [26]. As reported by Engelhardt et al. [26], standard risk patients are
characterized by Karnofsky Performance Status [40] (KPS) >70%, normal renal and organ
function, no impairment in Geriatric Assessment (GA) [41], Freiburg Comorbidity Index (FCI)
[42] and Charlson Comorbidity Index (CCI) [43] equal to 0 (all defined host factors), Durie-
Salmon stages I and II (tumor burden), ISS stages I and II, hiperdiploidy, t(11;14), and t(6;14) (all
tumor biology). In turn, high-risk patients present KPS <70%, estimated glomerular filtration rate
10
<30, organ impairment, reduced GA, advanced age (all host factors), Durie-Salmon stage III
(tumor burden), ISS stage III, t(4;14), t(14;16), t(14;20), 17p-, 1q/del1p, GEP high-risk signature,
high lactate dehydrogenase levels, and other aggressiveness determinants (presentation as plasma
cell leukemia, high proliferation rates, presence of extramedullary disease) (all tumor biology).
[26]. Of note, no specific association with eligible therapies was reported, but only indications
about intensity of treatment and preferential use of bortezomib for patients with some tumor
biology high-risk features, such as t(4;14) or del17p, were pinpointed [26]. Despite treatment
suggestions provided with the scheme, therapeutic approaches remain based on the initial
distinction of transplant ineligible and eligible patients: in transplant eligible, the strategy consists
of induction with 3 drug regimen (including at least one among bortezomib, lenalidomide and
thalidomide), followed by consolidation (considering second transplant in patients who did not
reach at least very good partial response) with suggested maintenance therapy, especially
bortezomib based therapy, in patients who failed to reach complete response or very good partial
response after ASCT; in transplant ineligible patients, addition of a new drug to melphalan and
prednisone containing regimens, with following maintenance therapy is recommended [26]. The
IMWG combined ISS-genetic prognostic system proposed as a standard for risk stratification of
myeloma patients recognizes 3 categories [28]. High-risk patients present ISS stages II/III, and
t(4;14) or 17p13 deletion; low-risk patients are characterized by ISS stages I/II and absence of
t(4;14), 17p13 deletion and gain of 1q21, and age <55 years; all other subjects are categorized as
standard-risk [28]. No specific therapy is suggested by Chng et al. [28], with the exception of
bortezomib based treatment for patients with t(4;14); the choice of therapeutic approach is left to
physicians, taking into account the cited cure vs control debate [28]. A risk adapted therapeutic
strategy was elaborated at the Mayo Clinic [21, 27, 44]. The update to risk stratification using
mSMART classification (as indicated in Vincent Rajkumar 2014) is depicted in Table 2 [21]. Also
high levels of lactate dehydrogenase and evidence of plasma cell leukemia on peripheral blood
smear analysis are associated with high-risk disease [21]. The risk adapted therapeutic approaches
are reported in Figure 1 [21, 44]. Patients with standard-risk disease exhibit a median survival of 6
to 7 years, whereas patients with high-risk and intermediate-risk disease show a median survival of
2 to 3 years and 4 to 5 years respectively [21, 27]. Another possible approach is allogenic stem cell
transplantation, which is investigational and currently pursued in clinical trials [21, 26]. This
paragraph has not the presumption to clarify all possible experts’ positions about influence of
prognostic factors in therapy choice. A detailed description of results inherent to ongoing clinical
trials about molecular subgroup adapted therapeutic protocols were not included since no clear
recommendation may be given [21, 26]. Moreover, such a type of in-depth report is not in line with
the topic of this thesis. The objective of this brief dissertation is emphasizing the absence of a
global consensus as regards the estimation of the impact of clinical and molecular data on
definition of prognosis and administered drug protocols.
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Table 2. Risk-stratification of myeloma as defined in mSMART classification
Standard-risk
Trisomies (hyperdiploidy)
t (11;14)
t (6;14)
Intermediate-risk
t (4;14)
High-riska
17p deletion
t (14;16)
t (14;20)
High risk gene expression profiling signature
aIn the presence of concurrent trisomies, patients with high risk cytogenetics should be considered
standard-risk.
Reproduced with permission from Vincent Rajkumar S. Multiple myeloma: 2014 Update on
diagnosis, risk-stratification, and management. Am J Hematol. 2014 Oct;89(10):999-1009. doi:
10.1002/ajh.23810. Review. http://onlinelibrary.wiley.com/doi/10.1002/ajh.23810/abstract
© 2014 Wiley Periodicals, Inc. [21].
Figure 1. Risk adapted treatment of newly diagnosed myeloma in patients eligible for transplantation (A)
and not eligible for transplantation (B). Rd, lenalidomide plus low-dose dexamethasone; Dex,
dexamethasone; CR, complete response; VGPR, very good partial response; VCD, bortezomib,
cyclophosphamide, dexamethasone; VRD, bortezomib, lenalidomide, dexamethasone; ASCT, autologous
stem cell transplantation.
Reprinted with permission from Vincent Rajkumar S. Multiple myeloma: 2014 Update on diagnosis, risk-
stratification, and management. Am J Hematol. 2014 Oct;89(10):999-1009. doi: 10.1002/ajh.23810. Review.
http://onlinelibrary.wiley.com/doi/10.1002/ajh.23810/abstract © 2014 Wiley Periodicals, Inc. [21] Adapted
with permission from Rajkumar SV, Nat Rev Clin Oncol, 2011, 8, 479-491, Copyright Nature Publishing
Group [44].
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1.2.3 Monitoring of response and impact on prognosis.
To assess response to therapy and disease progression, historically many categories has been
proposed; nowadays, usually (but not universally) the used criteria are those elaborated by the
International Myeloma Workshop Consesus Panel 1 [45], that adopted the International Myeloma
Working Group (IMWG) uniform response criteria [46-47] adding clarifications, with some
parameters inherited from the European Group for Blood and Marrow Transplantation (EMBT)
[48]. These criteria were summarized by Bird et al. [25]. Complete response (CR) requires negative
immunofixation of serum and urine, disapparence of any soft tissue plasmocytoma and <5% of
plasma cells in bone marrow. When the only measurable disease is by serum FLC levels, a normal
FLC ratio must be reported in addition to negative immunofixation [25, 45, 47]. The International
Myeloma Workshop Consesus Panel 1 [45] introduced the definition of molecular CR is indicated
as CR plus negative ASO-PCR (sensitivity 10-5) [45]. Stringent complete response (sCR) was
updated by the International Myeloma Workshop Consesus Panel 1 [45] as CR plus normal serum
FLC ratio, and absence of clonal plasma cells by immunohistochemistry or MFC (originally
immunohistochemistry or immunofluorescence) [25, 45-47]. Immunophenotypic CR, as approved
by International Myeloma Workshop Consesus Panel 1 [45], requires criteria of sCR plus absence
of clonal plasma cells in bone marrow with a minimum of 1 million total bone marrow cells
analyzed by MFC (with ≥4 colors) [45].Very good partial response (VGPR) implies that serum M-
component is detectable only by immunofixation (not on electrophoresis), or ≥90% reduction in 
serum M-protein with reduction in 24-h urinary M-protein to <100 mg/24 h. When SFLC assay is
used to monitor disease response, VGPR is defined by >90% decrease in the difference between
the involved and uninvolved FLC concentration [25, 45, 47]. Partial response (PR) includes ≥50% 
reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to <200 
mg/24 hours; if the serum and urine M-protein levels are not measurable, a decrease ≥50% in the 
difference between involved and uninvolved FLC levels is necessary. If FLC levels are
unmeasurable too, ≥50% reduction in bone marrow plasma cells is required (provided baseline 
percentage was ≥30%). In addition, if present at baseline,  ≥50% reduction in the size of soft tissue 
plasmacytomas is also indispensable to confirm a PR [25, 45-47]. Stable disease (SD) is
characterized by absence of meeting criteria for CR, VGPR, PR or progression of disease [25, 45-
46]. Progressive disease (PD) is the most articulated category. It requires any of the following:
≥25% increase in serum M-protein (absolute increase ≥5 g/l); ≥25% increase in urine M-protein 
(absolute increase must be ≥200 mg/24 h); ≥25% increase in the difference between involved and 
uninvolved FLC levels (only in patients without measurable serum and urine M-protein levels;
absolute increase >100 mg/l); ≥25% increase in bone marrow plasma cell percentage (only in 
patients without measurable serum and urine M-protein levels and without measurable disease by
FLC levels; absolute percentage of bone marrow plasma cells ≥10%); development of new bone 
lesions or soft tissue plasmacytomas or increase in the size of existing bone lesions or soft tissue
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plasmacytomas; development of hypercalcemia [25, 45]. In turn, minimal response (MR) (for
patients with relapsed and/or refractory myeloma) consists of ≥25% but ≤49% reduction of serum 
M protein and reduction in 24-hour urine M-protein by 50%-89%, 25%-49% reduction in the size
of soft tissue plasmacytomas if present at baseline, and no increase in size or number of lytic bone
lesions, as re-elaborated recently [45, 48].
On these basis, the International Myeloma Workshop Consesus Panel 1 [45] described relapsed and
refractory myeloma (nonresponsive while on salvage therapy, or progresses within 60 days of last
therapy in patients who have achieved MR or better before progressing), primary refractory
myeloma (nonresponsive in patients who have never achieved a minimal response or better with
any therapy) and relapsed myeloma (previously treated myeloma that progresses and requires the
initiation of salvage therapy without meeting criteria for “primary refractory myeloma” or
“relapsed-and-refractory myeloma”) [45].
An increasing number of studies have been performed in both transplant and non-transplant
settings to detect the prognostic role of the depth of response on prognosis. Resuming all these data
and organizing them in a comprehensive form in this thesis would be misleading, and would open a
complex debate on inter-study difference in significant results. A panel of factors may compromise
efficient comparisons of the studies: different definition of CR, dishomogeneity of evaluated
treatments, analysis of small subsets of patients, type of comparison – in some studies patients with
CR or CR plus VGPR are compared with partial remission patients, in others they are compared
with more heterogeneous groups of subjects, including patients with SD or PD [49]. Leaving
behind all possible reasons which make the comparisons of existing results difficult, a critical
review of literature permits to conclude that improvements in the quality of response (as depth and
durability) are generally associated with longer survival [28, 49-50]. Thanks to new therapeutic
strategies, both transplant eligible and ineligible patients are now able to reach quality responses
(markedly improving CR rates), in all phases of treatment [50]. The association of CR and VGPR
with improved survival is better defined in transplant setting, but lesser explored in transplant
ineligible patients [51-55]. Despite this premise, definitive data to validate the association between
quality of response and survival outcomes are missing. The ability to sustain a deep response is
becoming a crucial point to debate, since conflicting reports indicate that some patients may be able
to achieve deep but short responses, while others reach durable MR [28, 50]. Anyway, the
objective of achieving a maximal response should always be balanced with tolerability and patient
perceived quality of life [49-50]. All these considerations recall the “cure versus control” debate
treated in the paragraph 1.2.2. Clearly, the situation may be improved by intensive use of
technologies which allow predictive evaluation about the type of response a patient will be able to
reach, and estimation of the probability of relapse [50-51]. In this sense, progressions were
recorded for MFC approaches [49-50, 56], as I discuss in the following sections. However, a
universally recognized solution is still far.
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1.3 MFC applications in multiple myeloma and MGUS: when, how and why.
MFC utility extends from diagnosis to MRD assessment, monitoring of patients and definition of
response [15, 45, 57-58]. Prognostic role of MFC immunophenotyping is still waiting for a
universally validated correlation with therapeutic decisions [15, 59-60]. In addition, MFC may be
used to assess plasma cell labeling index (PCLI, proportion of plasma cells in S-phase) and ploidy
through calculation of DNA index (DNA content of neoplastic cells/DNA content of normal cells
in the sample), to deepen the study of documented bone marrow population-microenvironment
alterations related to disease esordium and progression, and to explore the modifications in
peripheral blood leukocytes [3, 15, 61-67]. Other possible uses of MFC (which are unrelated to this
thesis and for which I cross-refer to specific resources) include definition of new therapeutic targets
[68], characterization of circulating plasma cells [69], study of the effect of therapeutic regimens on
antigenic expression [70-71], identification of clonogenic compartment [72-75], quality graft
assessment and enumeration of CD34+ HPCs in peripheral blood after mobilization [76].
1.3.1 General considerations on MFC plasma cell detection.
MFC analysis of big amounts of cells in the same sample (in a short period of time), added to the
possibility of simultaneous analysis of surface and intracellular antigens, allows identification,
characterization and enumeration of even small percentages of plasma cells in both multiple
myeloma and MGUS samples [15, 77]. Lower bone marrow plasma cell counts have been found
during MFC vs morphological analysis through conventional microscopy; these discrepancies
affect also cytogenetics/FISH and molecular investigations [15, 57, 77]. The most relevant reasons
for this inequality are the highest quality of “first-pull” bone marrow aspirates used for
morphological evaluation (whereas secondary specimens are generally used for other laboratory
purposes) and technical issues related to morphological enumeration of plasma cells (begin of
enumeration from fields containing higher numbers of plasma cells rather than on randomly chosen
fields and/or focus on bone marrow particles with an increased concentration of plasma cells) [15,
57, 77]. Also plasma cell fragility may play an important role in causing methodological diversity
of results [57]. However MFC quantification of bone marrow plasma cells is strongly suggested in
clinical routine. It has been demonstrated that plasma cell counts obtained with MFC and
morphological examination exhibit a significant positive correlation [78]. Paiva et al. [78]
demonstrated that patients with bone marrow plasma cells < 15% as detected by MFC showed also
prolonged overall survival than cases with bone marrow plasma cells ≥ 15% (median 97 vs 54 
months, respectively); at multivariate analysis, bone marrow plasma cell counts obtained by
multiparameter flow cytometry were confirmed as an independent prognostic factor for overall
survival [78].
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MFC identification of plasma cells relies on the combined use of CD38, CD138, CD45 and light
scatter characteristics, setting the first gate in the bivariate dot plot CD38vsCD138 as reported by
the European Myeloma Network [77].
No single surface marker can make the distinction between normal and clonal plasma cells [58]. A
repertoire of studies indicated that the immunophenotype of clonal/aberrant plasma cells differs
from that of normal/reactive polyclonal plasma cells as regards a discrete number of markers,
which are routinely employed for characterization of myeloma cells and are also used in this thesis
(i.e. CD45, CD19, CD56, CD117, CD27, CD20, CD200) [18, 57-58, 77, 79-80]. A minimum MFC
panel should contain antibodies to test the surface expression of (at least) CD138, CD38, CD56,
CD19 and CD45 [77, 79]. Assessment of clonal restriction through cytoplasmic staining of light
chains is usually used to confirm adequate discrimination of aberrant plasma cells from polyclonal
counterpart [15, 18, 57-58, 77]. At diagnosis, the presence of >5% residual polyclonal plasma cells
(of total bone marrow plasma cells) is accepted as a reliable parameter to distinguish MGUS from
multiple myeloma cases [15, 81-82]. In the following sections the dissertation is deepened focusing
on classical characterization markers which have been studied in this thesis.
1.3.2 Challenges in plasma cell detection and myeloma cell discrimination.
Phenotypically aberrant plasma cells are typically CD19 negative (~95% of cases), CD45 negative
(~70% of patients), CD27 weak or negative (~40-50% of cases), CD56 positive (~60-70% of
subjects) and CD200 weakly/strongly positive (~70% of patients); in selected cases, CD20 is
heterogeneously expressed -negative to positive- (~17%) or positive (~30%) and CD117 is
reported positive (~30%) [15, 57-60, 77, 80, 83-86]. Comparing different studies, a negligible
degree of variability in frequency of these immunophenotypic characteristics is observed [15, 57-
60, 77, 80, 83-86]. On the contrary, normal plasma cells were usually described as CD19+ (>70%
of cells), CD27+ (~100% of cells), CD45+ (with fractions of CD45- plasma cells, ~6%), CD200
weakly positive or negative, CD20- (with fractions of CD20dim plasma cells, ~4%) and CD56-
(CD56+ plasma cells <15%) [15, 58-59, 77, 80, 87]. Although some groups suggested the use of
simplified antibody panels to distinguish neoplastic plasma cells from normal/reactive plasma cells
[79], recent reports demonstrate that features of “normal” and “aberrant” phenotypes are becoming
less solid with improvements in gating and detection strategies, and the abandon of cut-off values
to define positivity. In fact, normal plasma cells have been demonstrated to be more
immunophenotypically heterogeneous than previously understood, and subpopulations of non-
neoplastic plasma cells with an immunophenotype similar to myeloma plasma cells
(CD20+CD56+CD45-CD19-) have been described [85, 88-91]. As a consequence, in these last
years the scenario has been changing dramatically as regards ranges of expression of classical
immunophenotypic markers on normal plasma cells; the most cited papers and related disclosures
are indicated in Table 3 [57-58, 77, 87-93]. Precedent studies explored immunophenotype of
16
polyclonal plasma cells only in healthy individuals [87, 90], while others reunited in the same
category normal plasma cells of healthy and pathological subjects [88, 94], causing a loss of
information related to possible normal plasma cell heterogeneity among different categories of
patients.
It is not fully demonstrated if normal plasma cells in post therapy bone marrow may exhibit
immunophenotypic variations interfering with MRD detection, as well as if such (eventual)
variations may have a utility in diagnosis/monitoring of disease or for prognostic purposes. Post
therapy immunophenotypic changes have been demonstrated in clonal plasma cells [95-96], but it
is not clear if disease progression or response to therapy may be predicted analyzing plasma cell
ability to downregulate or upregulate surface antigen expression during treatment.
Table 3. Ranges of expression for classical immunophenotypic markers as
reported on normal plasma cells
Range for positive cells (%) Range for negative cells (%)
CD45 41-100 (Ref. 89)
CD19 61 - 100 (Ref. 87) 7 - 50 (Ref. 88)
44.2 - 77.1 (Ref. 90)
CD56 0 - 47 (Ref. 87)
5.7 - 41.8 (Ref. 90)
5 - 22 (Ref. 88)
<15 (Ref. 77)
10 - 100 (Ref. 91)
0 - 37 (Ref. 89)
CD117 0 (Ref. 57-58, 77, 87)
CD27 66 - 100 (Ref. 87)
>98 (Ref. 92)
100 (Ref. 77)
CD200 0 (Ref. 59)
0 (Ref. 87)
W Pos (not specified) (Ref. 77)
Pos (Ref. 93*)
CD20 19 - 91 (Ref. 87)
13 - 37 (Ref. 88)
0 (Ref. 77)
*Study not conducted on bone marrow. W Pos, weakly positive; Pos, positive – no specified
range.
The current list of MFC markers for myeloma and MGUS plasma cell evaluation remains limited if
compared to other clonal hematopoietic disorders and it has not augmented significantly in the past
years [15-16, 18, 57]. Moreover, not all surface antigens exhibit stable expression in samples; it is
the case of CD138, whose time- and apoptosis-dependent loss from plasma cell surface has been
previously demonstrated [97-98]. In addition, the introduction of new therapeutic approaches
targeting classical MFC surface markers with monoclonal antibodies (i.e. against CD38 or CD138)
[99-101], may compromise the utility of these molecules for after-treatment follow-up, limiting
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their value in plasmacellular detection, and the resolution power of current combinations; similar
experimental conclusions were described in other hematological malignancies and/or considering
other types of monoclonal antibodies [101-102].
Thus introduction of new markers in clinical routine is highly recommendable. These markers
should be suitable for discrimination of clonal plasma cells from their normal counterpart, and for
identification of plasma cells in absence of CD38 and CD138.
1.3.3 MFC in assessing prognosis
In recent years, an increasing interest about the role of MFC in establishment of prognosis has
started to appear; however, frequent discrepancies have been reported among various reports [15,
57, 60, 80]. This is probably due to an inappropriateness in study design and technical pitfalls, just
for example the use of different clones of monoclonal antibody conjugates, and adoption of
different cut-off values for definition of positivity [60]. Thus the prognostic value of
immunophenotyping in MGUS and multiple myeloma, although being accepted, needs validation.
Besides the utility of MFC enumeration of plasma cells at diagnosis (paragraph 1.3.1), a correlation
with prognosis has been made for an extended number of MFC markers [15, 57-58, 80]. As
reported by Mateo et al. [60] CD19 positivity and CD117 negativity associated with shorter
progression free survival compared with CD19- and CD117+ patients (median 26 vs 38 months
and 32 vs 44 months respectively). Similar considerations emerged as regards overall survival. For
CD19+ cases median overall survival was described 40 vs 68 months of CD19- patients [60].
Bataille et al. [103] affirmed that overall survival was 93% at 4 years in CD117+ vs 64% in
CD117− myeloma patients [103]. Lack of CD117 was associated with high levels of β2-
microglobulin, advanced ISS, non-hyperdiploid cases (or more specifically hypodiploidy), t(11;14)
and t(11;4) traslocations and del(13q) [60, 104]. CD20 expression has been associated with
t(11;14) [84, 86], although CD20 expression did not show any impact on survival [60]. Data about
CD45 are incoherent. It has been reported that CD45 has no impact on prognosis [60], despite the
association of CD45- cases with deletion 13 or aneuploidy and del(17p) by FISH [104], and the
trend towards longer overall survival for CD45+ (defined as >20% of CD45 expressing plasma
cells) patients vs the CD45- group (39 vs 18 months respectively), which did not reveal to be
significant [105]. On the contrary, this trend related to the effect CD45 positivity on survival
reached statistical significance in patients treated with high-dose therapy (median survival in
CD45- patients 42 months vs median not reached in CD45+ patients) [106]. As regards CD27,
Moreau et al. reported that overall survival was 92% at 3 years in CD27+ vs 50% in CD27–
myeloma patients [107]. Moreover loss of CD27 is correlated to loss of CD19 in myeloma cases
[92]. Sahara et al. [108] proved that median survival was lower in CD56- than in CD56+ patients
treated with conventional chemotherapies (22 vs 63 months) and that CD56- cases are
characterized by increased aggressiveness of disease; however authors failed to find any prognostic
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value of CD56 expression at multivariate analysis, probably because of a strong association
between CD56 expression and extramedullary disease [108]. In addition, CD56 showed no
prognostic value in patients undergone to high-dose chemotherapy [109]. A correlation between
CD56 negativity/down regulation on myeloma cells and t(11;14) has been described more than
once in literature [84, 109]. Considering existing data, the role of CD56 in determination of
prognosis needs clarification. Loss of CD200 expression in multiple myeloma was described as
associated with the possibility of a more clinically aggressive disease [59]; this contradicts a
precedent report based on Affymetrix microarrays, suggesting that patients with myeloma cells
devoid of CD200 expression have a better survival than patients showing CD200 expression after
high-dose therapy and stem cell transplantation [110]. So, also for CD200 data need to be deepen
and better interpreted.
Other than on immunophenotypic characteristics, elaboration of prognosis relies on MFC
quantitative data. Paiva et al. [111] demonstrated that, among myeloma patients, subjects with
more than 5% normal plasma cells from total bone marrow plasma cells had clinical characteristics
generally associated with a favorable outcome. These patients showed better response rates to both
induction (rate of complete remission 21% vs 11% in patients with ≤5% of normal plasma cells out 
of total bone marrow plasma cells) and ASCT (rate of complete remission 64% vs 33% in patients
with ≤5% of normal plasma cells out of total bone marrow plasma cells) [111]. Moreover, cases 
with more than 5% normal plasma cells from total bone marrow plasma cells exhibited a better
outcome than patients with ≤ 5% normal plasma cells from total bone marrow plasma cells as 
regards both progression free survival (median 54 vs 42 months respectively) and overall survival
(median not reached vs 89 months respectively) [111]. Examining a cohort of patients treated with
high-dose therapy and ASCT, and assessing MRD by MFC after transplantation, progression-free
survival and overall survival were longer in patients who were MRD negative versus MRD positive
(progression free survival median 71 vs 37 months respectively, and overall survival median not
reached vs 89 months respectively) [112]. Similarly Rawstron et al. [113] described that in patients
undergone to ASCT, comparing MFC MRD negative with MFC MRD positive cases, a significant
inferior outcome was reported for MRD positive patients vs MRD negative ones as regards
progression free survival (15.5 vs 28.6 months) and overall survival (59 vs 80.6 months) [113].
Coherently, Paiva et al. [114] reported that in a cohort of CR patients, the failure to reach
immunophenotypic CR at day +100 after high-dose therapy/ASCT produced a significant worse
outcome concerning time to progression (at 3 years 58% for no immunophenotypic CR vs 86% for
immunophenotypic CR) and overall survival (at 3 years 80% for no immunophenotypic CR vs 98%
for immunophenotypic CR). Moreover at multivariate analysis, immunophenotypic CR status was
confirmed as an independent factor able to predict unsustained CR (patients who lose their CR
status within 1 year of high-dose therapy/ASCT) [114]. Considering patients who achieved CR
with salvage therapy -with or without stem cell transplantation- after relapse, MFC MRD negative
19
patients (not undergone to allogenic stem cell transplantation) showed a median time to progression
of 75 months vs 14 months in MRD positive patients [115]. MFC may also be helpful in assessing
risk of progression towards symptomatic disease both in MGUS and SMM, as specified in
paragraph 1.2.2. Analyzing MGUS subjects, the cumulative probability of progression was 25% for
patients with ≥95% of clonal plasma cells (out of total bone marrow plasma cells) vs 5% for 
patients with less than 95% of clonal plasma cells (out of total bone marrow plasma cells) [116].
Also, in SMM cases, cumulative probability of progression at 5 years was 64% for patients with
more than 95% of clonal plasma cells (out of total bone marrow plasma cells) vs 8% for patients
with less than 95% of clonal plasma cells (out of total bone marrow plasma cells) [116]. Prognostic
value of these results was confirmed in a further study [117]. In addition, CD19 showed a
predictive value in MGUS, since Olteanu et al. [82] showed that MGUS patients with potential for
disease progression seemed to lack CD19 expression on >90% of their plasma cells [82]. This
overview emphasizes the deep connection between immunophenotypic characteristics of aberrant
plasma cells and possible patient outcomes, also underlining the lack of homogeneity among results
and the absence of information concerning normal plasma cells. In addition, the existing data
indicate that depth of response to therapeutic intervention may exhibit a relationship with MFC
results. Such a type of connection should be carefully considered in studies assessing the value of
immunophenotypic profiles in order to complete the already delineated frame.
1.3.4 Exploring the interaction with bone marrow microenvironment part I - Immunosuppression
The complex interaction between myeloma cells and bone marow microenvironment, and the
involvement of such interaction in myeloma pathophysiology, are the core of an expanding and
stimulating field of research. The key question is how mechanism supporting hematopoiesis are
manipulated by tumour cells in order to maintain their own growth. This process include both
direct contact with bone marrow components and action of soluble mediators, with triggering of
anti-apoptotic and pro-proliferative patterns, and appearance of immune dysfunction [3, 118]. Most
of all, suppression of full immune functions is a recognized cause of increased risk of infection in
multiple myeloma subjects [119-120]. Such a deterioration is related to not only intrinsic
characteristics of the disease, but also to the effect of age dependent complications and the use of
therapeutic approaches, which showed a documented impact at various levels on the immune
system [119-120]. Myeloma-related immunodeficiency involves deficit in fuction of dendritic cells,
and abnormalities in T cells (increase of CD4+ and CD8+ Tregs in myeloma patients vs normal
subjects; CD4+ lymphopenia; inversion of CD4:CD8 ratio; abnormal Th1/Th2 CD4+ ratio;
imbalance of T lymphocyte subsets), myeloid derived suppressor cells (MDSC) (including increase
in granulocytic MDSC in patient with progressive disease), and NK cells [3, 63, 65-67, 118].
However, broad studies on deficits involving bone marrow B cell branch in myeloma subjects have
not been performed yet. Most of data are about bone marrow alteration of total B cell percentage
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and B progenitor cells [121-123], but distribution of B transitional/naïve and memory B cells in
bone marrow among different categories of responding/relapsing patients still represent a critical
point to deepen. B cell compartment is defective in the elderly: humoral immune response differs
both in the quality (especially in terms of production of high affinity responses) and levels of the
produced antibodies, and the number of circulating B cells significantly decreases in the aged [124-
127]. In the elderly, naïve/transitional B cells are highly activated to produce both IL10 and TNF-α 
under physiological (anti-CD40 and IL4) stimulation; in turn, “double negative” (DN) IgD−CD27− 
population seems to be an “exhausted” memory population filling immunological space in aged
subjects [127-130]. Bulati et al. hypothesized that DN B cells are involved in the inflammatory
environment related to aging and that they might be either a by-product of systemic inflammation
or directly involved in the immune response [129-130]. DN B cells show the ability of being
stimulated to secrete granzyme B, and exhibit a tissue trafficking phenotype [129]. The reduction
in percentage of naïve B lymphocytes (IgD+CD27−) and the increase in percentage of a DN 
memory B cell population have been demonstrated in peripheral blood of the elderly [128]. No
experimental evidency about redistribution of these B cell subsets has been produced in the bone
marrow of myeloma and MGUS patients.
1.3.5 Exploring the interaction with bone marrow microenvironment part II – Connection with
the immunophenotype.
Residual clonal plasma cells may escape therapeutic effects in bone marrow niches, which has been
proved to be able to enhance myeloma cell survival and modulate immune system ability to
eradicate malignant cells [3, 33]. It has now become clear that, in order to cure multiple myeloma,
targeting bone marrow players other than myeloma cells and identifying the role of bone marrow
microenvironment in response to therapeutic intervention are necessary [3]. MFC allows
determination of immunophenotypic profiles of neoplastic plasma cells, and simultaneous study of
characteristics of other cellular populations in the same sample. This type of analysis may provide
useful pieces of information about the possible connection between clonal plasma cell
immunophenotype and bone marrow characteristics which may be related to outcome. Besides the
immune system deregulation, another (influencing survival) field which is currently receiving
growing attention is the analysis of graft content [76]. The CD34+ compartment is really
heterogeneous, containing several subpopulations of hematopoietic progenitor cells (HPCs). In
patients with myeloma and other hematological malignancies, studies about correlation between
graft composition and durability of engrafment and neutrophil or platelet recovery time were
performed especially as regards CD34+CD110+, CD34+CD133+, CD34+CD90+, CD34+CD38-
and CD34+L-selectin+ cells [131-133]. Moreover, graft composition was explored comparing good
and poor mobilizers, but no difference was detected about proportion of CD34+CD38− and 
CD34+HLA-DR− cells [134]. A report by Arber et al. [135] involving non-myeloma subjects 
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demonstrated graft-source dependent and donor-age dependent differences in progenitor subsets
[135]. Given these data, the analysis of bone marrow CD34+ HPC subset distribution in myeloma
patients would provide new insights in both relationship interesting medullary reserves-mobilized
fractions and mechanism of reciprocal influences between clonal plasma cells and bone marrow
niches. Precedent studies demonstrated alterations in bone marrow distribution of HPCs in multiple
myeloma subjects. Compared to healthy donors, a substantial reduction of CD34+ HPC subsets and
CD19+CD38+CD34+ Pro-B cells in terms of absolute cell count and proportion of mononuclear
cells respectively was described in untreated myeloma subjects [122]. Similarly, percentage of total
CD34+ cells and CD19+CD34+ cells (both defined as proportion of total leukocytes excluding
plasma cells) was proven to be decreased at presentation, and CD19+CD34+ cells also at relapse,
but not in patients at plateau/remission, vs normal individuals [121]. Coherently, a more recent
report confirmed reduction of percentage of CD34+ HPCs (from whole bone marrow cellularity)
and CD34+CD38+CD19+ progenitors (out of total CD34+ HPCs) in bone marrow of myeloma
patients vs healthy controls [123]. However no specific analysis of myeloma patients was
performed correlating immunophenotype of clonal plasma cells with bone marrow distribution of
HPC subsets, with the exception of the work from Schmidt-Hieber et al. [136], who studied
myeloma cases accordingly to clonal plasma cell CD117 positivity. The analysis demonstrated a
significant higher CD34+CD19-/CD34+CD19+ cell ratio in bone marrow of newly diagnosed
CD117- subjects vs CD117+ patients [136]. However, treated patients were not examined, and no
intragroup comparison in CD117- and CD117+ responding and relapsing groups of patients was
performed about distribution of CD34+ HPCs. Performing this analytical approach could reveal
important features strictly dependent on mechanisms by which CD117 positivity is associated with
a good prognosis, or open the research for a possible relationship of enumeration of bone marrow
CD34+CD19- and CD34+CD19+ HPC subtypes with depth of response, mobilizing capacities,
graft content and time to engrafment in CD117+ and CD117- patients. Moreover, it would make
possible the evaluation of the effect of therapeutic regimens on CD34+ subpopulation
reorganization in CD117- and CD117+ subjects.
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2. Finding solutions: objectives of this thesis .
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As emerged in previous paragraphs, one of the most urgent needs in multiple myeloma field is the
introduction in clinical routine of new markers for discrimination of normal and clonal plasma
cells, with simultaneous exact definition of normal plasma cell immunophenotype. In order to
avoid loss of information or misinterpretation of results, and to provide the basis for future
prognostic purposes, a rigorous approach should be used, exploring characteristics of MFC profiles
in both clonal and polyclonal plasma cells by comparison of different categories of untreated,
responding and non-responding patients.
With this in mind, in chapter 3 I explore the utility of some “old school” markers (CD19, CD45,
CD56, CD27, CD117, CD20, CD200) and CD49d, CD58, CD11a and CD30 in identification of
clonal and polyclonal plasma cells in MGUS, newly diagnosed and treated subjects. I focus my
attention on markers involved in cellular adhesion (CD49d, CD11a and CD58), because a better
understanding of quantitative changes in expression of adhesion molecules during the stages of the
disease may be fundamental for defining the mechanisms by which plasma cells moves to or from
the BM niches [91]. I also analyze the expression of CD30, which is present normally on only a
very small fraction of activated lymphocytes, contributes to negative selection of T-cells, and could
be an attractive target for therapeutic intervention [137]. CD49d, the integrin α subunit of VLA-4, 
has been found strongly expressed by myeloma plasma cells with a median percentage of positive
cells close to 100% [138], whereas mean percentage of positive normal plasma cells from healthy
donors has been reported ~75% [70]. CD11a, the integrin α subunit of LFA-1, has been reported 
positive as well as negative in literature on MGUS and myeloma samples [139-140]. The ranges of
expression on malignant plasma cells differs dramatically from one paper to another, ranging from
0 to 100% in newly diagnosed or remitting subjects, and from 0 to ~80% in relapsing subjects [91],
or reported as <30% for CD45+ cells and <<10% for CD45- cells [105]. On normal plasma cells, it
has been reported to range from 20 to 100% [91]. CD58, a CD2 receptor, was previously indicated
as present occasionally on polyclonal plasma cells and never expressed on MGUS clonal plasma
cells, but no clear range was defined through MFC analysis [139]. Similarly, CD30 expression on
clonal plasma cells was recognized as infrequent, but no data are available as regards normal
plasma cells [138]. For these markers, a prognostic role has not been defined yet. My primary
endpoint is structured as follows: 1) analysis of the expression of CD45, CD19, CD27, CD56,
CD117, CD20, CD200, CD49d, CD58, CD11a and CD30 in MGUS subjects, myeloma responding
and relapsing patients, in order to test the utility of these markers in detecting clonal plasma cells in
various clinical scenarios; 2) study of the differences in the immunophenotype of polyclonal
plasma cells comparing normal subjects with responding and relapsing patients; 3) detection of
variations in expression of the cited antigens on clonal plasma cells in groups of new or treated
patients, and comparison with polyclonal plasma cells of MFC MRD negative and normal subjects
[141]. As secondary endpoint I determine the existence of a correlation between exordium of
disease/response to therapy/disease progression and the expression of the listed markers on
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polyclonal and clonal plasma cells; then I verify if such a correlation is influenced by most
commonly considered clinical and prognostic variables [141]. The inclusive objective is to define
the utility of polyclonal plasma cell analysis in myeloma diagnosis and follow up, and the
possibility of elaborating disease stage related MFC panels [141].
In turn, in chapter 4 I deepen the research of new immunophenotypic markers for detection of
plasma cells. Critical revision of the literature resulted in a list of candidate markers to be
evaluated: CD54, CD229, and CD319. CD229 and CD319 from SLAM family are self-ligand
receptors [142], while immunoglobulin superfamily adhesion molecule CD54 has LFA-1 and Mac-
1 as physiological ligands [143]. Their expression profile on malignant plasma cells has been
previously described [68, 70, 144]; all of them have also been investigated as therapeutic targets for
multiple myeloma patients [68, 144-145]. Despite their presence on myeloma plasma cell surface
was documented in different experimental settings, none of the cited markers has been evaluated as
alternative candidates to antigens currently used in MFC detection and characterization of plasma
cells.
In chapter 5 I explore the interaction of the disease with bone marrow microenvironment, focusing
on one of the most essential clinical aspects of multiple myeloma: immunosuppression. Since data
about B cell branch are lacking, I concentrate my research on reorganization of B lymphocytes in
myeloma patients. I report the distribution of B cell subsets in bone marrow of healthy subjects,
MGUS, and newly diagnosed, responding and relapsing myeloma patients, also evaluating the
possible presence of clonal restriction in these lymphocytic subpopulations through MFC.
Finally in chapter 6 I focus my attention on possible alterations interesting CD34+ HPCs in
CD117+ and CD117- myeloma and MGUS patients. I verify the distribution of bone marrow
CD34+CD19- HPCs and Pro-B cells in healthy controls, MGUS patients and various categories of
responding/relapsing MM subjects. Moreover, after dividing patients accordingly to CD117
expression or absence on clonal plasma cell surface, I compare differences in percentage of
CD34+CD19- and Pro-B cells to detect a potential mechanism related to influence of CD117
positivity and negativity on prognosis.
All material in this thesis is an original research; content of chapters 3 has been accepted on
Cytometry Part B: Clinical Cytometry [141]. Content of chapter 5 and 6 has been submitted to a
peer reviewed journal, while results in chapter 4 are part of manuscripts in preparation. The
experimental activity described in chapters 3, 5 and 7 was performed at the U.O.S.D. Laboratorio
Specialistico Oncologia, Ematologia e Colture Cellulari per Uso Clinico, ARNAS Civico (Palermo,
Italy) from April 2013 to December 2013, from July to August 2014 and in December 2014. In
turn, investigation exposed in chapter 4 was performed at the Centro de Investigación del Cáncer
(Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL), Instituto Biosanitario de
Salamanca (IBSAL), Servicio General de Citometría y Departamento de Medicina (NUCLEUS),
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Universidad de Salamanca (Salamanca, Spain), from January 2014 to June 2014 and from
September 2014 to November 2014.
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Background: Multiple myeloma is an incurable disease characterized by proliferation of clonal malignant
plasma cells (CPCs), which can be immunophenotypically distinguished from polyclonal plasma cells
(PPCs) by multiparameter flow cytometry (MFC). The utility of PPCs analysis in detecting prognostic and pre-
dictive information is still a matter of debate. Methods: we tested the ability of 11 MFC markers in detecting
differences in the immunophenotype of CPCs and PPCs among patients in various disease stages; we veri-
fied if these markers could be associated with disease stage/response to therapy despite the role of clinical
parameters. Results: significant changes in the expression of markers occurred both in CPCs and PPCs.
CD58 on PPCs of responding patients was downregulated compared with PPC of relapsing group. Fraction of
CD200 expressing PCs was lower in control subjects than in PPCs from MGUS and myeloma groups. CD11a
levels of expression on both CPCs and PPCs showed an upregulation in newly diagnosed and relapsing
patients versus PCs of controls; CD20 was less expressed on control PCs than on MGUS CPCs and PPCs.
CD49d revealed to be advantageous in discrimination of PPCs from CPCs. In our multiple regression model,
CD19 and CD49d on CPCs, and CD45, CD58 and CD56 on PPCs maintained their association with groups of
patients independently of other prognostic variables. Conclusions: we provide a feasible start point to put in
order ranges of expression on PPCs in healthy and myeloma subjects; we propose a new approach based
on PPC analysis to monitor the stages of the disease. VC 2014 International Clinical Cytometry Society
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Multiple myeloma (MM) is an incurable neoplastic
plasma cell (PC) disorder characterized by proliferation
of clonal malignant plasma cells (CPCs) in bone marrow
(BM), and presence of monoclonal protein (M protein)
in blood and/or urine, associated with organ dysfunction
(1). The first stage in the development of MM is the
emergence of asymptomatic monoclonal gammopathy of
undetermined significance (MGUS). In some of these
patients, this progresses to smoldering MM and ulti-
mately to symptomatic MM, with an annual risk of
around 1% for patients with MGUS (2). MM accounts for
approximately 1% diseases and is the second most com-
mon hematologic cancer. The incidence of MM in
Europe is 4.5–6.0/100,000/year with a median age at
diagnosis of between 63 and 70 years; the mortality is
4.1/100,000/year (3). Treatment differs among autolo-
gous stem cell transplantation eligible patients and those
who are not candidates (4); responsiveness to treat-
ments varies largely among patients due to the high het-
erogeneity of MM. The decision of which treatment is
best has been a difficult issue in MM. However, due to
the introduction of novel drugs (bortezomib, lenalido-
mide and thalidomide) that have been able to achieve
good quality responses, changes in treatment strategies
can be seen (5). The importance of reaching complete
response (CR) is undoubtedly recognized in the trans-
plant setting (6–8) although it is less clear in the non-
trasplant setting. Clinicians may benefit from multipara-
meter flow cytometry (MFC), since this technology
allows to define the immunophenotypic characteristics
of CPCs, to study normal/reactive polyclonal PCs (PPCs)
of both healthy and MM subjects, to distinguish CPCs
from PPC pool (9–14), to evaluate the risk of progres-
sion from MGUS to MM (15,16) and the presence of
minimal residual disease (MRD) (10,17,18), to identify
new therapeutic targets (19–21), and to provide prog-
nostic information. For some markers, immunopheno-
typic appropriateness and prognostic role have already
been explored (CD27, CD56, CD117, CD19, CD45)
(22–25), instead other markers have been less investi-
gated (CD20 and CD200) (12,22,26,27) or their utility is
still a matter of debate (CD30, CD49d, CD11a and
CD58) (28–36). MFC data flank other factors influencing
prognosis such as ISS and Durie-Salmon stage at diagno-
sis, hyper- and hypodiploidy and lactate dehydrogenase
levels (37–39). A commonly described experimental
approach is based on the study of immunophenotype of
CPCs (and sometimes residual PPCs), dividing patients
in newly diagnosed subjects and treated/relapsed
patients. It is not fully demonstrated if PPCs in BM post
therapies may exhibit immunophenotypic variations
interfering with MRD detection; similarly it is not clear
if disease progression or response to therapy may be
predicted analyzing PC ability to downregulate or upreg-
ulate surface antigen expression during therapy. In addi-
tion, BM PPCs have been demonstrated to be more
immunophenotypically heterogeneous than previously
understood, and subpopulations of non-neoplastic PCs
with an immunophenotype similar to myeloma PCs have
been described (40–45). In this article, our primary end-
point was structured as follows: (1) analysis of the
expression of CD45, CD19, CD27, CD56, CD117, CD20,
CD200, CD49d, CD58, CD11a, and CD30 in MGUS sub-
jects, MM responding and relapsing patients, to test the
utility of these markers in detecting CPCs in various clin-
ical scenarios; (2) study of the differences in the immu-
nophenotype of PPCs comparing normal subjects with
responding and relapsing patients; (3) detection of varia-
tions in expression of the cited antigens on CPCs in
groups of new or treated patients, and comparison with
PPCs of MRD negative and normal subjects. As second-
ary endpoint we determined the existence of a correla-
tion between exordium of disease/response to therapy/
disease progression and the expression of the listed
markers on PPCs and CPCs; then we verified if such a
correlation is influenced by most commonly considered
clinical and prognostic variables. The inclusive objective
is to define the utility of PPCs analysis in MM diagnosis
and follow up, and the possibility of elaborating disease
stage related MFC panels. In our knowledge, this is the
first time that this kind of approach has been used to
evaluate the expression of all these markers simultane-
ously in the same group of subjects.
MATERIALS AND METHODS
Patients and BM Samples
A total of 60 subjects (42 male and 18 female) were
included in this study. Control specimens consisted of
10 BM samples from patients who were suspected to
have a haematological disease and revealed to be non
oncological subjects (Control group). These patients
have no history of MM, MGUS or lymphoid/myeloid neo-
plasm. BM samples of 40 patients with MM and 10
patients with already documented (7 subjects) or newly
diagnosed (3 subjects) MGUS submitted to our labora-
tory for routine analysis were evaluated by MFC and
morphology. For every patient clinical chemical and
immunological profiles, as well as reference intervals
were provided by the U.O. Patologia Clinica – Labora-
torio Analisi Cliniche of ARNAS Civico, Palermo (Italy).
Clinical data and history for MGUS and MM cases were
provided by U.O. Oncoematologia of ARNAS Civico,
Palermo (Italy). Disease stage was defined according to
Durie-Salmon and ISS staging criteria (46,47). Response
to therapy was defined according to Bird et al. (48). Of
MM samples, 10 were obtained at presentation (group
New), 10 from patients with progressive disease (group
Progressive), 10 from patients in partial remission (3
very good partial response, 6 partial response and 1 sta-
ble disease – group Therapy) and 10 from patients that
achieved stringent CR (group Complete). All MGUS
patients were considered as a separate group (MGUS
group). Informed consent procedures and forms were
proposed to and approved by the ARNAS Civico Medical
Ethics Committee. Written informed consent was given
by all subjects in line with the Declaration of Helsinki
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Protocol. BM samples were collected in EDTA tubes and
processed in one hour since collection.
Multiparameter Flow Cytometry
Details about antibodies and instrument are indicated
in on line Supporting Information Tables SI1 and SI2.
Specimens were fragmented with a sterile syringe and
filtered using a 80lm filter; nucleated cells were enum-
erated using UniCelVR DxHTM 800 CoulterVR Cellular Anal-
ysis System (Beckman Coulter, Miami, FL) and brought
to a final concentration of 106cells/100ll with PBS w/o
calcium and magnesium (EuroClone, Milan, Italy). Com-
binations of antibodies used to stain surface and intracel-
lular markers are listed in TableT1 1. For staining of surface
markers, 100ll of each sample were incubated with the
opportune combinations of antibodies for 15 minutes in
the dark. Erythrocytes were lysed adding 1 mL of Versa-
LyseTM Lysing Solution and incubating tubes for 20
minutes in the dark. For intracellular staining of kappa
and lambda light chains, 50ll of sample were washed 5
times with 2 mL of PBS w/o calcium and magnesium
(EuroClone, Milan, Italy), and processed with PerFix-nc
(Beckman Coulter, Miami, FL) following instructions.
Samples were all acquired with NaviosTM Flow Cytome-
try System, data were collected with Navios v1.0 Soft-
ware (Beckman Coulter, Miami, FL) and then analyzed
with KaluzaVR Flow Cytometry Analysis Software v1.2
(Beckman Coulter, Miami, FL). Daily testing of instru-
ment was performed as indicated: standardization of
light scatter, fluorescence intensity and optimal hydrody-
namic focusing instrument settings were verified using
Flow-Set Pro Fluorospheres (Beckman Coulter, Miami,
FL); compensation matrix for each combination of anti-
bodies was tested with CYTO-COMPTM Cell Kit (Beck-
man Coulter, Miami, FL); optical alignment and fluidics
were checked using Flow-Check Pro Fluorospheres
(Beckman Coulter, Miami, FL). To identify PCs, a combi-
nation of CD38, CD138, and CD45 together with side
scatter properties was used; the first gate was set on
CD38 versus CD138 as suggested (10). Distinction
between normal/reactive and clonal PC compartments
was performed on the basis of their most frequent aber-
rant phenotypes (as regards CD38, CD19, CD27, CD56,
and CD45); results were confirmed by the presence of
clonal restriction in population showing the abnormal
phenotype, and the absence of restriction in normal PCs
(10,22). The j:k ratio was defined as abnormal if< 0.5
or> 3 (49). A minimum of 200 events were collected in
the PC gate for each tube; to reach this result, a total of
200,000–2,000,000 events were acquired. For each
marker, an internal negative population present within
the sample was used to define gates and sample fluores-
cence background (23,50). Data were measured as per-
centage of cells presenting the antigen (percentage of
positive cells) and Mean Fluorescence Intensity Ratio
(MFI ratio). MFI ratio for each fluorochrome-marker con-
jugate was defined as the geometric mean fluorescence
of the positive population normalized for the geometric
mean fluorescence of the negative population. Cellular
DNA content and ploidy were analyzed by
CYCLOSCOPE-MM (Cytognos, Salamanca, Spain) follow-
ing instructions. DNA index was used to define the pres-
ence of aneuploidies as follows: hypodiploidy when the
DNA index was <0.95, pseudodiploidy when the DNA
index was 0.95–1.05 (excluding those subjects with
DNA index of 1, who were indicated as perfect diploid),
hyperdiploidy (HRD) when DNA index was >1.05, and
near tetraploidy when DNA index was >1.75 (51).
BM Film Staining
BM films were prepared and stained with May-
Gr€unwald-Giemsa staining method as described else-
where (52,53). All reagents were supplied by Merck
Millipore, Darmstadt, Germany.
Statistical Analysis
Continuous non normal data are expressed as median
values (range); normal variables are indicated as
mean6SD. Baseline differences between groups were
assessed by the v2 test or Fisher’s exact test, as needed
for categorical variables. The univariate analysis of var-
iance (ANOVA) was performed for parametric variables,
and post hoc analysis with the Tukey’s test was used to
determine pairwise differences. The Kruskal-Wallis statis-
tic test was performed for nonparametric analysis. The
Wilcoxon signed-rank test was used to evaluate intra-
group difference. For multiple comparisons the Bonfer-
roni correction was performed. Multinomial logistic
Table 1
Combinations of Antibodies
FITC PE PC5.5 PC7 APC
APC-Alexa
Fluor 750 PB KO
Tube 1 Cyt j Cyt k CD38 CD56 CD138 CD27 CD19 CD45
Tube 2 CD20 CD56 CD38 CD117 CD138 CD27 CD19 CD45
Tube 3 CD11a CD200a CD38 CD56 CD138 CD27 CD19 CD45
Tube 4 CD30a CD58 CD38 CD56 CD138 CD27 CD19 CD45
Tube 5 CD49da CD38 CD56 CD138 CD27 CD19 CD45
Cyt: cytoplasmic; FITC: fluorescein isothiocyanate; PE: phycoerythrin; PC5.5: phycoerythrin-cyanin 5.5; PC7: phycoerythrin-
cyanin 7; APC: allophycocyanin; PB: pacific blue; KO: krome orange.
aAll antibodies were purchased from Beckman Coulter (Miami, FL), except those with which were purchased from BD Pharmin-
genTM (San Jose, CA).
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regression analysis examined the correlation between
various patients groups (dependent variables) and
markers measurements (independent variable) in simple
and multiple regression models. v2 and Likelihood Ratio
v2 statistics were used in assessing goodness of fit in
Regression model. Data were analyzed by the Epi Info
software (version 6.0, Centers for Disease Control and
Prevention, Atlanta, GA) and IBM SPSS Software 21.0
version (IBM Corp., Armonk, NY). All P-values were
two-sided and P< 0.05 was considered statistically
significant.
RESULTS
Characteristics of Patients
Characteristics of patients and statistical significant dif-
ferences as regards sex, stage, and therapies are summar-
ized in TableT2 2. Examining age, MGUS patients (70.96 5.6
years) were significantly older than Control and Complete
subjects (58.36 5.8 and 59.86 8.5 years, respectively; vs.
Control P5 0.008 and vs. Complete P5 0.027). Progres-
sive patients (80.36 4.2 years) also presented a more
advanced age compared with Control, Complete, and
Therapy (61.96 9.5 years) (P< 0.0005 in all cases), and
with New subjects (66.36 10.8 years, P5 0.002). When
MFC analysis was performed, 40% of Complete, 30% of
Therapy and 30% of Progressive patients have interrupted
treatment from at least 15 days. Lenalidomide was the
treatment of choice in 40% of Complete and 20% of Pro-
gressive cases. Thalidomide as monotherapy was adminis-
tered to 20% of Complete subjects. Bortezomib-
dexamethasone therapy was taken by 20% of Therapy
and 50% of Progressive patients (Progressive vs. Complete
P5 0.032). In Therapy group, 20 and 30% of subjects
underwent bortezomib-cyclophosphamide-dexamethasone
and bortezomib-thalidomide-dexamethasone regimens,
respectively. Statistical analysis was extended to therapeu-
tic regimens administered to patients before the time of
this study. Frequencies of each type of therapeutic regi-
men was recordered. Significant differences were found
for vincristine-melphalan-cyclophosphamide-prednisone
(VMCP) therapy, only given in 50% of progressive cases
(Progressive vs. Complete and Therapy P5 0.032), and
bortezomib-thalidomide-dexamethasone (VTD) regimen,
used in 20% and 50% of Complete and Therapy patients,
respectively, (Therapy vs. Progressive P5 0.032). Clinical
variables recorded for each group are indicated in Table
T33. Patients in each group were also subgrouped depend-
ing on presence of serum albumin 3.5 or <3.5 g/dL,
serum creatinine levels< or 2 mg/dL and M protein pro-
duction rates low, high or comprised between 5 and 7 g/
dL (for IgG) and 3 and 5 g/dL (for IgA), just as reported
for Durie-Salmon and ISS staging criteria, but in these
cases no significant difference emerged (data not shown).
In addition, data about presence of eventual comorbidities
were recorded. No significant differences were observed
Table 2
General Characteristics of Subjects Included in This Study
Control MGUS Complete Therapy New Progressive PW comp
Sex M 100% (10) 70% (7) 40% (4) 80% (8) 30% (3) 100% (10) Ct, P vs. N 0.02
F 30% (3) 60% (6) 20% (2) 70% (7)
Time fd 768.1 (7) 361.8 1.561.5 060 4.461.8 M vs. T 0.021
(years) M vs. N 0.002
Subtype IgA k 30% (3) 30% (3) NT
IgA j 10% (1) 50% (5) NT
IgG k 30% (3) 20% (2) 30% (3) 60% (6) NT
IgG j 50% (5) 40% (4) 40% (4) 10% (1) 50% (5) NT
k 40% (4) 20% (2) NT
j 20% (2) NT
D-S Stage I A 20% (2) 30% (3) 70% (7) T vs. P 0.003
II A 20% (2) 50% (5) 50% (5) 30% (3)
II B 10% (1) 10% (1)
III A 60% (6) 10% (1) Cp vs. N, P 0.01
III B 30% (3) 10% (1)
ISS Stage I 10% (1) 30% (3) 40% (4)
II 90% (9) 40% (4) 30% (3) 80% (8) Cp vs. N 0.02
III 30% (3) 30% (3) 20% (2)
ASCT 60% (6) 50% (5) Cp vs. P 0.01
T vs. P 0.032
Continous variables are indicated as mean6SD; other results are expressed as percentage of cases. The number of subjects is
indicated between brackets. Y, years; Time fd, time passed from diagnosis of the disease; k, myeloma secerning only lambda chain;
j, myeloma secerning only kappa chain; D-S stage, Durie-Salmon stage; ASCT, autologous stem cell transplantation; PW comp,
pairwise comparison; Ct, Control; M, MGUS; Cp, Complete; T, Therapy; N, New; P, Progressive; NT, not tested. Everytime different
pairwise comparison against one group gave the same P value, groups that were compared with that group are reported separated
by a comma.
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for chronic renal insufficiency, hypothyroidism, obesity,
thalassemia trait, HCV, and HBV related chronic hepatitis
(data not shown). Diabetes interested 20% of Complete,
40% of MGUS and 70% of Progressive subjects (Progres-
sive vs. Control, Therapy and New P5 0.003 in all cases).
Cardiopathy was a complication in 20% of MGUS and
50% of Progressive patients (Progressive vs. all other
groups except MGUS P5 0.032). Hypertension was
observed in 40% of complete and new, 50% of therapy
and 80% of progressive subjects (progressive vs. control
and MGUS P5 0.007; therapy vs. control and MGUS
P5 0.032).
PCs Analysis and Intragroup Comparisons between
PPCs and CPC
As evidenced by morphology, at the time of diagnosis
mean percentage6 SD of PC was 6.46 2.4% for MGUS,
296 7.4% for Complete, 33.56 14.7% for Therapy, and
296 11.7% for Progressive (MGUS vs. complete and pro-
gressive P5 0.001; MGUS vs. Therapy P< 0.0005).
Instead, at the time of this study, values changed as fol-
lows: 16 0% for Control, 66 2.1% for MGUS, 2.16 1.6%
for Complete, 10.46 10.5% for Therapy, 206 7.8% for
New, and 296 22.2% for Progressive (Progressive
vs.Control, MGUS and Complete, and New vs. Control
P< 0.0005 in all cases; MGUS vs. New P5 0.049; Com-
plete vs. New P5 0.005; Therapy vs. Progressive
P5 0.003). Median percentages of PCs (range) detected
by MFC were 1.9% (1.4–2%) for Control, 1.5% (0.4–
2.4%) for MGUS, 0.5% (0.05–0.7%) for Complete, 0.9%
(0.2–13.5%) for Therapy, 8.7% (1.6–18.8%) for New and
3.8% (1.4–35.2%) for Progressive (Complete vs. Control
P5 0.015; Complete vs. New and Progressive
P< 0.0005 in both cases; Therapy vs. New P5 0.036).
Median values (range) of CPCs of total PCs were 79.5%
(64–87.2%) for MGUS, 64.8% (2.8–99.8%) for Therapy,
98.2% (89.5–99.6%) for New and 98.9% (91.3–99.1%) for
Progressive (MGUS vs. New P5 0.008, vs. Progressive
P5 0.023). In Complete and Control 100% of PCs were
polyclonal, while observed median percentage values
Table 3
Clinical Characteristics of Patients
Control Mgus Complete Therapy New Progressive PW comp
CRP>0.3 20% (2) 40% (4) 40% (4) 100% (10) P vs.Ct, M <0.0005
P vs.Cp 0.0007
B2M<3.5 100% (10) 80% (8) 100% (10) 40% (4) 40% (4) P vs.Ct, Cp <0.0005
P vs.M 0.0007
B2M5.5 20% (2) 40% (4) 30% (3) 50% (5) P vs.Ct, Cp 0.032
3.5B2M<5.5 20% (2) 30% (3) 50% (5) P vs.Ct, M, Cp 0.032
HB<8.5 10% (1)
HB>10 100% (10) 100% (10) 100% (10) 70% (7) 80% (8) 50% (5) P vs.Ct, M, Cp 0.032
8.5HB10 30% (3) 10% (1) 50% (5) P vs.Ct, M, Cp 0.032
BUN>25 10% (1) 20% (2) 50% (5) P vs.Ct, M, Cp 0.032
LDH>530 20% (2) 20% (2) 50% (5) P vs.Ct, M, Cp 0.032
S IFE1 100% (10) 100% (10) 100% (10) 100% (10) Ct, Cp vs.all <0.0005
U IFE1 50% (5) 80% (8) 30% (3) 80% (8) N vs.Ct, Cp;
P vs.Ct, Cp
0.0007
S AB FLC ratio
(range 0.31–1.56)
100% (10) 50% (5) 100% (10) 100% (10) M vs.Ct, Cp;
N vs.Ct, Cp;
P vs.Ct, Cp
<0.0005
U AB FLC ratio
(range 2.04–10.37)
80% (8) 10% (1) 40% (4) 50% (5) M vs.Ct, Cp 0.0007
M vs.T 0.005
Results are expressed as percentage of cases, the number of subjects is indicated between brackets. CRP>0.3, C-reactive
protein>0.3 mg/dL; B2M<3.5, b-2-microglobulin<3.5 mg/L; B2M>5.5, b-2-microglobulin>5.5 mg/L; 3.5B2M<5.5,
3.5 mg/Lb-2-microglobulin<5.5 mg/L; HB<8.5, hemoglobin<8.5 g/dL; HB>10, hemoglobin>10 g/dL; 8.5<HB<10,
8.5 g/dL<hemoglobin<10 g/dL; BUN>25, blood urea nitrogen>25 mg/dL; LDH>530, lactate dehydrogenase>530 IU/L; S IFE
1, serum immunofixation positive; U IFE1, urine immunofixation positive, S AB FLC ratio, serum abnormal free light chain ratio;
U AB FLC ratio, urine abnormal free light chain ratio; PW comp, pairwise comparisons; Ct, Control; M, MGUS; Cp, Complete; T,
Therapy; N, New; P, Progressive; all, M, T, N, P. Everytime different pairwise comparison against one group gave the same P value,
groups that were compared with that group are reported separated by a comma. Different pairwise comparisons giving the same P
value are reported separated by a semicolon.
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(range) for PPCs in the other groups were: 20.5% (12.8–
36%) for MGUS, 35.2% (0.2–97.2%) for Therapy, 1.8%
(0.4–10.5%) for New and 1.1% (0.9–8.7%) for Progres-
sive (Control and Complete vs. New and Progressive
P< 0.0005 in all cases; vs. Therapy P5 0.018). In Con-
trol and Complete group, 100% of PCs were perfect dip-
loid (Control and Complete vs. all groups P< 0.0005).
Pseudodiploidy was detected in 20% of MGUS, 10% of
Therapy and 10% of New subjects; instead, hypodiploidy
interested 20% of New patients. HRD was identified in
80% of MGUS, 90% of Therapy, 70% of New, and 100%
of Progressive subjects (Therapy and Progressive vs.
Control and Complete P< 0.0005 in all cases; Control
and Complete vs. MGUS P5 0.0007 and vs. New
P5 0.003). Ranges of expression and median values for
each studied marker on CPCs and PPCs as revealed by
MFC are indicated in TableT4 4. Levels of expression for all
studied markers expressed as MFI ratio are reported in
TableT5 5. The analyzed markers showed different utility
in distinguishing CPCs from PPCs in MGUS, new, ther-
apy and progressive groups, except for CD30 and
CD11a, which never showed differences comparing nor-
mal and neoplastic populations. Results for intragroup
comparisons between CPCs and PPCs in all groups are
indicated in Table 4 (ranges of positive PCs), and in
Table 5 (MFI ratio).
Definition of Normal Immunophenotype
In order to verify if PPCs are immunophenotipically
different from one group to another, we compared the
expression of allF1 markers on PPCs from all groups.
Results are summarized in Figures 1A–1T. PPCs showed
a relevant grade of immunophenotypic heterogeneity
among groups.
Differences among Control and Complete PCs and CPCs
To define how CPCs differ from normal/reactive poly-
clonal PCs found in subjects who do not present signs
of clonal expansion, we compared the expression of all
markers on PCs in Complete and Control groups with
CPCs in MGUS, therapy, new and progressive groups.
Results are summarized in FiguresF2 2A–2V.
Regression Analysis
Multinomial logistic regression analysis was used to
evaluate the relation existing between the expression of
MFC markers (independent variables—considered as
both percentage of positive cells and intensity of expres-
sion measured by MFI ratio) and disease status defined
as the appartenence of each patient to one precise
group (dependent variables). Significant results are sum-
marized in TableT6 6. As reference categories, we chose
Control in analyzing PPCs, and MGUS in studying CPCs,
since MGUS is considered a “preneoplastic” condition.
To test the hypothesis that the significant markers
remained informative also considering common prognos-
tic variables we performed a multivariate regression
analysis; among parameters showing statistical signifi-
cant differences in this study, we selected age, sex,
Durie-Salmon, and ISS stages at diagnosis, ASCT and
HRD, since they were considered highly reliable in
determining prognosis, and allowed us to obtain
the best fitting models. Other variables did not exhibit
explicative power in our model (data not shown).
Results are indicated in Table 6.
DISCUSSION
Since the 90’s, multiparameter immunophenotyping
has been providing relevant information for the diagno-
sis, classification and monitoring of hematological malig-
nancies. Immunophenotypic differences between nor-
mal and neoplastic cells are essential in detecting MRD
in myeloma when there are fewer than 5% of PCs by
morphologic examination and a very small percentage
of PCs to detect clonality by histological examination.
Moreover MFC immunophenotyping may be useful to
define potential prognostic markers and new therapeu-
tic targets. MFC is perceived as highly dependent on
expertise and is regarded to have limited reproducibility
in multicenter studies, mostly because of the lack of
standardization in data interpretation, analysis, and pre-
sentation, and limited evaluation of “new” vs. “classical”
markers (54). Since larger complexity of the multivariate
data analyses of both major and minor cell populations
produced new insights in what is commonly known as
“normal” phenotype (41,42), and MM and MGUS pres-
ent both a strong component of interaction between
neoplastic compartment and surrounding cells, includ-
ing residual PPCs, there is the urgent need to review
phenotypic differences among subjects. In this study,
we propose an accurate approach to investigate the role
of various immunophenotypic markers in discriminating
CPCs from PPCs. We clearly demonstrate that PPCs are
not equal among patients, showing a great variability in
terms of percentage of positive cells and levels of
expression of many antigens. Immunophenotypic differ-
ences in CPCs between MGUS and MM subjects, as well
as changes in the immunophenotype of MM CPCs after
therapy have been described (14,18,24,45); here we
observe that these changes may also interest PPCs. We
focused our attention on some markers involved in cel-
lular adhesion (CD49d, CD11a, and CD58), because a
better understanding of quantitative changes in expres-
sion of adhesion molecules during the stages of the dis-
ease may be fundamental for defining the mechanisms
by which the PCs adhere to or detach from the BM
niches (32). We also analyzed the expression of CD30,
which is present normally on only a very small fraction
of activated lymphocytes. CD30 contributes to negative
selection of T-cells, and could be an attractive target for
therapeutic intervention (55). The classic immunophe-
notype of myeloma PCs has been described as CD38
bright positive (dimmer than normal PCs), CD138 posi-
tive, CD19 negative, CD45 dim to negative and CD56
positive with CD20 and CD117 positivity in selected
cases (10,22,23,40). However recent reports demon-
strate that PPCs could display a CD201CD561CD45-
CD19- phenotype (40–42,56). Precedent studies
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Table 4
Ranges of Expression for the Studied Markers in All Groups
% of positive CPCs % of positive PPCs
P valueMedian Min Max Median Min Max
CD45 Control 98.9 54.7 99
MGUS 89.2 33.8 97.8 99.1 80.3 100 0.005
Complete 92.2 76.5 99.9
Therapy 26.7 11.1 100 97.6 89.1 100 0.011
New 87.2 12.7 99.6 98 0 100
Progressive 89.9 3.7 98.2 100 78.8 100 0.005
CD19 Control 72.4 58.9 87.4
MGUS 0 100 0.002
Complete 50 33.5 86.6
Therapy 0 0 95.3 96.1 13.6 100 0.01
New 2.8 0 95.6 100 0 100
Progressive 0 100 0.002
CD56 Control 4.8 4.7 5.6
MGUS 23 4.8 92.9 27.5 24.1 35.7
Complete 12 0 18.6
Therapy 95.1 0 100 10 0 100 0.05
New 95.8 4.9 100 10 10 35.3 0.023
Progressive 96.2 86.7 98.5 25.3 10 26.4 0.005
CD49d Control 88.4 48.5 100
MGUS 48.7 42.9 88.6 75 74.2 91.9 0.012
Complete 90.8 78.4 100
Therapy 77.9 34.6 100 86.5 59.9 100 0.028
New 74.2 25.3 92.8 73.9 50 100
Progressive 74.6 50.8 100 100 45.7 100
CD30 Control 2 0 3
MGUS 1.1 0 3.8 0 0 5.4
Complete 0 0 24.5
Therapy 0.6 0 68 0 0 12.5
New 3.1 0 9.8 3.4 0 37.3
Progressive 1 0 43.6 0 0 100
CD58 Control 96.1 92.2 100
MGUS 95.9 94.7 96.4 96.9 92.6 99.2
Complete 98.8 83.9 100
Therapy 98.4 57.7 100 90.2 82.7 100
New 94.1 58.2 100 100 96.5 100
Progressive 94.9 59.8 98.2 100 93.5 100 0.005
CD11a Control 96.6 81.5 98.9
MGUS 98.3 97.1 99.3 98.2 89.2 98.8
Complete 83.7 64.7 100
Therapy 96.4 79.6 100 94.9 93.2 100
New 98.6 88.1 100 100 99.7 100
Progressive 98.4 20.4 99.3 97 64.7 98.4
CD117 Control 0
MGUS 85.4 15.2 94.7 0 0.005
Complete 0
Therapy 62.6 0 100 0 0.012
New 21.4 0.3 71.7 0 0.027
Progressive 49.7 26.2 64.9 0 0.005
CD27 Control 98 97.3 100
MGUS 77.7 31.8 100 93.8 83.4 100 0.017
Complete 97.3 94.2 100
Therapy 97.8 0 100 98.2 45.5 100
New 80.9 11.6 100 100 28.3 100
Progressive 55.4 19.5 100 85.3 72.4 96.5 0.012
CD200 Control 1.3 0 7
MGUS 10.6 6.4 42.7 29.7 17.8 65.9 0.035
Complete 15.5 5.1 100
Therapy 53.2 0 88.6 36.3 0 69
New 90.4 0.6 99.2 57.5 28.7 69.2
Progressive 54.1 17.8 83.4 48.7 11.9 60.7
CD20 Control 0
MGUS 2.4 0 9.2 3.3 0 9.1
Complete 4.3 0 26.1
Therapy 8.5 0 72.7 9.6 1.9 64.6
New 0 0 99.6 0 0 2.7
Progressive 0.8 0 4.1 6.6 0 28 0.038
P values referred to intragroup pairwise comparison between CPCs and PPCs are indicated.
Min: minimum; Max: maximum.
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Table 5
Levels of Expression of the Studied Markers in all Groups
MFI Ratio for CPCs MFI ratio for PPCs
Median Min Max Median Min Max P value
CD45 Control 12.1 4.7 16.3
MGUS 5 4.4 10.5 12 8.4 16.4 0.005
Complete 11.1 4.3 24.7
Therapy 5.2 2.8 25.3 8.1 3.8 23.3
New 9.4 3.5 23.5 5.5 1 20.4
Progressive 7.6 4.3 9.3 22.3 11 25 0.005
CD19 Control 11 6.2 15.7
MGUS 1 9.2 8.6 26.1 0.005
Complete 8.7 6.7 16.4
Therapy 1 1 20.1 8.2 5.2 17.1
New 5.3 1 11.6 7.8 1 7.9
Progressive 1 9 6.5 16.1 0.005
CD56 Control 16.5 9.4 17.7
MGUS 13.1 11 19.3 16.8 8.4 47.2
Complete 10.1 1 63.4
Therapy 13.9 1 43.4 10.2 1 31.4
New 13.3 6.1 19.9 16.7 13 27.3 0.027
Progressive 15.8 5.9 18 14.4 11.4 19
CD49d Control 17.4 11.4 18.2
MGUS 14.5 10.1 25.1 19.9 19.1 20.6
Complete 21.1 8.5 43.6
Therapy 11.8 6.1 39.4 15.3 7 43.4
New 11.2 5.5 24.6 13.5 11.1 16.7 0.027
Progressive 8.2 5 12.5 12.8 6.1 35.1 0.035
CD30 Control 6.5 1 8.2
MGUS 9.8 1 10.7 1 1 11.2
Complete 1 1 20.7
Therapy 4.1 1 39.3 1 1 8.6
New 7.3 1 10.9 6 1 12.4
Progressive 4.5 1 8.3 1 1 11.9
CD58 Control 10.2 4 19.5
MGUS 7.6 7.2 16.7 11.8 8.5 14.8
Complete 12.5 6.6 21.1
Therapy 8.9 3.2 30.2 5 3.7 10.5
New 6.8 3.7 34.6 11.7 5.3 29.1
Progressive 10.3 4 12.2 21.8 7.2 35.1 0.005
CD11a Control 3.8 3.2 4.6
MGUS 4.7 4.3 5.5 4.6 3.7 5.8
Complete 4.5 3.3 5.7
Therapy 4.6 3.7 18.1 5 3.1 7.6
New 6.4 3 15.8 8.1 5.1 17.2
Progressive 5.7 2.1 9.2 5.8 4.1 16.5
CD117 Control 1
MGUS 14.4 8.6 14.7 1 0.005
Complete 1
Therapy 7.3 1 23 1 0.012
New 10.7 6.9 16.3 1 0.027
Progressive 6 5 11.6 1 0.005
CD27 Control 38.7 19.9 47.3
MGUS 37.1 7.9 55.8 46.8 24.5 67.8 0.027
Complete 42.2 12 55
Therapy 29.2 1 62.5 51.6 6 104.2
New 11.6 3.6 30.7 21.1 14.5 34.3
Progressive 15.7 6.4 44.1 35.8 21 58.4 0.005
CD200 Control 5.2 1 5.8
MGUS 7.4 6.3 8.2 8.2 7.7 8.3 0.005
Complete 8 1.3 12.6
Therapy 6.8 1 16.8 8.5 1 12.9
New 15.2 7.2 43.4 9.5 9 10
Progressive 7.8 4.8 11.6 8.6 5.9 15.4 0.005
CD20 Control 1
MGUS 16.9 1 44.2 18.8 1 37.6
Complete 6.3 1 36.5
Therapy 12.2 1 42.1 14.4 4.4 46.1
New 1 1 30.6 1 1 16.9
Progressive 16.9 1 32 3.3 1 37.7
P values referred to intragroup pairwise comparison between CPCs and PPCs are indicated. Min, minimum; Max, maximum.
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FIG. 1. A–J: Immunophenotypic differences in PPCs among groups.
Box plots indicate the median and 25th and 75th percentiles. Whiskers
indicate minimum and maximum values. •,*5 outliers. The following
markers exhibited statistically significant differences as regards the
mean percentage of positive cells: CD19 (P<0.0005), CD56
(P<0.0005), CD58 (P50.004), CD11a (P50.01), CD27 (P50.01),
CD200 (P<0.0005), and CD20 (P<0.0005). Also statistically signifi-
cant differences as regard MFI ratios were demonstrated: CD45
(P50.005), CD49d (P50.02), CD58 (P50.011), CD11a
(P<0.0005), CD200 (P50.001), and CD20 (P50.008). P values of
pairwise comparisons are indicated. CD117 is never expressed on PPCs
(data not shown). Levels of expression of CD45 were higher in Progres-
sive than in New and Therapy (A,B). The proportion of CD191 PCs was
lower in Control and Complete than in MGUS and Progressive (C,D).
Median percentage of CD561 PCs was lower in Control versus MGUS
and Progressive, and in Complete versus MGUS (E,F). Levels of expres-
sion of CD49d did not exhibit statistically significant differences at post
hoc analysis (G,H). CD30 did not show variability in expression among
groups (I,J). K–T: Immunophenotypic differences in PPCs among groups.
Box plots indicate the median and 25th and 75th percentiles. Whiskers
indicate minimum and maximum values. •,*5 outliers. P values of pair-
wise comparisons are indicated. CD581 fraction was littler in Therapy
than in New and Progressive; also levels of expression of CD58 were
lower in Therapy than in Progressive (K,L). CD11a1 fraction was larger
in New than in Complete and Progressive; moreover expression of
CD11a was less intense in Control than in Progressive and New (M,N).
the proportion of CD271 PCs was lower in Progressive versus Control
and New (O,P). CD200 was expressed by a less extended percentage of
PCs in Control than in MGUS, New, Progressive and Therapy. MFI ratio
for CD200 was lower in Control than in New, Therapy and Progressive
(Q,R). Median percentage of CD201 PCs was higher in Therapy than in
Control and New. Intensity of expression of CD20 was reduced in PCs of
Control compared with MGUS and Therapy (S,T). [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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FIG. 1. Continued. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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explored immunophenotype of PPCs only in healthy
individuals (42,56), while others reunited in the same
category PPCs of healthy and pathological subjects
(40,45), causing a loss of information related to possible
PPC heterogeneity among different categories of
patients. Analyzing our data, it can be easily noted that
for CD19, CD45, CD27, and CD117 percentages of posi-
tive PPCs reflect the ranges found in precedent studies
(10,22,23,40–42,56,57); CD20 was never expressed on
PCs in Control group, but the range of expression was
broad on PPCs in all other groups. CD200 was
expressed on both normal and neoplastic PCs, as previ-
ously reported (10,58). CD58, CD49d, and CD11a were
never completely absent on PPCs and CPCs, while fre-
quency of CD301 cells was modest in both plasmacellu-
lar compartments in all groups (36). In this study, range
of expression for CD56 (NCAM – Neural Cell Adhesion
Molecule) on PPCs essentially did not depart from those
described elsewhere (40,42,56), except for an outlier
identified in Therapy; however expression close or cor-
responding to 100% for this antigen has occasionally
been reported (32,56). The proportion of CD561 PCs is
constantly described to be low in BM of healthy controls
(10,57), however CD561 PCs may be artificially low in
MFC analysis; acting as an anchor, CD56 could make
PCs more resistant to BM aspiration (42). Focusing on
ranges of expression on PPCs, we observed that CD561
fraction is reduced in Control than in MGUS and Pro-
gressive, and in Complete than in MGUS. This is openly
conflicting with report by Perez-Andres et al. who
described no phenotypic differences for CD56 between
PCs from healthy individuals and PPCs from MGUS sub-
jects (45). This discrepancy may be explained consider-
ing differences in gating strategies, and in the use of
monoclonal antibody clones or fluorochromes between
the cited study and ours. As expected, CD561 CPCs
were more numerous than CD561 PPCs in New, Pro-
gressive, and Therapy; the same type of relation was
maintained in comparisons with Control and Complete
PCs. However, in New, MFIs ratio of PPCs was higher
than that of CPCs; to the best of our knowledge, this
observation has never been described since the intro-
duction of >4 color FC in analysis of MM patients. On
the basis of these results, the expression of CD56 on
PPCs should be further elucidated. CD45 on PPCs is
reported to be expressed heterogeneously
(10,22,23,40,57); in our study it was effective in distin-
guishing PPCs from CPCs in MGUS, Progressive and
Therapy. Expression of CD45 was more intense on PPCs
in Progressive than on PPCs in New and Therapy. Con-
sidering that CD45 expression characterizes proliferating
compartment of normal, reactive and malignant PCs
(13,22), this increased level of expression on Progressive
PPCs may depend on the proliferative BM microenviron-
ment to which all PCs of relapsing subjects are exposed
(24). CD19 is downregulated in PCs maturation, and
CD19-CD561 PCs are believed to represent long lived
terminal stage PPCs (22,40). CD19 was persistently neg-
ative in MGUS and Progressive CPCs. This pattern of
expression has already been described in literature
(22,40), although cases of CD191 MGUS cells have
been reported (22). Clearly, PCs from Control and Com-
plete exhibited a reduced CD191 fraction compared to
PPCs from MGUS and Progressive. Exact mechanism rul-
ing expression in MGUS and Progressive subjects
remains to be explored. CD27 is strongly expressed on
PPCs (9,10,56), but CPCs are reported to be weak or
negative (9,10,57); in our study it showed no differences
in expression comparing CPCs with Control and Com-
plete PCs, contradicting previous data (9), probably
because of discrepancies in methods or the small sample
size. We evidenced that CD271 Progressive PPCs were
less numerous than CD271 PPCs of New and Control.
Since this antigen is involved in apoptosis induced by
CD27–CD70 interactions (59), it would be interesting to
evaluate if other molecules required for programmed
cell death show variable expression in PPCs of Progres-
sive patients. CD117 was never present on normal PCs,
thus being highly effective in distinguishing PPCs from
CPCs (when present on CPCs). The data about CD20 in
PCs of healthy people are conflicting. Reported ranges
vary from a minimum of 0 to maximum of 91%
(10,22,40,56,57), but it is universally accepted that low
CD20 expression is associated to PC maturity. Expres-
sion of CD20 on MM cells is reported to range from 2
to 90% (42). CD20 was a poor antigen in distinguishing
CPCs from PPCs, as previously described (56), except in
Progressive group, in which proportion of CD201 PPCs
was higher than proportion of CD201 CPCs. Expression
of CD20 on CPCs is associated t(11;14) (Refs. 22) and
(23)); since cytogenetic analysis was not performed, we
can not say if t(11;14) is present in Progressive CPCs. In
FIG. 1. Continued. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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FIG. 2. A–L: Results of comparisons among PCs of Control and
Complete and CPCs of MGUS and MM groups. Box plots indicate the
median and 25th and 75th percentiles. Whiskers indicate minimum and
maximum values. •,*5 outliers. Kruskal-wallis test revealed that the fol-
lowing markers showed statistically significant differences as regards the
median percentage of positive cells among groups: CD19 (P<0.0005),
CD56 (P<0.0005), CD117 (P<0.0005), CD200 (P<0.0005), and
CD20 (P50.004). Moreover, statistically significant differences in
intensity of expression emerged among groups for: CD19 (P<0.0005),
CD49d (P<0.0005), CD11a (P50.01), CD117 (P<0.0005), CD200
(P<0.0005), and CD20 (P50.013). P values of pairwise comparisons
are indicated. CD45 did not show variability in expression among groups
(A,B). Median percentage of CD191 PCs in Control was higher than in
MGUS and Progressive; also CD191 fraction of PCs was larger in Com-
plete than in Progressive and MGUS. Levels of expression of CD19 were
higher in Control and Complete than in MGUS and Progressive (C,D).
Proportion of CD561 PCs was lower in Complete than in Progressive,
and in Control than in New, Therapy, and Progressive (E,F). Levels of
expression of CD49d were higher in Complete and Control than in
Progressive (G,H). CD30 did not show variability in expression among
groups (I,J). CD58 did not exhibit any statistical significant difference
(K,L). M–V: Results of comparisons among PCs of Control and Complete
and CPCs of MGUS and MM groups. Box plots indicate the median and
25th and 75th percentiles. Whiskers indicate minimum and maximum
values. •,*5 outliers. P values of pairwise comparisons are indicated.
Intensity of expression of CD11a was lower in Control versus Progressive
and New (M,N). Since PPCs did not express CD117, the difference of
Control and Complete versus all other groups was extremely significant,
except versus New (P50.16). MFI ratio measured for CD1171 cells
was different comparing Control and Complete versus New, MGUS and
Therapy (O,P). CD27 was homogeneous in its expression comparing all
subjects (Q,R). CD2001 fraction is less extended in Control than in
CPCs of New, Therapy and Progressive. Levels of expression of CD200
were higher in New versus Control (S,T). CD201 proportion of PCs was
lower in Control than in Therapy. Intensity of expression of CD20 was
reduced in Control versus MGUS (U,V). [Color figure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
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addition, deeper molecular studies are necessary to
explain the reasons why MFI ratio was reduced in Con-
trol versus MGUS CPCs and PPCs. Therapy PPCs
showed upregulation of CD20 compared with Control
and New PPCs, and also proportion of CD201 CPCs in
Therapy is larger compared with Control PCs. Recently
a study described the transcriptional effects of bortezo-
mib on human myeloma cell lines, showing a
FIG. 2. Continued. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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downregulation of many antigens but no effect on CD20
expression (60). Since in this study 70% of Therapy
patients are currently treated with bortezomib contain-
ing regimens, we hypotize that instead bortezomib
could directly influence expression of CD20 in PCs,
although confirmation with larger groups of patients is
necessary to confirm or reject this hypothesis. CD200 is
a cell surface glycoprotein expressed on normal B-cells
and some T-cell subsets; the expression of CD200
showed to be positive on MM PCs up to 78% (27,61).
CD200 on PPCs has been poorly investigated, and no
clear range of expression has been defined; however
our data match with both papers reporting its absence
(26,56) and those indicating positivity (10,58). Evaluat-
ing its utility in CPC detection, we observed that in
MGUS CD200 was expressed by a higher percentage of
PPCs vs.CPCs. In addition, expression was more intense
on MGUS and Progressive PPCs vs. MGUS and Progres-
sive CPCs. Defining normal phenotype, Control PCs
showed less extended fraction of CD2001 cells vs.
MGUS, New, Progressive, and Therapy PPCs, and a
dimmer expression vs. MM groups. Comparing Control
and Complete PCs with CPCs, once again Control dis-
played a smaller proportion of CD2001 cells vs. Ther-
apy, New, and Progressive. CD2001 positive cells pres-
ent reduced immunogenicity compared with normal
lymphocytes (27) and absence of CD200 correlates with
a better prognosis compared to its presence in MM (12);
on this basis, we would have expected a higher expres-
sion of CD200 in Progressive patients vs. Complete.
Deeper investigation on relapse molecular mechanisms
is necessary before excluding a role of CD200 in pro-
gression of MM. CD11a, the integrin a subunit of LFA-1,
has been reported positive as well as negative in litera-
ture on MGUS and MM samples (28,30). The ranges of
expression on CPCs are really different from one paper
to another, ranging from 0% to 100% in newly diagnosed
or remitting subjects, and from 0 to 80% in relapsing
subjects (32), or reported as <30% for CD451 cells and
10% for CD45- cells (34). On PPCs, it has been
reported to range from 20 to 100% (32). In our study,
CD11a1 proportion of CPCs showed no differences
compared to CD11a1 Control and Complete PCs, while
levels of expression of CD11a were higher on both
CPCs and PPCs of New and Progressive vs.Control PCs;
these results diverges from a precedent report demon-
strating a downregulation of CD11a in patients in
chronic phase, but in that case results might be compro-
mised by the inclusion of newly diagnosed and remitting
subjects in the same group (32). Examining PPCs,
CD11a1 fraction was expanded in New vs.Complete
and Progressive. CD58, a CD2 receptor, was previously
indicated as present occasionally on PPCs and never
expressed on MGUS CPCs (28); in our study, it is posi-
tive in a fraction of PPCs and MGUS CPCs close to
100%. This discrepancy may be attributed to differences
regarding methods (immunofluorescence microscopy vs.
MFC) and choose of control samples. CD58 was more
expressed on PPCs than on CPCs in Progressive (consid-
ering both proportion of CD581 cells and MFI ratio).
Therapy PPCs showed downregulation of CD58 vs.New
and Progressive. These data suggest that CD58 should
be considered in further studies to assess its ability in
predicting response to therapy or progression of disease
when evaluated on non neoplastic population. We did
not notice any difference comparing Control and Com-
plete with CPCs, contrary to previous data (28).
CD49d, the integrin a subunit of VLA-4, has been found
strongly expressed by MM PCs (36), while mean per-
centage of positive normal PCs has been reported 75%
FIG. 2. Continued. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Table 6
Results of Multinomial Logistic Regression Analysis
Univariate Multivariate
Independent variable PCs Exp (B) 95% CI P value Exp (B) 95% CI P value
MFI ratio for CD45 PPCs 1.03 0.88–1.20 0.722a
1.06 0.91–1.23 0.472b
0.93 0.79–1.11 0.438c
0.81 0.63–1.03 0.086d
1.25 1.06–1.50 0.011e 1.23 1.04–1.46 0.015
Percentage of CD191 cells CPCs 111.1 111.1–111.1 Naf
111.6 108.9–114.4 <0.0005g 144.9 139.8–150.3 <0.0005
1 1.0h
MFI ratio for CD19 CPCs 67.6 67.6–67.6 Naf
64.6 54.9–76.0 <0.0005g 61.5 49.6–76.2 <0.0005
1 1.0h
PPCs 1.04 0.87–1.22 0.670a
0.93 0.77–1.14 0.502b
0.88 0.71–1.11 0.298c
0.57 0.36–0.89 0.016d 0.53 0.26–1.08 0.082
0.95 0.78–1.15 0.606e
Percentage of CD561 cells PPCs 1.51 1.16–1.96 0.002a 1.71 1.19–2.42 0.003
1.33 1.03–1.71 0.029b 1.53 1.08–2.16 0.016
1.48 1.14–1.92 0.004c 1.66 1.17–2.36 0.005
1.43 1.10–1.87 0.008d 1.61 1.13–2.29 0.009
1.46 1.13–1.90 0.004e 1.54 1.07–2.21 0.019
MFI ratio for CD49d CPCs 0.98 0.86–1.09 0.684f
0.94 0.82–1.08 0.394g
0.68 0.51–0.92 0.012h 0.62 0.38–0.99 0.046
MFI ratio for CD58 PPCs 0.99 0.86–1.13 0.882a
1.03 0.90–1.16 0.695b
0.64 0.45–0.93 0.019c 0.55 0.37–0.84 0.025
1.06 0.93–1.22 0.373d
1.13 0.99–1.27 0.057e
MFI ratio for CD11a PPCs 4.29 1.10–16.7 0.036a 3.19 0.63–15.9 0.158
4.01 1.03–15.6 0.045b 2.41 0.50–11.6 0.273
5.51 1.38–21.9 0.016c 4.82 1.20–19.3 0.027
10.8 2.64–44.6 0.001d 13.7 1.95–95.9 0.008
10.1 2.48–41.5 0.001e 14.1 2.74–72.4 0.02
Percentage of CD1171 cells CPCs 0.99 0.95–1.02 0.448f
0.93 0.88–0.97 0.003g 0.94 0.89–0.99 0.023
0.97 0.93–1.01 0.095h
MFI ratio for CD117 CPCs 0.84 0.66–1.06 0.143f
0.95 0.77–1.17 0.625g
0.71 0.53–0.94 0.017h 0.65 0.42–1.01 0.054
Percentage of CD2001 cells CPCs 1.04 0.99–1.07 0.057f
1.05 1.01–1.09 0.008g 1.06 1.01–1.11 0.012
1.04 1.01–1.08 0.032h 1.04 0.99–1.09 0.084
PPCs 1.31 1.07–1.61 0.009a 1.36 0.95–1.95 0.089
1.3 1.07–1.60 0.010b 1.36 0.95–1.94 0.089
1.3 1.06–1.60 0.011c 1.36 0.95–1.94 0.091
1.34 1.09–1.64 0.005b 1.38 0.97–1.97 0.073
1.32 1.08–1.62 0.007e 1.63 0.95–2.80 0.075
MFI ratio for CD200 CPCs 1.01 0.78–1.30 0.957f
1.31 1.02–1.68 0.034g 1.38 1.02–1.88 0.038
1.06 0.83–1.35 0.656h
PPCs 1.56 1.12–2.16 0.008a 2.02 1.19–3.41 0.008
1.45 1.06–1.98 0.020b 1.35 0.88–2.07 0.172
1.49 1.08–2.07 0.016c 1.73 1.11–2.70 0.016
1.8 1.12–2.65 0.003d 2.59 1.25–5.35 0.01
1.86 1.30–2.65 0.001e 2.23 1.28–3.89 0.005
aControl vs. MGUS.
bControl vs. Complete.
cControl vs. Therapy.
dControl vs. New.
eControl vs. Progressive.
fMGUS vs. Therapy.
gMGUS vs. New.
hMGUS vs. Progressive.
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(29). In our study, CD49d showed a more pronounced
expression on PPCs than on CPCs in all groups (fraction
of positive cells for MGUS and Therapy, MFI ratio for
New and Progressive), thus beeing highly useful to
refine CPC population when combined with common
used marker. Intensity of expression was higher in Con-
trol and Complete PCs vs.Progressive CPCs, so it would
be intriguing to verify if this marker has a role in drug
resistance during progression of disease. As we could
not identify a univocous pattern of expression of these
three adhesion involved markers, regulatory pathways
determining their expression should be explored individ-
ually. Continuous efforts are made in MM to improve
the sensitivity of immunophenotypic detection of PCs.
On the basis our results, we suppose that in future pan-
els of markers specific for the clinical question could be
used, with the addition of appropriate MFC markers to
the backbone ones (CD38, CD138, CD19, CD45, and
CD56); the evaluation of the disease should involve
PPCs, in order to follow progressions and explore the
opportunity to obtain predictive information. CD49d
should be universally present to distinguish CPCs from
PPCs; for MGUS diagnosis and monitoring, CD20 and
CD200 are suggested to be added; newly diagnosed
patients may benefit the addition of CD11a; assessment
of disease progression or response to therapy would be
more accurate by the introduction of CD27, CD58,
CD11a, and CD20. The prognostic value of specific anti-
genic profiles (CD19, CD117, and CD27) has already
been assessed; positive staining for CD19 and absence
of CD117 detected on clonal PCs were associated with
significantly shorter progression free survival and OS
(overall survival) rates of MM patients. Moreover, OS
rates were higher in patients with CD271 MM than in
those who were CD27- (57,62,63). The absence (or
presence) of CD200 expression in MM cells is predictive
for event-free survival independently of ISS stage or b-2-
microglobulin serum levels (12). For CD45 and CD56
results from precedent studies are contradictory, and
require further investigation (24,57). No information is
available about the prognostic value of the other
markers used in this study, or about their role in predict
response to therapy and disease progression, and their
utility in distinguishing disease stages without consider-
ing other clinical variables. To see if a correlation exists
between the expression of each marker and the attribu-
tion of the patients to their own groups, we performed
a multinomial logistic regression analysis; results surpris-
ingly revealed that the most abundant associations
regarded PPCs, with percentage of cells positive for
CD200 and CD56, and levels of expression of CD45,
CD19, CD58, CD11a, and CD200 showing statistical sig-
nificance. In addition, fractions of CPCs positive for
CD19 and CD200, and intensity of expression of CD19,
CD49d, CD117, and CD200 on CPCs were significant.
But when the model was elaborated again including sig-
nificant prognostic variables (37,38,43), percentage of
CD2001 PPCs and levels of expression of CD117 on
CPCs and CD19 on PPCs loosed their association, as did
levels of expression of CD11a comparing Control with
Complete and MGUS PPCs, MFI ratio for CD200 analyz-
ing Control vs. Complete PCs, and percentage of
CD2001 CPCs comparing MGUS vs. Progressive. This is
not surprising, since other works have already demon-
strated relations between variation in expression of MFC
markers and BM features (64). Our data comfort the
hypothesis that, in assessing the predictive/prognostic
values of MFC markers and their utility in following dis-
ease steps, immunological-biochemical-hematological
profile must not be ignored since it is the “mirror” of
the altered BM microenvironment influencing/being
influenced by PC phenotype (37,64). However CD19
and CD49d on CPCs, and CD45, CD58 and CD56 on
PPCs maintained their explicative power, so they are
good candidates for further studies, especially CD19,
which was considered a “reliable” antigen in a report
exploring relationship between MFC and histological
results (56). In conclusion, we have provided a feasible
start point to put in order the ranges of expression on
PPCs in healthy and myeloma subjects; we propose a
new approach based on analysis of PPCs to monitor the
stages of the disease. However, the study size is small,
and we could not provide a prospective cohort to exam-
ine fluctuations in expression of MFC markers related to
time and disease progression, just as we could not
define a threshold of expression for each marker that
allows to clearly attribute each subject to his own
group. Confirmation by larger and deeper independent
studies, as well as by the elaboration of an adequate
Cox proportional-hazard model, is indicated.
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Supplementary Information
Table SI 1. Antibodies used in this study
Antigen Manufacturer Catalogue # Clone Fluorochrome Isotype
CD11a Beckman Coulter IM0860U 25.3 FITC IgG1 Mouse
CD19 Beckman Coulter A86355 J3-119 Pacific Blue IgG1 Mouse
CD20 Beckman Coulter IM1455U B9E9 (HRC20) FITC IgG2a Mouse
CD27 Beckman Coulter B12701 1A4CD27 APC-Alexa Fluor 750 IgG1 Mouse
CD30 BD Pharmingen™ 555829 BerH8 FITC IgG1 Mouse
CD34 Beckman Coulter A89309 581 APC-Alexa Fluor 750 IgG1 Mouse
CD38 Beckman Coulter A70205 LS198-4-3 PC5.5 IgG1 Mouse
CD45 Beckman Coulter A96416 J.33 Krome Orange IgG1 Mouse
CD49d BD Pharmingen™ 555503 9F10 PE IgG1 Mouse
CD56 Beckman Coulter IM2073U N901 (NKH-1) PE IgG1 Mouse
CD56 Beckman Coulter A51078 N901 (NKH-1) PC7 IgG1 Mouse
CD58 Beckman Coulter IM1430 AICD58 PE IgG2a Mouse
CD117 Beckman Coulter IM3698 104D2D1 PC7 IgG1 Mouse
CD138 Beckman Coulter A87787 B-A38 APC IgG1 Mouse
CD200 BD Pharmingen™ 561762 MRC OX-104 PE IgG1 Mouse
κ CHAIN Beckman Coulter A64828 Polyclonal FITC F(ab’)2 Rabbit
λ CHAIN Beckman Coulter A64827 Polyclonal PE F(ab’)2 Rabbit
Catalogue #, catalogue number; FITC, Fluorescein Isothiocyanate; PC5.5, R-Phycoerythrin-Cyanin 5.5; PE, R-Phycoerythrin; PC7, R-Phycoerythrin-Cyanin 7; APC,
Allophycocyanin. Beckman Coulter (Miami, FL, USA), BD Pharmingen™(San Jose, CA, USA).
Table SI 2. Characteristics of the instrument.
Model (manufacturer) Lasers Detector Filters
Navios (Beckman Coulter) Blue Solid State Diode: 488nm,
22mW laser output
Forward Scatter: 488/10
10 colors, 3 lasers (5+3+2
configuration)
Blue Laser: 525/40, 575/30, 620/30, 675/20,
695/30, 755LP
Red Solid State Diode: 638nm,
25mW laser output Red Laser: 660/20, 725/20, 755 LP
Violet Solid State Diode: 405nm,
40mW laser output Violet Laser: 450/50, 550/40
Beckman Coulter (Miami, FL, USA)
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Abstract
Background: Multiparameter flow cytometry (MFC) characterization of aberrant plasma cells
(aPC), in contrast to normal PC (nPC), is a useful tool to support diagnosis, prognostication and
monitoring of plasma cell dyscrasias (PCD). The current list of MFC markers for PCD evaluation
remains limited and has not augmented significantly in the past years. Moreover, therapies based
on antibodies against CD38 or CD138 compromise the utility of these molecules for PCD follow-
up. Revision of literature resulted in a list of candidates to be evaluated as alternatives to classical
markers: CD54, CD229, and CD319. Methods: we characterized the expression of CD229, CD54
and CD319 on PC and their utility in MFC evaluation of PCD, analyzing bone marrow (BM)
samples from healthy controls (HC) and PCD patients, and PB specimens from HC. Results: In
both BM and PB PC, the expression of the studied markers is better preserved compared to CD138.
Setting the initial gate in the bivariate dot plots CD319, CD229 or CD54 vs CD38 allowed the
inclusion of 100% PC. When the markers were combined with SSC and CD138, CD229 allowed
the best identification of PC; in turn CD54 and CD319 showed to be of limited utility, because the
expression pattern of myeloid populations may overlap with that of PC. Conclusions: We have
demonstrated that CD229 could be considered as a marker able to bypass the need of CD38 in PC
detection and needs to be tested in clinical practice, so more efforts should be performed in this
sense in future.
Introduction
Neoplastic plasma cell disorders (PCD) are a heterogeneous group of disorders characterized by the
presence and accumulation of abnormal clonal plasma cells (aPC), typically associated with
presence of monoclonal immunoglobulin (M protein) in the serum and urine. The clinical spectrum
of PCD ranges from asymptomatic (monoclonal gammopathy of uncertain significance -MGUS-
and smoldering multiple myeloma –SMM-) to symptomatic multiple myeloma -MM- and plasma
cell leukemia (PCL) [1]. Multiparameter flow cytometry (MFC) quantification and characterization
of aPC (in contrast to normal/reactive polyclonal PC -nPC-) is recognized as a very useful tool to
support diagnosis, prognostication and monitoring of PCD [2-6]. The current list of useful MFC
markers for PCD evaluation remains limited if compared to other clonal hematopoietic disorders
and it has not augmented significantly in the past years [6-9]. More recently, important many
efforts have been made in order to standardize methodological grounds and clearly define the PC
staining profiles obtained with the use of distinct antibody (Ab) reagents combinations [8],
nonetheless, evaluation of new candidate markers with potentially contribution for PC
identification and nPC vs cPC discrimination has not been deeply explored [9]. Moreover, the
introduction of new therapeutic approaches targeting classical PC surface molecules with
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monoclonal antibodies (i.e. therapies directed against CD38 or CD138) [10, 11], impacts the utility
of these molecules for MM after-treatment follow-up. Similarly, sample “age” may also
compromise the detection of markers like CD138 [12, 13]. The need of new useful markers for PC
detection and discrimination of aPC from nPC becomes evident.
Critical revision of the literature resulted in a list of candidate markers to be evaluated: CD54,
CD229, and CD319. Their expression profile on malignant PC has been previously described [14-
16]; all of them have also been investigated as therapeutic targets for multiple myeloma
patients[14, 15, 17]. CD229 and CD319 from SLAM family are self-ligand receptors [18], while
immunoglobulin superfamily adhesion molecule CD54 has LFA-1 and Mac-1 as physiological
ligands [19]. Despite their presence on MM plasma cell surface documented in different
experimental settings, none of the cited markers has been evaluated, to the best of our knowledge,
as alternative candidate to antigens currently used in MFC detection and evaluation of PC [20]. We
characterized the expression of these markers in PC and evaluated their utility as
complementary/alternative candidates for MFC evaluation of PCD.
Materials and Methods
As indicated in Table 1, a total of 51 patients -48 BM and 3 extraosseous (extramedullary)
plasmacytoma (EMP) samples- and 10 healthy controls - 5 BM, and 5 peripheral blood (PB)
samples- were included in this study, after obtaining informed consent according to local ethical
committees, in line with Declaration of Helsinki Protocol. BM and EMP samples were obtained
from 32 male and 24 female patients [median age 59 (23-79) years]. In turn, PB samples were
obtained from 3 male and 2 female healthy donors [median age 41 (37-49) years].
All samples in this study were stained following EuroFlow sample processing Standard Operative
Procedures (SOPs) for diagnostic EuroFlow panels [21], both for surface membrane and
intracellular markers, with combinations of antibodies indicated in Supplementary Table I. Clones
and manufacturer of antibodies are also indicated in Supplementary Table I. We acquired a median
of 270,025 events (range 34,151 - 1,629,575) in FACSCanto II instrument (BD Biosciences, San
Jose, CA, USA), set-up and monitored according to EuroFlow SOP [21]. Data were analyzed
using Infinicyt software v1.8 (Cytognos, Salamanca, Spain). Expression levels are reported as
median fluorescence intensity values (MFI; arbitrary units). Statistical analysis was performed with
IBM SPSS Software v22 (IBM Corp., Armonk, NY, USA). Mann–Whitney U test was used to
assess significance of comparisons between two groups. Kruskal Wallis test with multiple
comparisons was used to assess the statistical significance (p<0.05) of the differences observed in
multiple group comparisons.
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Results
In BM samples both CD319 and CD54 were positive virtually on total PC (tPC). CD229 also
exhibited 100% positivity on tPC in all but 3 cases (1 MM sample at diagnosis and 2 MRD), on
which we observed an heterogeneous expression (from negative to positive) pattern. Negative
population included a median 10.9% (range 1.7-26.8) of aPC, and 4.1% (range 4.1-16.3) of nPC.
Of note, these samples were stained using a different fluorochrome (i.e. PerCP-Cy5.5), less
sensitive compared with APC. In addition, they followed a different sample processing, using a
cytoplasmic staining protocol for light chain evaluation. In EMP samples, the studied markers
always exhibited 100% positivity. In PB, only CD229 maintained full positivity on tPC. CD319
and CD54 showed a heterogeneous expression ranging from negative to positive in 1/5 (14.3% of
negative PC) and 4/5 cases -median 17.4% (14.3%-33.3%) of negative PC-, respectively (Table 1).
In both BM and PB, we noticed that the expression of the studied markers is better preserved on PC
compared to CD138 expression (Table 1).
In order to detect PC with the evaluated markers, the most useful combinations as initial gate
involved the use of CD319, CD229 or CD54 vs CD38. In all analyzed samples, these combinations
allowed the inclusion of 100% of both aPC and nPC present as identified with the initial gate set in
the classical bivariate dot plot CD38 vs CD138 (Figure 1A-B). Other combinations involving
tested markers (i.e vs SSC or CD138) were less powerful, because of a lower intensity observed for
them in PB PCs or because the expression pattern in other myeloid populations may overlap with
that of the PC, lowering their resolution power, as happened for CD54 and CD319 (Figure 2A-B).
More specifically, comparing the efficiency of these markers combined with SSC and CD138 in
PC detection, CD229 allowed the best identification of PC in all cases in comparison with the other
two markers. In fact, CD229 was expressed simultaneously also on plasmacytoid dendritic cells
(pDC) (Figure 2C), whose overlap with PC detection may be overcome using light scatter
parameters and other markers present in the panel. In turn CD54 and CD319 vs SSC and/or
CD138 showed to be of limited utility to detect PC, especially in case in cases exhibiting
compromised expression of CD138. This could be easily explained considering that CD54 was
usually positive on monocytes with an heterogeneous pattern (from -/+) (Figure 2A), and both BM
and PB staining profiles for CD319 caused PC to be poorly resolved from monocytes (Figure 2B).
A different CD319 conjugate, using a brighter fluorochrome (PE; panel 2), did not qualitatively
impact the expression pattern described (data not shown). To verify if these three markers can be
used for a better separation of aPC from nPC, we compared levels of expression measured on both
nPC and aPC for all the samples groups. At the same time, we chose to look for variation in
expression of CD54, CD319 and CD54 on PC detected in PB vs BM of healthy and PCD subjects.
Results are summarized in Figure 3A-C; in brief in HC, CD54, CD319 and CD229 were
significantly downregulated on PB PC compared with BM PC. Additionally, levels of expression
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of CD54 and CD319 were lower on aPC vs nPC, although these differences did not reach statistical
significance. No difference between aPC/nPC was reported for CD229 in samples stained with
panel 1 (Figure 3C) or panel 3 (data not shown). Since CD229 emerged as a reliable and promising
identification marker, we explored its expression on other cell types in BM and PB samples from
HC (Figure 4A-D). Our objective was to identify other cell types contaminating initial gates in
bivariate dot plots CD229vsSSC and CD229vsCD138. In PB and BM, CD229 was expressed on
NK-, B- and T-cells (no significant differences among T or B subsets to be shown). Both in PB and
BM samples, plasmacytoid dendritic cells (pDC) were always positive whereas neutrophils,
eosinophils, monocytes (including CD16+ monocytes/macrophages) showed persistently
negativity. BM B-cells showed a spread pattern of expression, ranging from mostly negative
CD34+CD19+ cells, to immature and naïve B-cells showing an extended amount of positive cells
(figure 4A).
Discussion
MFC enumeration of BM PC and particularly the discrimination between normal and abnormal
plasma cell populations in patients with PCD proven to be of utility in diagnosis, prognostic
stratification and monitoring of MRD levels [2-6]. Accuracy in PC identification and
discrimination of normal/reactive vs abnormal/clonal is therefore crucial. No specific PC markers
have been described so far, perhaps with the exception of CD138, so MFC detection of PC heavily
relies on a relative small number of antigens for which PC show a characteristic expression pattern,
just like CD38, CD138, CD19 and CD45 [20], a gating strategy and an experienced operator.
Despite this, limited progress have been made in recognition of new markers for PC identification
in the last 10 years. More recently, therapeutic antibodies against a variety of PC surface
molecules, such as CD38 and CD138, have been developed and are currently under evaluation for
treatment of MM patients [10, 11, 22]; the effect of these treatments on MFC staining has not been
deeply explored yet, but based on experienced accumulated in similar situations, usage of these
therapies will compromise utility of these monoclonal antibodies used as therapeutic agents, thus
limiting their value for MFC PC detection, and probably limiting the resolution power of current
combination [22, 23]. Moreover, not all antigens used in PC identification and characterization are
stable: it is the case of CD138, whose time- and apoptosis-dependent loss from PC surface has been
previously demonstrated [12-13]. Although the importance of introduction of new markers in MFC
panels has already been assessed [9], many efforts have been made in the identification of
therapeutic targets or prognostic combinations but not in detection markers for aPC vs nPC
discrimination. Here we discuss the utility of CD229, CD319 and CD54 as potential complements
or alternatives to the mostly used markers in identification of PC. The SLAM family member
CD229 (Ly9) was reported to be expressed by T-, NK-, B- cells, macrophages and dendritic cells,
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in addition to primary MM cells [14-15, 18]. It could be strongly over-expressed and
phosphorylated in MM cell lines; as reported by Atanackovic et al. [14] anti-CD229 monoclonal
antibody produce complement- and cell-mediated lysis of myeloma cells, suggesting that CD229
may be of potential utility for the treatment of MM [14]. CD319 (CS1), another member of the
SLAM family, is also expressed by normal NK- and B-cells, by activated CD4 and CD8 T- cells,
and by DC [15, 18]. CD319 (CS1) is reported to be expressed at high levels on myeloma cells
independently of the molecular background [15], which has lead Frigyesi et al.[24] to propose
CD319 to be a more robust marker than CD138 for PC isolation [24]. At present clinical trials are
ongoing which use the anti-CS1 mAb elotuzumab [15]. CD54 (ICAM-1) is a well chasracterized
adhesion molecule which is broadly expressed on leukocytes and endothelial cells [19]. As regards
PC, CD54 has been shown to be expressed on PC from healthy volunteers, MM cell lines, and
primary MM PC [16]. Veitonmäki et al. [17] reported that an antibody specifically targeting
ICAM-1, BI-505, exhibited a pronounced antimyeloma activity , and this antitumour function was
macrophage-dependent [17]. In our experimental setting, expression of CD229 was persistently
positive in both BM and PB PC. We observed that full positivity is preserved in BM samples
stained with APC conjugated antibodies, while in 1.1% of samples analyzed with the use of PerCP-
Cy5.5 conjugate in combination with fixation/permeabilization technique some PC showed no
staining. It’s reasonably to speculate that in these samples, the use of a less sensitive fluorochrome
compared with APC and fixation/permeabilization protocol might have played a role. In BM and
PB samples, CD229 was also expressed by B cells, T cells subsets and pDC, while it was absent on
monocytes, eosinophils and all stages of maturing neutrophils. This is in line with previous
observations which also showed expression of CD229 on tissue macrophages [14-15, 18]. In turn,
CD319 and CD54 were uniformly positive only on BM PC. Although none of the three markers
showed clear expression differences between normal and clonal PC populations, they show value in
identifying PC. When used together with CD38 in the initial gate, the three markers allow an
efficient identification of PC, which can be precisely defined using further backgating in other
classic recommended representations, like CD38 vs SSC, CD38 vs CD45 and FSC vs SSC [20]; so
the combinations CD229 vs CD38, CD319 vs CD38 and CD54 vs CD38 may be considered as
potent alternatives to CD38 vs CD138, especially in cases particularly prone to loss or
downregulation of CD138, and patients undergoing to anti-CD138 therapy. Moreover we explored
the potential values of CD229, CD54 and CD319 as alternatives to CD38 in initial PC MFC
separation from all other BM and PB cell types. With CD54/CD319 vs SSC or CD138 gate, the
major problem is detection of all aPC, since on aPC levels of expression are lower compared to
nPC, despite the fact that no significant difference has been observed, and partially overlapping
with other non-PC populations. On the contrary, although initial PC identification gate is
contaminated with lymphocytes and pDC, exclusion of non-PC events was more efficient using
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CD229 vs SSC and CD138 when compared with CD54/CD319 vs SSC and CD54/CD319 vs
CD138.
We propose that CD229 should be considered in further studies on patients undergoing to anti-
CD38 therapies in order to assess its possible use in clinical settings.
In conclusion, we have provided the basis for the investigation of these new markers in the MFC
identification of PC, especially in those cases in which CD138 or CD38 expression are lost or
compromised. We have also demonstrated that CD229 could be considered as a surface antigen
able to bypass the need of CD38 in PC detection and needs to be tested in clinical practice, so more
efforts should be performed in this sense in future.
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Table 1. Different percentage of PC positive for identification markers
HC PB1 HC BM1 PCD BM1 NI-NHL BM2 PCD BM2 EMP3 BM3
MARKER nPC nPC nPC aPC nPC nPC aPC aPC nPC aPC
CD38 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
(100%-100%) (100%-100%) (100%-100%) (100%-100%) (100%-100%) (100%-100%) (100%-100%) (100%-100%) (100%-100%) (100%-100%)
CD138 29% 98% 97% 99% 99% 100% 100% 100% 95% 100%
(24%-69%) (97%-100%) (50%-100%) (79%-100%) (97%-100%) (91%-100%) (96%-100%) (100%-100%) (47%-100%) (76%-100%)
CD54 85% 100% 100% 100%
(67%-100%) (100%-100%) (100%-100%) (100%-100%)
CD319 100% 100% 100% 100% 100% 100% 100%
(86%-100%) (100%-100%) (100%-100%) (100%-100%) (100%-100%) (100%-100%) (100%-100%)
CD229 100% 100% 100% 100% 100% 100% 100%
(100%-100%) (100%-100%) (100%-100%) (100%-100%) (100%-100%) (84%-100%) (73%-100%)
15HC BM, 1SMM, 2MGUS, 2MM, 5HC PB samples; 21 MM, 3 MRD, 1 MGUS, 2 NI-NHL samples; 33 MM, 1 MGUS, 1 PCL, 3 EMP, 1 SBP, 30 MRD. HC, healthy control; PB, peripheral blood; HC, BM, bone
marrow; NI-NHL, not infiltrated BM from non-Hodgkin lymphoma patients; PCD, plasma cell dyscrasia; EMP, extraosseous (extramedullary) plasmocytoma; nPC, normal plasma cells; aPC aberrant plasma cells.
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Supplementary Table I. Clones and manufacturer of antibodies used in
this report.
MARKER FLUOROCHROME CLONE MANUFACTURER
CD3 PerCP-Cy5.5 SK7 BD
CD4 PacB RPA-T4 BD
CD8 FITC RPA-T8 BD
CD10 APC H7 HI10a BD
CD11b FITC Bear1 BC
CD13 PE L138 BD
CD14 APC H7 MϕP9 BD
CD16 PE-Cy7 3G8 BD
CD19 APC H7 SJ25C1 BC
PE-Cy7 J3-119 Immunostep
CD27 BV421 M-T271 BD
CD20 PacB 2H7 BioLegend
CD34 PerCP-Cy5.5 8G12 BD
APC-A750 581 BC
CD38 FITC LD38 Cytognos
PacB HIT2 ExBio
V450 HB7 BD
APC H7 HB7 BD
CD45 PacB T29/33 Dako
APC ML2 Cytognos
BV510 HI30 BD
CD54 PE 3E2 BD
CD56 PE C5.9 Cytognos
APC-Cy7 HCD56 BioLegend
PE-Cy7 B159 BD
CD64 FITC 32.2 BC
CD117 APC-A750 104D2D1 BC
CD123 BV421 9F5 BD
CD138 PerCP-Cy5.5 MI15 BD
PacO B-A38 ExBio
V450 MI15 BD
CD229 APC HLy9.25 BioLegend
PerCP-Cy5.5 HLy9.25 eBioscience
CD300e PE UP-H2 Immunostep
CD319 FITC 162 ABD SEROTEC
PE 162 eBioscience
anti-κ APC Polyclonal Dako 
anti-λ APC H7 1-155-2 BD
HLA DR PerCP-Cy5.5 L243 BD
PacB L243 BioLegend
IgM FITC Polyclonal Dako
IgD PerCP-Cy5.5 IA6-2 BioLegend
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TCRγδ PE-Cy7 11F2 BD
Panel FITC PE PerCP-Cy5.5 PE-Cy7 APC APC-H7 PacB PacO
1a CD319 CD54 CD138 CD19 CD229 CD56* CD38# CD45§
2b CD319 CD56 CD45 CD19 CD38 CD138
3c CD38 CD56 CD229 CD19 Cytκ Cytλ CD45 CD138
4d
CD8 CD56 CD3 CD19-TCRγδ CD229 CD14 CD4-CD20 CD45
§
5d sIgM CD56 sIgD CD19 CD229 CD38 CD27$ CD45
§
6e CD64 IREM2 HLA DR CD16 CD229 CD14-CD34& CD123$ CD45
§
7f CD11b CD13 CD34 CD16 CD229 CD117& HLADR CD45
§
8f CD38 CD56 CD34 CD19 CD229 CD10 CD138# CD45§
PerCP-Cy5.5, Peridinin-chlorophyll protein-Cyanine5.5; PacB, Pacific Blue; FITC, Fluorescein isothiocyanate; APC, Allophycocyanin; H7,
Hilite7; PE, R-phycoerythrin; Cy7, Cyanine7; APC-A750, APC-Alexa Fluor 750; BV421, Brilliant Violet 421; BV510, Brilliant Violet 510;
PacO, Pacific Orange. *APC-Cy7 conjugate; &APC-Alexa Fluor 750 conjugate; #V450 conjugate; $BV421 conjugate; §BV510, Brilliant Violet 510
conjugate.
BD, BD BIoscience (San Jose, CA, Usa); BC, Beckman Coulter (Brea, CA, USA); Immunostep (Salamanca, Spain); Biolegend (London, UK);
Cytognos SL, (Salamanca, Spain); Dako (Glostrup, Denmark); ExBio (Vestec, Czech Republic); eBioscience (San Diego, CA, USA); ABD
Serotec (Kidlington, UK).
a5HC BM, 1SMM, 2MGUS, 2MM, 5HC PB samples; b1 MM, 3 MRD, 1 MGUS, 2 NI-NHL samples; c3 MM, 1 MGUS, 1 PCL, 3 EMP, 1 SBP,
30 MRD; d5HC PB; e5 HC PB and 5 HC BM; f5 HC BM.
HC, healthy controls; BM, bone marrow; PB, peripheral blood; N°, number of samples; SMM, smoldering myeloma; MGUS, monoclonal
gammopathy of uncertain significance; MM, multiple myeloma; NI-NHL, not infiltrated BM from non-Hodgkin lymphoma patients; MRD,
minimal residual disease evaluation cases; EMP, extraosseous (extramedullary) plasmocytoma; SBP, solitary bone plasmocytoma; PCL, plasma
cell leukemia.  Cyt, cytoplasmic; κ, kappa light chain; λ, lambda light chain.  
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Figures
Figure 1. Illustrating examples of the expression of CD54, CD319 and CD229 on BM populations of PC
from 2 multiple myeloma patient samples stained with the first panel. The three markers evaluated are plotted
against SSC, CD38 and CD138, respectively. Panel A and B correspond each to a different patient. Please
note that a lower intensity of aPC occurs for CD54 in panel A and for CD319 in both panel A and B. In turn,
PC from panel A show higher CD138 expression than in the case displayed in panel B. As may be seen,
CD54 and CD319 showed a poor discrimination of PC from the other BM cells vs CD229, mostly because of
the stronger staining index on PC vs the myeloid BM cell compartment. PC, plasma cells; SSC, side scatter;
nPC, normal plasma cells; aPC, aberrant plasma cells.
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Figure 2. Levels of expression (Fluorescence intensity – arbitrary units) of CD54 (A), CD319 (B) and
CD229 (C) in PB and BM plasma cells from healthy controls and PCD patients compared with monocytes
and plasmacytoid dendritic cells (pDC). This graphical representation was obtained performing a merge
operation of 5 PCD BM, 5 HC BM and 5 HC PB, respectively. All samples were stained with panel 1. Box
plots indicate the median and 25th and 75th percentiles. Whiskers indicate minimum and maximum values.
nPC, normal plasma cells; aPC, aberrant plasma cells.
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Figure 3. Levels of expression of CD54 (A), CD319 (B) and CD229 (C) in PB and BM plasma cells from
healthy controls and PCD patients (antibody panel 1). Results are expressed as median fluorescence intensity
(arbitrary units scaled from 0 to 262 144). Box plots indicate the median and 25th and 75th percentiles.
Whiskers indicate minimum and maximum values. Black dots and stars indicate the outliers. PC, plasma
cells; PB, peripheral blood; BM, bone marrow; nPC, normal plasma cells; aPC, aberrant plasma cells; PCD,
plasma cell disorders.
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Figure 4. Illustrating bivariate dot plots showing CD229 expression on non PC PB and BM cell populations
vs PC. Panels A, BM B-cells are displayed (green dots). Panel B shows expression of CD229 on PB B-
(green dots), T- (red dots) and NK-cells (cyan dots) vs PC (blue dots). In turn, expression of CD229 major
myeloid populations present in PB and BM - on monocytes (yellow dots) and CD16+ monocytes (brown
dots), neutrophils (fuchsia dots), plasmacytoid dendritic cells (pale blue dots) and eosinophils (pink dots)- vs
PC (blue dots) is depicted in panels C and D, respectively. Of note, CD229 expression among the PB and
BM myeloid cell compartment was restricted to plasmacytoid dendritic cells. No positivity was observed on
macrophages, monocytes, neutrophils and eosinophils.
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ABSTRACT
Multiple myeloma (MM) is an incurable disease principally of older patients, caused by the
proliferation of clonal plasma cells (cPCs) in bone marrow (BM). Expansion of cPCs causes not
only several systemic disorders, but also numerical and functional defects in many immune subsets.
Although T lymphocytes and dendritic cells are the most studied lineages, also an impairment of B
cell compartment is involved in onset and progression of the disease. We studied the distribution of
naïve/transitional (IgD+CD27−), memory unswitched (IgD+CD27+), memory switched 
(IgD−CD27+) and double negative (DN) (IgD−CD27−) B lymphocytes in BM of control subjects 
and different categories of responding and relapsing patients. We observed an increased percentage
of IgD−CD27+ in healthy controls compared with responding patients. The IgD+CD27− 
subpopulation was significantly larger in stringent complete responders than in other treated
patients; the situation was inverted for DN B cells, with treated patients exhibiting an expanded
compartment compared to deep responders. None of the studied B cell subsets exhibited clonal
restriction. We have provided a feasible start point to explore the importance of B cells in the
immunosuppressive MM BM microenvironment. Moreover, we propose a possible role of
naïve/transitional and DN B cells as predictive markers in treated patients.
KEYWORDS:
Multiple Myeloma
MGUS
B cells
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Introduction
Multiple myeloma (MM) is a disease principally of older patients, with a median age at diagnosis
of 65–70 years. It is caused by proliferation of clonal plasma cells (PCs) in the bone marrow,
associated with the presence of monoclonal immunoglobulin (Ig) in the serum or urine and signs of
multi-organ impairment that can include anemia, lytic bone lesions, immunodeficiency, and
reduced renal function [1-2]. MM is preceded by an asymptomatic premalignant stage, called
monoclonal gammopathy of undetermined significance (MGUS), which progresses to myeloma at
a rate of 1% per year [1]. Progression to MM is characterized by a series of complex genetic events
in MM clones and changes in the bone marrow microenvironment, including (and most notably)
suppression of the immune response [1-2]. Immunosenescence is defined as the insurgence of
deterioration in the normal functions of the immune system in parallel with physiologic ageing [3].
It progresses with changes in adaptive immune functions mediated by T and B cells in the elderly,
directly influenced by environmental and genetic factors, and by the antigenic pressure to which
individuals are exposed during their entire life [3-4]. This phenomenon causes an impaired ability
to respond to vaccines and new infectious agents, and an increased susceptibility to infectious
diseases, autoimmunity and cancer [3-5]. The immune system of the elderly has been extensively
studied, for the most part involving the T cell branch, however B cell compartment is also defective
in the elderly: humoral immune response differs both in the quality (in terms of production of high
affinity responses) and levels of the produced antibodies, and the number of circulating B cells is
reduced in the aged [3-4]. The  reduction in percentage of naïve B lymphocytes (IgD+CD27−) and 
the increase in percentage of a “double negative” (DN, IgD−CD27−) memory B cell population 
have been demonstrated in peripheral blood of the elderly [6]. This DN population seems to be an
“exhausted” memory population [4, 6-8]. As reported by Bulati et al. [7], it has been hypothesized
that DN B cells are involved in the inflammatory environment related to aging and that they might
be a by-product of systemic inflammation or directly involved in the immune response [7]. In
multiple myeloma field, most of the studies have focused on T regulatory and dendritic cells (DCs),
in order to explain the immunosuppressive BM microenvironment that allows the expansion of the
neoplastic clone [9-10]. To the best of our knowledge, nobody has already explored the distribution
of B cell subsets and presence of DN B cells in bone marrow of MM subjects in different stages of
the disease. In this paper we report the distribution of B cell subsets in BM of healthy subjects, and
MGUS, newly diagnosed, responding and relapsing MM patients. Moreover we also evaluate the
possible presence of clonal restriction in these lymphocytic subpopulations.
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Materials and Methods
Patients and BM samples
Control specimens consisted of 9 BM samples from patients who were suspected to have a
haematological disease and revealed to be non onco-hematological subjects (group Control). These
patients have no history of MM, MGUS or lymphoid/myeloid neoplasm. BM samples of 44
patients with MM and 10 patients with MGUS submitted to our laboratory for routine analysis
were evaluated by multiparameter flow cytometry (MFC). For every patient clinical chemical and
immunological profiles, as well as reference intervals were provided by the U.O. Patologia Clinica
– Laboratorio Analisi Cliniche of ARNAS Civico, Palermo (Italy). Disease stage was defined
according to Durie-Salmon and ISS staging criteria [11-12]. Response to therapy was defined
according to Bird et al. [13]. Of MM samples, 12 were obtained at presentation (group New), 8
from patients with progressive disease (group Progressive), 14 from patients in partial remission (4
Very Good Partial Response, 6 Partial Response and 4 Stable Disease - group Therapy) and 10
from patients who achieved stringent CR (group Complete). MGUS patients were considered as a
separate group (MGUS group). Clinical data and history for MGUS and MM cases were provided
by U.O. Oncoematologia of ARNAS Civico, Palermo (Italy). Informed consent procedures and
forms were proposed to and approved by the ARNAS Civico Medical Ethics Committee. Written
informed consent was given by all subjects in line with the Declaration of Helsinki Protocol. BM
samples were collected in EDTA tubes and processed within one hour since collection.
Multiparameter Flow Cytometry
Details about the instrument and antibodies used in this study are summarized in Supplementary
Table 1 and Supplementary Table 2 respectively. Specimens were fragmented with a sterile syringe
and filtered using a 80μm filter; nucleated cells were enumerated using UniCel® DxH™ 800
Coulter® Cellular Analysis System (Beckman Coulter, Miami, FL, USA) and brought to a final
concentration of 106cells/100μl with PBS w/o calcium and magnesium (EuroClone, Milan, Italy). 
Combinations of antibodies used to stain surface and intracellular markers were: Tube 1,
CytκFITC/CytλPE/CD38PC5.5/CD56PC7/CD138APC/CD27APC-AlexaFluor 750/CD19PB/CD45KO; Tube 2,
CD27FITC#/IgDPE#/CD38PC5.5/CD10PC7#/CD138APC/CD34APC-AlexaFluor 750/CD19PB/CD45KO; Tube 3
CytκFITC/CytλPE/CD10ECD/CD38PC5.5/IgDPC7#/CD138APC/CD34APC-AlexaFluor 700/CD27APC-AlexaFluor
750/CD19PB/CD45KO (Cyt, Cytoplasmic; FITC, Fluorescein Isothiocyanate; PE, Phycoerythrin;
ECD, Phycoerythrin-Texas Red; PC5.5, Phycoerythrin-Cyanin 5.5; PC7, Phycoerythrin-Cyanin 7;
APC, Allophycocyanin; PB, Pacific Blue; KO, Krome Orange). All antibodies were purchased
from Beckman Coulter (Miami, FL, USA), except those with # which were purchased from BD
Biosciences (San Jose, CA, USA). For staining of surface markers, 100μl of each sample were 
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incubated with the appropriate combinations of antibodies for 15 minutes in the dark. Erythrocytes
were lysed adding 1 ml of VersaLyse™ Lysing Solution (Beckman Coulter, Miami, FL, USA) and
incubating tubes for 20 minutes in the dark. For intracellular staining of kappa and lambda light
chains, 50μl of sample were washed 5 times with 2 ml of PBS w/o calcium and magnesium 
(EuroClone, Milan, Italy), and processed with PerFix-nc (Beckman Coulter, Miami, FL, USA)
following instructions. Samples were all acquired with Navios™ Flow Cytometry System
(Beckman Coulter, Miami, FL, USA), data were collected with Navios v1.0 Software (Beckman
Coulter, Miami, FL, USA) and then analyzed with Kaluza® Flow Cytometry Analysis Software
v1.3 (Beckman Coulter, Miami, FL, USA). Daily testing of instrument was performed as indicated:
standardization of light scatter, fluorescence intensity and optimal hydrodynamic focusing
instrument settings were verified using Flow-Set Pro Fluorospheres (Beckman Coulter, Miami, FL,
USA); compensation matrix for each combination of antibodies was tested with CYTO-COMP™
Cell Kit (Beckman Coulter, Miami, FL, USA); optical alignment and fluidics were checked using
Flow-Check Pro Fluorospheres (Beckman Coulter, Miami, FL, USA). In order to identify PCs, a
combination of CD38, CD138 and CD45 together with side scatter properties was used; the first
gate was set on CD38vsCD138 as suggested [14]. Distinction between normal/reactive (nPC) and
clonal plasma (cPC) cell compartments was performed basing on their most frequent aberrant
phenotypes (as regards CD38, CD19, CD27, CD56 and CD45); results were confirmed by the
presence of clonal restriction in population showing the abnormal phenotype, and the absence of
restriction in normal PCs [14-15]. The κ:λ ratio was defined as abnormal if < 0.5 or > 3 [16]. In 
tube 2 and 3, B cells were selected setting the first gate on CD19+ cells in CD19vsSSC plot; then
precursors and immature B cells were excluded from the analysis in order to restrict the study to
naïve/transitional B cells, and switched/unswitched and DN memory B cells (in this paper called on
the whole “total B cells”), according to the recognized phenotypes: IgD+CD27-CD10±
transitional, IgD+CD27-CD10-CD38-/+dim naïve, CD27+ switched/unswitched memory and
CD27-IgD- double negative B cells [17]. All these subsets together are indicated in this paper as
total B cells. A minimum of 200 events in the plasma cell gate and 20000 events in the mature
lymphocyte gate in CD45vsSSC plot were collected for each tube; in order to reach this result, a
total of 200,000-2,000,000 events were acquired. For each marker, an internal negative population
present within the sample was used to define gates and sample fluorescence background [18-19].
Data were measured as percentage of cells presenting the antigen (percentage of positive cells).
Statistical analysis
Continuous non normal data are expressed as median values (range); normal variables are indicated
as mean±SD. Baseline differences between groups were assessed by the chi-square test or Fisher’s
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exact test, as needed for categorical variables (with Bonferroni correction for multiple
comparisons). The univariate analysis of variance (ANOVA) was performed for parametric
variables, and post hoc analysis with the Tukey’s test was used to determine pairwise differences.
The Kruskal-Wallis statistic test with pairwise comparisons was performed for nonparametric
analysis. Data were analyzed by IBM SPSS Software 22 version (IBM Corp., Armonk, NY, USA).
All p-values were two-sided and p<0.05 was considered statistically significant.
Results
Characteristics of patients
As indicated in Table 1, no significant difference were found about sex distribution, comorbidities
and ISS staging at diagnosis, but Durie-Salmon stage IIIA was met more frequently in Complete
than in New patients. Autologous stem cell transplantation was performed in 6 Complete, 6
Therapy and 2 Progressive patients at least 12 months before the time of this study (not
significant). Data inherent administered therapeutic regimens were recorded, but no statistically
significant differences were detected. Bortezomib+Dexamethasone based treatment was
administered to 5 Therapy and 3 Progressive patients. Thalidomide as monotherapy or in
combination with bortezomib was given to 1 Complete and 3 Therapy patients respectively.
Lenalidomide or lenalidomide containing regimens were the treatment of choice in 4 Complete and
1 Progressive subjects, while Pomalidomide was administered to 1 Progressive patient. In addition
5 Complete, 6 Therapy and 2 Progressive patients underwent suspension of therapy before for at
least 15 days before this study was performed. Median percentage of total PCs was significantly
higher in New [8.64% (0.26-60.50)] and Progressive [6.47% (0.75-30.29)] compared with Control
[0.15% (0.01-1.71), vs New p<0.0005, vs Progressive p=0.001], Complete [0.38% (0.03-2.49), vs
New p=0.006, vs Progressive p=0.013] and Therapy [0.48% (0.12-14.40), vs New p=0.012 and vs
Progressive p=0.029], while no difference was observed with MGUS [1.39% (0.36-2.40)]. All PCs
in Control and Complete were polyclonal, while nPCs were 19.12% (5.24-82.52) in MGUS,
29.24% (0.14-96.12) in Therapy, 1.18% (0.05-66.12) in New (vs Therapy p=0.016), and 1.60%
(0.25-12.88) in Progressive. As regards cPCs, New showed the highest median percentage [98.83%
(33.88-99.95)] compared with Therapy [70.76% (3.88-99.86), p=0.016], but no difference emerged
with MGUS [80.88% (17.48-94.76)] and Progressive [98.40% (87.12-99.75)].
Distribution of B cells among groups and relationship with the neoplastic clone.
Median percentage of total B cells, naïve/transitional (IgD+CD27−), memory unswitched 
(IgD+CD27+), memory switched (IgD−CD27+) and DN (IgD−CD27−) B lymphocytes and their 
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relative ranges are reported in Figure 1 (A-E). Progressive showed the most modest percentage of
total B cells compared with Control and New. Control patients showed the highest percentage of
memory unswitched cells compared with Complete and Therapy. Naïve/Transitional subpopulation
was significantly larger in Complete than in Therapy patients; the situation was inverted for DN B
cells, with Therapy exhibiting an expanded compartment compared to Complete. Moreover DN B
cells were more numerous in Therapy than in Control subjects. No differences were observed for
memory switched B cells among groups. In order to explore at a preliminary level a possible
relationship with the neoplastic clone, a total of 10 patients (4 New, 2 MGUS, 3 Therapy and 1
Progressive) underwent clonal restriction assessment in B cell subsets. No patient exhibited signs
of clonal restriction in all studied subpopulations (Figure 1F).
Discussion
In MM patients, the expansion of cPCs in the BM, and consequential alteration of the homeostatic
equilibrium of both staminal hematopoietic/stromal and immune compartments, causes not only
end organ damage (including increased calcium levels, defective renal function, anemia, and lytic
bone lesions), but also defects in immune system; many of these alterations are reported to be
associated with poor disease outcome [1, 9, 10]. Tumour-rejection immune responses of the earlier
phases of the disease are gradually evaded, and ultimately are defeated in their battle to stop and
eradicate the proliferating plasma cell clones [10]. Multiple myeloma is associated with cellular
and humoral immune deficiencies. Patients frequently exhibit poor response to vaccination against
influenza, Streptococcus pneumoniae and Haemophilus influenzae type B [10]. Many (soluble or
not) mediators of the bone marrow immunological microenvironment (including TGF-β, IL-10, 
VEGF, MUC-1 and PGE2) and direct contact are involved in supporting the malignant
microenvironment and in suppression of the host anti-myeloma immune response [1, 10]. A
number of efforts have been made to characterize disfunctions in T cell compartment, and the role
of DCs and myeloid derived suppressor cells (MDSCs) [9-10, 20-21], but B cell subsets were less
considered in describing reciprocal interactions between the immune system and myeloma cells.
We found that healthy subjects showed a higher percentage of IgD+CD27+ memory cells
compared to the two responding groups (Therapy and Complete), but no difference with pre-
malignant group MGUS, and with newly diagnosed and relapsing subjects. IgD+IgM−CD27+ 
memory cells appear to play an important role in respiratory mucosal defense via, while
CD27+IgM+IgD+ memory cells are involved in the response to encapsulated bacteria [22]. With
this in mind, we find our result is an intriguing piece of data in order to discover alternative
explanations to increased susceptibility to infections in MM patients [23-24], especially in the look
for mechanisms which could be specific of responding patients. In fact, it has already been
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documented that anti-myeloma therapies exhibit a profound impact on immune system and
emergence of infections [24], but a well dissected relationship among effect of therapy-bone
marrow B cell subset distribution-depth of response is still missing. Naïve/Transitional cells were
expanded in Complete vs Therapy patients, showing a possible reorganization of B cell
compartment in patients who do not show signs of BM neoplastic clone. It has been demonstrated
in the elderly that naïve/transitional B cells are highly activated to produce both IL10 and TNF-α 
under physiological (anti-CD40 and IL4) stimulation [8], so it will be interesting to evaluate the
impact of this subpopulation in modulating inflammation and its resolution in MM patients. As
regards DN B cells, observed results revealed an increase of this subset in Therapy patients
compared to Complete. This is not surprising, since DN B cells are described as exhausted B
lymphocyte population filling the immunological space especially in elderly subjects. DN B cells
have also been reported to be expanded in subjects affected by SLE and challenged with RSV [4],
and presented a very low ability to be activated by different stimuli, including physiological ones
[4, 6-8]. Moreover these cells exhibit a tissue trafficking phenotype and can be stimulated to
secrete granzyme B, which plays a critical role in cancer immunosurvellance [7]. Differences in
percentage of DN B cells may reflect the ability of various categories of patients to reach stringent
complete response in the MM scenario. Considering our results, monitoring fluctuations in
percentage of Naïve/Transitional and DN B cells may reveal a useful tool in predicting the type of
response, although larger cohort studies are necessary to identify a cut-off value in order to
distinguish stringent complete from other responding patients. Some works have reported
conflicting results about clonotypic CD19+CD34+ or CD19+CD34- B cell, which are considered
as a non plasmacellular proliferating MM compartment [25-28]. So we decided to investigate at a
preliminary level if B cell subsets showed clonal restriction. We observed that none of the studied
patients showed signs of expansion of a clonal B population. Although this result must be
confirmed by deeper molecular studies, it is really interesting since it would exclude the presence
of a relation between B cells and neoplastic clone, opening the space to new speculations about the
interplay involving MM PCs and pre and post switch B lymphocytes. In conclusion we have
provided an elegant start point to explore the role of B cells in the immunosuppressive MM BM
microenvironment. Moreover, we propose a possible role of Naïve/Transitional and DN B cells as
predictive markers in treated patients.
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Tables
Table 1. Characteristics of subjects included in this study
Control MGUS Complete Therapy New Progressive p Value
N° of cases 9 10 10 14 12 8
Age (years) 62±
5.36
70.8±
7.3
61.1±
8.85
61.21±
9.01
63.58±
12.8
75.13±
10.06
Cp vs P 0.029
T vs P 0.017
Sex Male 6 7 3 11 6 6 NSFemale 3 3 7 3 6 2
Subtype
IgA λ 1 1 1 3 2   
IgA κ 4 3   
IgG λ 3 2 4 6   
IgG κ 6 3 3 2 3   
λ 3 2 1   
κ 1   
D-S Stage
IA 2 4 4 NS
IIA 1 5 5 2 NS
IIB 3 2 2 NS
IIIA 6 2 Cp vs N 0.018
IIIB 1 4 1 NS
ISS Stage
I 3 3 3 NS
II 7 4 5 5 NS
III 7 4 3 NS
Comorbidities
CRI 2 1 1 2 NS
Diabetes 2 1 2 2 4 NS
Hypothyroidism 1 2 NS
Obesity 1 2 1 NS
Cardiopathy 1 1 3 NS
HCV 1 1 NS
HBV 2 2 NS
Thalassemia Trait 1 NS
Pregress Cancer 2 2 1 NS
D-S Stage, Durie Salmon stage; CRI, chronic renal insufficiency; HCV, HCV related chronic hepatitis; HBV, HBV related chronic hepatitis;
Pregress Cancer, patients who reported non hematological types of cancer in the last 10 years; Ct, Control; M, MGUS; Cp, Complete; T,
Therapy; N, New; P, Progressive. NS, not significant.
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Figure
Fig. 1 Results of statistical analysis performed on total B cells and the various subpopulations. Box plots and
p values are reported. Moreover, an exemplificative dot plot displaying clonal restriction analysis is depicted.
Box plots indicate the median and 25th and 75th percentiles. Whiskers indicate minimum and maximum
values. •,* = outliers. To follow, median percentage [range] of total B cells and different subsets. a) Total B
cells: Control 1.79% [0.37-2.26], MGUS 1.23% [0.01-3.30], Complete 0.79% [0.29-2.63], Therapy 0.66%
[0.10-10.17], New 1.20% [0.34-4.26], Progressive 0.29% [0.06-0.69]. b) IgD+CD27- (naïve/transitional) B
cells: Control 7.01% [2.31-58.47], MGUS 31.88% [4.78-71.46], Complete 61.33% [1.10-81.53], Therapy
10.79% [0.12-69.51], New 26.25% [3.85-54.01], Progressive 36.89% [5.45-55.90].c) IgD+CD27+ (memory
unswitched) B cells: Control 17.22% [1.34-40.29], MGUS 2.48% [0.39-20.41], Complete 1.61% [0.19-
80
7.79], Therapy 1.14% [0.08-8.16], New 2.51% [0.31-17.63], Progressive 1.11% [0.99-23.42]. d) IgD-CD27+
(memory switched) B cells: Control 48.63% [0.94-81.31], MGUS 7.31% [1.92-31.01], Complete 10.08%
[1.30-28.28], Therapy 11.23% [0.21-33.18], New 29.52% [0.31-63.94], Progressive 11.23% [3.60-32.67]. e)
IgD-CD27- (Double Negative) B cells: Control 20.87% [3.27-39.25], MGUS 32.02% [8.90-88.64],
Complete 31.95% [8.53-70.41], Therapy 71.49% [28.42-97.18], New 39.57% [11.17-87.77], Progressive
42.64% [26.39-71.21]. f) Exemplificative bivariate dot plots of a MGUS case showing clonal restriction in
cPCs and absence of restriction in all B cell subsets (bivariate dot plots were elaborated with Infinicyt flow
cytometry software version 1.3, Cytognos SL, Salamanca, Spain)
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Supplementary Table 1. Characteristics of the instrument.
Model (manufacturer) Lasers Detector Filters
Navios (Beckman Coulter) Blue Solid State Diode:
488nm, 22mW laser output
Forward Scatter: 488/10
10 colors, 3 lasers (5+3+2
configuration)
Blue Laser: 525/40, 575/30, 620/30,
675/20, 695/30, 755LP
Red Solid State Diode:
638nm, 25mW laser output Red Laser: 660/20, 725/20, 755 LP
Violet Solid State Diode:
405nm, 40mW laser output Violet Laser: 450/50, 550/40
Beckman Coulter (Miami, FL, USA)
Supplementary Table 2. Antibodies used in this study
Antigen Manufacturer Catalogue # Clone Fluorochrome Isotype
CD10 BD Biosciences 341112 HI10a PC7 IgG1 Mouse
CD10 Beckman Coulter IM3608U ALB1 ECD IgG1 Mouse
CD19 Beckman Coulter A86355 J3-119 PB IgG1 Mouse
CD27 Beckman Coulter B12701 1A4CD27 APCA750 IgG1 Mouse
CD27 BD Biosciences 340424 L128 FITC IgG1 Mouse
CD34 Beckman Coulter A89309 581 APCA750 IgG1 Mouse
CD34 Beckman Coulter A86354 581 APCA700 IgG1 Mouse
CD38 Beckman Coulter A70205 LS198-4-3 PC5.5 IgG1 Mouse
CD45 Beckman Coulter A96416 J.33 KO IgG1 Mouse
CD56 Beckman Coulter A51078 N901 (NKH-1) PC7 IgG1 Mouse
CD138 Beckman Coulter A87787 B-A38 APC IgG1 Mouse
IgD BD Biosciences 562024 IA6-2 PE IgG2a Mouse
IgD BD Biosciences 561314 IA6-2 PC7 IgG2a Mouse
κ CHAIN Beckman Coulter A64828 Polyclonal FITC F(ab’)2 Rabbit
λ CHAIN Beckman Coulter A64827 Polyclonal PE F(ab’)2 Rabbit
PC7, R-Phycoerythrin-Cyanin 7; ECD, Phycoerythrin-Texas Red; PB, Pacific Blue; APCA750, Allophycocyanin-Alexa Fluor 750; APCA700,
Allophycocyanin-Alexa Fluor 700; FITC, Fluorescein Isothiocyanate; PC5.5, R-Phycoerythrin-Cyanin 5.5; KO, Krome Orange; APC,
Allophycocyanin; PE, R-Phycoerythrin. Beckman Coulter (Miami, FL, USA), BD Biosciences (San Jose, CA, USA)
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Abstract
Background: Multiple myeloma (MM) remains an incurable disease, mostly because of the strong
interplay between clonal plasma cells (cPCs) and bone marrow (BM) microenvironment.
Multiparameter flow cytometry (MFC) allows the simultaneous study of the cPC
immunophenotype and alterations involving other cells in BM, but rarely these data are interpreted
as connected. One exception to this habit are previous studies about relationship between cPC
CD117 positivity and hematopoietic progenitor cell (HPC) distribution in newly diagnosed
patients. Methods: we verified distribution of BM CD34+ HPCs in healthy controls and MGUS
patients and various categories of responding/relapsing MM subjects divided accordingly to CD117
positivity. Results: Our data completely agree with precedent reports as regards untreated patients.
In group with progression of disease, CD117- patients exhibited a lower CD34+CD19-
/CD34+CD19- ratio vs CD117+ subjects. Among CD117- cases, CD34+CD19-/CD34+CD19+
ratio was higher in CD117- New vs CD117- Therapy subjects, as reflected by recorded HPC
distribution. No differences emerged comparing CD117+ patients. Conclusions: We demonstrate
that response to treatment take place through different forms in CD117- and CD117+ patients,
implying a distinct regulation in distribution of CD34+ HPC subsets, which becomes evident
comparing untreated and treated CD117- patients, but it is impossible to detect in CD117+ cases.
Introduction
Multiple myeloma (MM) is an incurable neoplastic plasma cell disorder characterized by
proliferation of clonal/aberrant malignant plasma cells (cPCs) in bone marrow, and presence of
monoclonal immunoglobulin (M-protein) in serum and/or urine, associated with immunodeficiency
and related organ or tissue impairment [1-3]. With a median age at diagnosis of 65-70 years [3],
MM is a disease affecting mainly elderly subjects. MM is usually preceded by a premalignant PC
proliferative stage characterized by asymptomatic M-protein production known as monoclonal
gammopathy of undetermined significance (MGUS), which is associated with a rate of progression
to multiple myeloma of 1% per year [4-5]. In MM long term control of the disease is still an
elusive objective. Despite the dramatic progress in therapeutic approaches, due to the introduction
of novel categories of drugs (proteasome inhibitors and immunomodulatory agents) [6], no curative
strategies has currently been defined. Even patients undergoing to high-dose therapy (HDT) and
autologus stem cell transplantation (ASCT) may experiment relapse [7-8]. This phenomenon is
strictly related to the strong interplay between cPCs and bone marrow (BM) microenvironment.
Residual cPCs may escape therapeutic effects in bone marrow niches, which has been proved to be
able to enhance cPC survival and modulate immune system ability to eradicate malignant cells [3,
9-10]. It has now become clear that, in order to cure MM, targeting BM players other than MM
cells, and identifying the role of BM microenvironment in response to therapeutic intervention are
necessary. In diagnosis and managing of MM and its preceding condition MGUS, multiparameter
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flow cytometry (MFC) plays a key role, allowing enumeration of cPCs, and definition of their
immunophenotypic characteristics in comparison with normal/reactive polyclonal plasma cells
(nPCs) . Although MFC makes possible the simultaneous study of the immunophenotype of cPCs
and the alterations involving other cellular components in the BM microenvironment in the same
samples (belonging or not to the immune system) [11-16], rarely these data are used to make a
connection between immunophenotypic PC characteristics and modifications in BM populations.
This is true also in studies regarding hematopoietic progenitor cell subset (HPC) distribution, which
has been shown to be impaired in MM patients at diagnosis and relapse [14-16]. CD117 may be
aberrantly expressed on cPCs in MM and MGUS [11-12, 17-18], and positivity for this marker
confers a favourable prognosis [12, 17-18]. Schmidt-Hieber et al. [19] hypothesized that CD117
might act as an anchor, favouring the adhesion of cPCs to myeloid precursor-associated BM
niches mediated by c-kit ligand expressed by stromal cells [19]; no clear mechanism has been
defined yet. Previous studies demonstrated that in newly diagnosed patients, no differences were
observed as regards CD34+CD38-/dim fraction, but the ratio between BM CD34+CD19- and
CD34+CD19+ progenitors was increased in CD117- patients compared to CD117+ subjects [19].
Despite the recent augmented interest in hematopoietic progenitor cell (HPC) distribution,
depending on the debate about the utility of quantification of HPC fractions in grafts [20-22],
observations about CD34+CD19- and CD34+CD19+ subsets and related ratio (CD34+CD19-
/CD34+CD19+ ratio) were not examined in responding and relapsing patients, and currently it is
not known whether differences in CD34+CD19- and CD34+CD19+ (Pro-B) cell fractions are
preserved in treated patients or may influence depth of response. In this study, we verified
distribution of BM CD34+ HPCs in healthy controls and MGUS patients and various categories of
responding/relapsing MM subjects. Moreover, after dividing patients accordingly to CD117
expression or absence on PC surface, we compared differences in percentage of CD34+CD19-
HPCs and Pro-B cells to detect a potential mechanism related to influence of CD117 positivity on
prognosis.
Materials and Methods
Patients and BM samples
Control specimens consisted of 9 BM samples from patients who were suspected to have a
haematological disease and revealed to be non onco-hematological subjects (group Control). These
patients have no history of MM, MGUS or lymphoid/myeloid neoplasm. BM samples of 44
patients with MM and 10 patients with MGUS submitted to our laboratory for routine analysis
were evaluated by MFC. For every patient clinical chemical and immunological profiles, as well as
reference intervals were provided by the U.O. Patologia Clinica – Laboratorio Analisi Cliniche of
ARNAS Civico, Palermo (Italy). Disease stage was defined according to Durie-Salmon and ISS
staging criteria [23-24]. Response to therapy was defined conforming to Bird et al. [25]. Of MM
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samples, 12 were obtained at presentation (group New), 8 from patients with progressive disease
(group Progressive), 14 from patients in non complete remission (4 Very Good Partial Response, 6
Partial Response and 4 Stable Disease - group Therapy) and 10 from patients who achieved
stringent CR (group Complete). MGUS patients were considered as a separate group (group
MGUS). Clinical data and history for MGUS and MM cases were provided by U.O.
Oncoematologia of ARNAS Civico, Palermo (Italy). Informed consent procedures and forms were
proposed to and approved by the ARNAS Civico Medical Ethics Committee. Written informed
consent was given by all subjects in line with the Declaration of Helsinki Protocol. BM samples
were collected in EDTA tubes and processed in one hour since collection.
Multiparameter Flow Cytometry
Details about antibodies and instrument are indicated in Table 1 and Table 2 respectively.
Specimens were fragmented with a sterile syringe and filtered using a 80μm filter; nucleated cells 
were enumerated using UniCel® DxH™ 800 Coulter® Cellular Analysis System (Beckman Coulter,
Miami, FL, USA) and brought to a final concentration of 106cells/100μl with PBS w/o calcium and 
magnesium (EuroClone, Milan, Italy). To stain surface and intracellular markers, the following
combinations of antibodies were used: CytκFITC/CytλPE/CD38PC5.5/CD56PC7/CD138APC/CD27APC-
AlexaFluor 750/CD19PB/CD45KO; Tube 2, CD27FITC#/CD56PE/CD38PC5.5/CD117PC7/CD138APC/CD34APC-
AlexaFluor 750/CD19PB/CD45KO (Cyt, Cytoplasmic; FITC, Fluorescein Isothiocyanate; PE, R-
Phycoerythrin; PC5.5, R-Phycoerythrin-Cyanin 5.5; PC7, R-Phycoerythrin-Cyanin 7; APC,
Allophycocyanin; PB, Pacific Blue; KO, Krome Orange). All antibodies were purchased from
Beckman Coulter (Miami, FL, USA), except for # which was purchased from BD Biosciences (San
Jose, CA, USA). For staining of surface markers, 100μl of each sample were incubated with the 
opportune combinations of antibodies for 15 minutes in the dark. Erythrocytes were lysed adding 1
ml of VersaLyse™ Lysing Solution and incubating tubes for 20 minutes in the dark. For
intracellular staining of kappa and lambda light chains, 50μl of sample were washed 5 times with 2 
ml of PBS w/o calcium and magnesium (EuroClone, Milan, Italy), and processed with PerFix-nc
(Beckman Coulter, Miami, FL, USA) following instructions. Samples were all acquired with
Navios™ Flow Cytometry System, data were collected with Navios v1.0 Software (Beckman
Coulter, Miami, FL) and then analyzed with Kaluza® Flow Cytometry Analysis Software v1.3
(Beckman Coulter, Miami, FL, USA). Daily testing of instrument was performed as indicated:
standardization of light scatter, fluorescence intensity and optimal hydrodynamic focusing
instrument settings were verified using Flow-Set Pro Fluorospheres (Beckman Coulter, Miami, FL,
USA); compensation matrix for each combination of antibodies was tested with CYTO-COMP™
Cell Kit (Beckman Coulter, Miami, FL, USA); optical alignment and fluidics were checked using
Flow-Check Pro Fluorospheres (Beckman Coulter, Miami, FL, USA). In order to identify PCs, a
combination of CD38, CD138 and CD45 together with side scatter properties was used; the first
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gate was set on CD38 vs CD138 as suggested [11]. Distinction between normal/reactive and clonal
plasma cell compartments was performed basing on their most frequent aberrant phenotypes
(CD38, CD19, CD27, CD117, CD56 and CD45); results were confirmed by the presence of clonal
restriction in population showing the abnormal phenotype, and the absence of restriction in normal
PCs [11, 26]. The κ:λ ratio was defined as abnormal if < 0.5 or > 3 [27]. A minimum of 200 events 
in the plasma cell gate and 500 events in CD34+ gate on the CD34/SSC plot were collected for
each tube; in order to reach this result, a total of 200,000-2,000,000 events were acquired. For each
marker, an internal negative population present within the sample was used to define gates and
sample fluorescence background [28-29]. Results for total PCs and CD34+ HPCs are expressed as
percentage of cells out of total acquired cells. Data for cPCs and nPCs are indicated as percentage
of cells out of total PCs. Fractions of CD34+CD19- and CD34+CD19+ cells are reported as
percentage of cells out of total CD34+ HPCs. CD34+CD19+ Pro B cells were recognized through
the available markers accordingly to their recognized immunophenotype [30].
Statistical analysis
Continuous non normal data are expressed as median values (range); normal variables are indicated
as mean±SD. Baseline differences between groups were assessed by the chi-square test or Fisher’s
exact test, as needed for categorical variables (with Bonferroni correction for multiple
comparisons). The univariate analysis of variance (ANOVA) was performed for parametric
variables, and post hoc analysis with the Tukey’s test was used to determine pairwise differences.
The Mann–Whitney U-test was used for intragroup analysis. The Kruskal-Wallis statistic test with
pairwise comparisons was performed for nonparametric analysis. Data were analyzed by IBM
SPSS Software 22 version (IBM Corp., Armonk, NY, USA). All p-values were two-sided and
p<0.05 was considered statistically significant.
Results
Characteristics of patients and plasma cell analysis
A total of 63 subjects (39 male and 24 female, no intergroup significant differences) were included
in this study. Patients in Progressive group were significantly older (75.13±10.06 years) than
Complete (61.1±8.85 years, p=0.029) and Therapy (61.21±9.01 years, p=0.017) subjects, while no
significant differences emerged with Control (62±5.36 years), MGUS (70.8±7.3 years) and New
(63.58±12.8). Autologous stem cell transplantation was performed in 6 Complete, 6 Therapy and 2
Progressive patients at least 12 months before the time of this study (not significant). No
statistically significant differences as regards therapeutic regimen was detected.
Bortezomib+Dexamethasone based treatment was administered to 5 Therapy and 3 Progressive
patients. Thalidomide as monotherapy or in combination with bortezomib was given to 1 Complete
and 3 Therapy patients respectively. Lenalidomide or lenalidomide containing regimens were the
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treatment of choice in 4 Complete and 1 Progressive subjects, while Pomalidomide was
administered to 1 Progressive patient. Finally, a total of 13 patients (5 Complete, 6 Therapy and 2
Progressive) underwent suspension of therapy before for at least 15 days before this study was
perfomed. No differences emerged for ISS staging at diagnosis (ISS I, 3 Complete, 3 Therapy and
3 New; ISS II 7 Complete, 4 Therapy, 5 New and 5 Progressive; ISS III 7 Therapy, 4 New and 3
Progressive). Instead as regards Durie-Salmon staging at diagnosis, the cases were distributed as
follows: IA, 2 Complete, 4 New and 4 Progressive; IIA, 1 Complete, 5 Therapy, 5 New and 2
Progressive; IIB, 3 Therapy, 2 New and 2 Progressive; IIIA, 6 Complete and 2 Therapy (Complete
vs New, p=0.018); IIIB, 1 Complete, 4 Therapy and 1 New.
According to literature, nPCs were always CD117-. In turn, cPCs were CD117+ in 50% (5) of
MGUS, 42.86% (6) of Therapy, 59.17 (7) of New and 62.5% (5) of Progressive patients (not
significant). Considering each group separately, characteristics of patients were homogeneous
comparing CD117- and CD117+ cases, except in group New, in which none of CD117+ patients
presented characteristics of ISS III stage (vs 4/5 of CD117- patients, p=0.01), and in group
Progressive, in which CD117+ patients were significantly older than CD117- ones (81.20±4.09 vs
65±8.66 years respectively, p=0.01).
Significant differences were detected comparing median percentage of total PCs in New [8.64%
(0.26%-60.50%)] and Progressive [6.47% (0.75%-30.29%)] with Control [0.15% (0.01%-1.71%),
vs New p<0.0005, vs Progressive p=0.001], Complete [0.38% (0.03%-2.49%), vs New p=0.006, vs
Progressive p=0.013] and Therapy [0.48% (0.12%-14.40%), vs New p=0.012 and vs Progressive
p=0.029], while no difference was observed with MGUS [1.39% (0.36%-2.40%)]. All PCs in
Control and Complete were polyclonal, whereas nPCs were 19.12% (5.24%-82.52%) in MGUS,
29.24% (0.14%-96.12%) in Therapy, 1.18% (0.05%-66.12%) in New (vs Therapy p=0.016), and
1.60% (0.25%-12.88%) in Progressive. As regards cPCs, New showed the most elevated median
percentage [98.83% (33.88%-99.95%)] compared with Therapy [70.76% (3.88%-99.86%),
p=0.016], but no difference emerged in comparisons with MGUS [80.88% (17.48%-94.76%)] and
Progressive [98.40% (87.12%-99.75%)]. As regards proportion of CD117+ cPCs, we observed a
trend depicting the highest percentage of CD117+ plasma cells in MGUS and the lowest in
Progressive (Figure 1).
Intragroup comparisons between CD117+ and CD117- cases as regards percentages of total plasma
cells, nPCs and cPCs are indicated in Table 3.
Relationship between CD117 positive and negative cPCs and CD34+ bone marrow HPCs.
No statistical significant differences emerged comparing percentage of total CD34+ HPCs,
CD34+CD19+ cells (out of total CD34+ HPCs) and CD34+CD19- cells (out of total CD34+ cells),
as well as CD34+CD19-/CD34+CD19+ ratio, despite the fact that Therapy exhibited the highest
CD34+CD19+ fraction and the lowest CD34+CD19- fraction and CD34+CD19-/CD34+CD19+
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ratio (Table 4). Performing intragroup comparisons between CD117+ vs CD117- cases, we noticed
that Therapy CD117- patients showed a higher percentage of total CD34+ cells compared to
Therapy CD117+ patients. In New, CD117+ subjects exhibited a higher percentage of total CD34+
and CD34+CD19+ cells vs CD117- patients; in turn, CD117- cases showed a more extended
proportion of CD34+CD19- cells and a higher CD34+CD19-/CD34+CD19+ ratio. The frame
seemed to be reversed in Progressive group: CD117+ patients exhibited higher percentages of
CD34+CD19- cells, and CD117- presented a higher CD34+CD19+ fraction and a lower
CD34+CD19-/CD34+CD19+ ratio (Table 5). Exploring relationship between percentage of
CD117+ cPCs and CD34+CD19-/CD34+CD19+ ratio, Sperman’s correlation coefficients were -
0.718 (p=0.009) for New, and 0.952 (p<0.005) for Progressive. To further deepen how CD117
positivity or negativity may influence distribution of HPCs, we compared Control and Complete
data with results obtained from CD117- and CD117+ (Figure 2A-D) cases. CD117- New cases
showed the lowest percentage of total CD34+ BM cells compared to Complete and CD117-
Therapy patients. In turn, percentage of CD34+CD19- cells and CD34+CD19-/CD34+CD19+ ratio
were higher in CD117- New vs CD117- Therapy subjects, while inverted situation was recorded
for CD34+CD19+ cells. When we compared Control, Complete and CD117+ cases, no statistical
significant differences were observed.
Discussion
The interaction of cPCs with BM microenvironment is fundamental to ensure development and
progression of MM. Destruction of BM homeostasis, by a complex system of direct, autocrine and
paracrine interactions between components of the BM microenvironment and cPCs, influences
proliferation and triggering of anti-apoptotic mechanisms [3, 10]. Normal hematopoiesis is
impaired in MM subjects, with anemia being one of MM characteristic clinical features [8].
Precedent studies demonstrated alterations in BM distribution of HPCs in MM subjects. Compared
to healthy donors, a substantial reduction of CD34+ HPC subsets and CD19+CD38+CD34+ Pro-B
cells in terms of absolute cell count and proportion of mononuclear cells respectively was described
in untreated MM subjects [15]. Similarly, percentage of total CD34+ cells and CD19+CD34+ cells
(both defined as proportion of total leukocytes excluding PCs) was proven to be decreased at
presentation, and CD19+CD34+ cells also in patients at relapse, but not in patients at
plateau/remission, vs normal individuals [14]. Coherently, a more recent report confirmed
reduction of percentage of CD34+ HPCs (from whole BM cellularity) and CD34+CD38+CD19+
progenitors (out of total CD34+ HPCs) in BM of MM patients vs healthy controls [16]. In all listed
studies, no categorization of patients on the basis cPC immunophenotype was performed. In newly
diagnosed patients, divided accordingly to CD117 positivity and negativity, percentage
CD34+CD38+CD19+ progenitor cells was reported to be higher in CD117+ vs CD117- cases,
leading to a significant decreased CD34+CD19-CD38+/CD34+CD19+CD38+ ratio [19]. On the
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basis of precedent reports, we were interested in exploring the relationship between
presence/absence of CD117 on cPCs surface and distribution of HPCs into CD34+CD19- and Pro-
B subsets in MGUS, newly diagnosed, stringent complete responders, treated (but not complete
responder) patients, and subjects with progressive disease. We did not observed significant
differences among frequency of CD117 positivity comparing all categories of patients,
contradicting previous reports [18]. However this discrepancy could be related to variations in
sample size. In New, only CD117- were classified as stage ISS III, while none of CD117+ cases
showed association with the most advanced ISS stage. These data, together with the trend exhibited
by CD117+ cPCs (the highest percentages recorded in MGUS, decreasing through Therapy and
New, to the most reduced fraction observed in Progressive) strongly recalls the association of
CD117 negativity with features of a more aggressive disease in MM [17], and supports the
hypothesis that CD117+ clones might be deleted during progression [18]. In intragroup
comparisons of percentages of total, normal and clonal PCs, we observed that in New CD117+
patients nPCs were significantly higher and cPCs were significantly lower vs New CD117-
subjects, accordingly to precedent reports [19]. No significant differences were observed in other
groups, but the exact mechanism ruling expansion of cPCs vs nPCs remains to be elucidated. As
regards distribution of CD34+ HPCs, we did not recorded general variations in percentage of
CD34+ HPCs, and CD34+CD19- and Pro-B cell subsets comparing all groups among them. This is
openly conflicting with precedent papers [14-16], but may be easily explained considering three
important factors: 1) the studies were conducted following different methods of measuring and
expressing fractions of CD34+ HPCs; 2) the statistical analysis was performed through different
tests; 3) patients were not divided in groups according to the immunophenotype of cPCs, so we
cannot evaluate carefully the impact of CD117 positivity on previously reported data. In fact,
carrying on our analysis, we noticed that CD117 has a strong influence on CD34+ HPC distribution
both in New and Progressive groups, but with different outcomes. In New our findings are
consistent with those described by Schmidt-Hieber et al. [19], with a significant inverse correlation
between CD117 positivity and CD34+CD19-/CD34+CD19+ ratio. Instead, the opposite situation
was recorded in Progressive, with a significant direct correlation between CD117 and
CD34+CD19-/CD34+CD19+ ratio reflected by detected measured fractions of CD34+CD19- and
Pro-B cells. However, given the small sample size, confirmation by a larger cohort of patients is
recommendable. The most surprising results emerged from analysis of Control and Complete data
with measured values for CD117- cases. Total CD34+ HPCs were less expanded in CD117- New
vs both Complete and CD117- Therapy subjects, thus reflecting a possible reorganization of BM
niches in patients able to respond to treatment. Moreover, significant differences were observed
between CD117- New and Therapy patients, with New displaying a more extended CD34+CD19-
fraction and a reduced Pro-B population compared to Therapy. This was concretized in a higher
CD34+CD19-/CD34+CD19+ ratio in CD117- New cases vs CD117- Therapy patients. In turn,
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when we compared Control, Complete and CD117+ subjects, no significant differences emerged.
These pieces of information are extremely intriguing, since they clearly demonstrate that response
to treatment take place through different forms in CD117- and CD117+ patients. Specifically, it
implies a distinct regulation in distribution of CD34+ HPC subsets which clearly rises comparing
untreated and treated CD117- patients, but it is impossible to detect in CD117+ cases. Given that
alterations in distribution of CD34+ HPC subsets exclusively regards patients unable to reach
complete response, it will be interesting to evaluate the influence of other immunophenotypes (not
described in this studies) on the ability of CD117- patients to achieve a deeper response. Moreover,
a possible future step might be study of an eventual correlation between plasma cell
immunophenotypic characteristics and mobilization/graft contents. In conclusion, we confirmed
previous trends in CD34+ HPC subset distribution in newly diagnosed patients divided accordingly
to CD117 positivity. Moreover, we provided some insights in CD34+ HPC distribution in relapsing
patients. We also describe different impact of treatment on CD34+ HPCs in CD117- patients vs
CD117+ subjects, thus opening the debate about effect of CD117 on mechanism determining
prognosis.
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Tables
Table 1. Characteristics of the instrument.
Model (manufacturer) Lasers Detector Filters
Navios (Beckman Coulter) Blue Solid State Diode: 488nm,
22mW laser output
Forward Scatter: 488/10
10 colors, 3 lasers (5+3+2
configuration)
Blue Laser: 525/40, 575/30, 620/30,
675/20, 695/30, 755LP
Red Solid State Diode: 638nm,
25mW laser output Red Laser: 660/20, 725/20, 755 LP
Violet Solid State Diode:
405nm, 40mW laser output Violet Laser: 450/50, 550/40
Beckman Coulter (Miami, FL, USA)
Table 2. Antibodies used in this study
Antigen Manufacturer Catalogue # Clone Fluorochrome Isotype
CD19 Beckman Coulter A86355 J3-119 PB IgG1 Mouse
CD27 Beckman Coulter B12701 1A4CD27 APCA750 IgG1 Mouse
CD27 BD Biosciences 340424 L128 FITC IgG1 Mouse
CD34 Beckman Coulter A89309 581 APCA750 IgG1 Mouse
CD38 Beckman Coulter A70205 LS198-4-3 PC5.5 IgG1 Mouse
CD45 Beckman Coulter A96416 J.33 KO IgG1 Mouse
CD56 Beckman Coulter IM2073U N901 (NKH-1) PE IgG1 Mouse
CD56 Beckman Coulter A51078 N901 (NKH-1) PC7 IgG1 Mouse
CD117 Beckman Coulter IM3698 104D2D1 PC7 IgG1 Mouse
CD138 Beckman Coulter A87787 B-A38 APC IgG1 Mouse
κ CHAIN Beckman Coulter A64828 Polyclonal FITC F(ab’)2 Rabbit
λ CHAIN Beckman Coulter A64827 Polyclonal PE F(ab’)2 Rabbit 
Catalogue #, catalogue number; PB, Pacific Blue; APCA750, Allophycocyanin-Alexa Fluor 750; FITC, Fluorescein Isothiocyanate; PC5.5, R-Phycoerythrin-Cyanin 5.5; KO, Krome
Orange; PE, R-Phycoerythrin; PC7, R-Phycoerythrin-Cyanin 7; APC, Allophycocyanin. Beckman Coulter (Miami, FL, USA), BD Biosciences (San Jose, CA, USA)
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Table 3. Intragroup comparisons between CD117+ and CD117- cases for
plasma cells
Group CD117+ CD117- p value
MGUS Tot PCs 1.30 1.48 NS
(0.71-2.40) (0.36-2.08)
nPCs 19.17 10.74 NS
(6.17-82.52) (5.24-51.64)
cPCs 80.83 89.26 NS
(17.48-93.83) (48.36-94.76)
Therapy Tot PCs 0.62 0.41 NS
(0.14-14.40) (0.12-1.15)
nPCs 25.19 71.79 NS
(0.14-70.80) (1.23-96.12)
cPCs 74.82 28.21 NS
(29.20-99.86) (3.88-98.77)
New Tot PCs 6.48 13.03 NS
(0.26-20.19) (0.44-60.50)
nPCs 1.68 0.32 0.01
(0.75-66.12) (0.05-1.32)
cPCs 98.32 99.68 0.01
(33.88-99.25) (98.68-99.95)
Progressive Tot PCs 2.14 9.03 NS
(0.75-30.29) (8.11-23.98)
nPCs 6.38 0.32 NS
(0.59-12.88) (0.25-1.67)
cPCs 93.62 99.68
NS
(87.12-99.41) (98.33-99.75)
Results are expressed as median percentage (range). Tot PCs, total plasma cells; nPCs,
normal/reactive polyclonal plasma cells (out of total plasma cells); cPCs, clonal/aberrant
plasma cells (out of total plasma cells); NS, not significant
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Table 4. Percentages of total CD34+ cells and CD34+ fractions
Tot CD34+ CD34+CD19- CD34+CD19+ Ratio
Control 1.17 85.74 14.26 6.01
(0.72-2.17) (72.94-90.62) (9.38-27.06) (2.70-9.66)
MGUS 1.34 88.51 11.49 7.82
(0.30-2.46) (82.58-97.99) (2.01-17.42) (4.74-48.75)
Complete 1.98 88.10 11.91 18.75
(0.45-8.26) (24.18-98.75) (1.25-75.97) (0.32-79)
Therapy 1.28 73.12 26.88 2.73
(0.14-2.84) (33.91-98.71) (1.29-66.09) (0.51-76.52)
New 1.26 87.11 12.90 6.77
(0.06-2.61) (74.98-98.89) (1.11-25.02) (3-89.09)
Progressive 0.70 84.24 15.76 5.66
(0.22-0.87) (75.73-94.83) (5.17-24.27) (3.12-18.34)
Results are presented as median values (range). Tot CD34+, total CD34+ hematopoietic
progenitor cells; CD34+CD19-, fraction of CD34+CD19- cells (out of total CD34+ cells);
CD34+CD19+, fraction of CD34+CD19+ cells (out of total CD34+ cells); Ratio,
CD34+CD19-/CD34+CD19+ cellular fraction ratio.
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Table 5. Intragroup comparisons between CD117+ and CD117-
cases for total CD34+ cells and CD34+ fractions
Group CD117+ CD117-
p
value
MGUS Tot CD34+ 1.47 1.19 NS
(0.50-2.46) (0.30-1.63)
CD34+CD19- 95.49 86.72 NS
(82.58-97.99) (85.73-96.34)
CD34+CD19+ 4.51 13.28 NS
(2.01-17.42) (3.66-14.27)
Ratio 21.17 6.53 NS
(4.74-48.75) (6.01-26.32)
Therapy Tot CD34+ 0.73 1.83 0.013
(0.14-2) (0.85-2.84)
CD34+CD19- 78.71 70.97 NS
(33.91-98.71) (62.86-91.42)
CD34+CD19+ 21.29 29.04 NS
(1.29-66.09) (8.58-37.14)
Ratio 4.27 2.50 NS
(0.51-76.52) (1.69-10.66)
New Tot CD34+ 1.80 0.56 0.018
(0.49-2.61) (0.06-1.22)
CD34+CD19- 82.42 94.59 0.003
(74.98-87.70) (90-98.89)
CD34+CD19+ 17.58 5.41 0.003
(12.30-25.02) (1.11-10)
Ratio 4.69 17.48 0.003
(3-7.13) (9-89.09)
Progressive Tot CD34+ 0.80 0.60 NS
(0.22-0.87) (0.23-0.62)
CD34+CD19- 88.75 77.88 0.036
(80.79-94.83) (75.73-80.77)
CD34+CD19+ 11.25 22.12 0.036
(5.17-19.21) (19.23-24.27)
Ratio 7.89 3.52
0.036
(4.21-18.34) (3.12-4.20)
Results are expressed as median percentage (range). Tot CD34+, total CD34+
hematopoietic progenitor cells; CD34+CD19-, fraction of CD34+CD19- cells (out of
total CD34+ cells); CD34+CD19+, fraction of CD34+CD19+ cells (out of total
CD34+ cells); Ratio, CD34+CD19-/CD34+CD19+ cellular fraction ratio.
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Figures
Figure 1. Percentage of CD117+ cPCs. Observed median values (range) were: MGUS 50.15% (3.41%-
93.63%); Therapy 18.36% (9.82%-51.69%); New 9.68% (2.44%-38.45%); Progressive 2.67% (1.85%-
56.78%). Box plots indicate the median and 25th and 75th percentiles. Whiskers indicate minimum and
maximum values. •,* = outliers. p values of pairwise comparisons are indicated.
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Figure 2. Percentages of CD34+ cells and fractions, and CD34+CD19-/CD34+CD19- ratios for all groups.
Box plots indicate the median and 25th and 75th percentiles. Whiskers indicate minimum and maximum
values. •,* = outliers. p values of pairwise comparisons are indicated.
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7. Integrated discussion and conclusions.
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This is a “getting old” world. The analysis performed by the United Nations [146] has shown that
there were 205 million elderly (≥60 years old) persons worldwide in 1950; the proportion has 
increased to 606 million in 2000. This trend is expected to go on, with the elderly people reaching
nearly 2 billion in 2050 [146]. Having their onset usually in advances phases of life, and being
monitorable and/or treatable but not curable, MGUS and multiple myeloma represent a challenge
both from a clinical and economical point of view [147]. Despite enormous progresses in treatment
and MRD detection techniques, disease progression and response cannot be predicted at the time of
diagnosis. Beyond the patient stress associated with continue monitoring in both asymptomatic and
symptomatic conditions, there is no consensus about therapeutic strategies and establishment of
prognosis [148]. Ideally, a laboratory methodology suitable for diagnosis/MRD
assessment/prognostic purposes should be widely applicable, offer a good degree of sensitivity,
guarantee contained costs, take into account clonal evolution of the diseases, and provide
information requiring reasonably short times for manipulation of samples and data elaboration [15,
148]. Among all possible approaches, currently only MFC has the potential of contributing all these
advantages at the same time [15, 56, 148]. However, a great reticence in deep application of MFC
to various aspects of myeloma and MGUS clinical course may still be met. This depends
essentially on absence of specific clonal plasma cell markers, insufficient research on new
identification/characterization markers, and most of all discordant results from different reports
usually attributable to poor quality design of the studies. As I explained in the introduction, it has
already been observed that depth of response may influence outcome, and immunophenotypic
variations consequent to drug administration may be observed [28, 49-50, 95-96]. Despite these
important premises, a commonly described experimental approach remains based on the study of
immunophenotype of clonal plasma cells (and only sometimes polyclonal plasma cells) dividing
patients in newly diagnosed subjects and treated/relapsed patients, without considering
systematically the effect of treatment, clinical parameters and above all the type of response in
rigorous multivariate analysis to detect how all these variables may be related to
immunophenotypic characteristics of plasma cells. In addition, an increasing amount of data
regarding heterogeneity of normal plasma cell immunophenotype [85, 88-91] produces a
discouraging effect on clinicians who have no extended experience in clonal plasma cell
identification. Moreover, considering the probability of immunophenotypic changes in normal
plasma cells among various categories of patients, and the possibility of using these data to obtain
predictive or prognostic information, still represents a completely innovative strategy, although
both myeloma and MGUS present a strong component of interaction between neoplastic
compartment and surrounding cells [3], including residual polyclonal plasma cells. In the end, the
importance of bone marrow microenvironment related characteristics is underrated, and research of
a correlation between modifications in other bone marrow populations and type of response and/or
immunophenotype is not a common strategy [121-123, 136]. Such a type of investigation would be
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particularly useful in order to define patient ability of achieving a good degree of response to
therapy, or to start an accurate analysis of immunophenotype related mechanisms which may
influence bone marrow cellular composition in last analysis influencing therapy and post ASCT
outcome. During my PhD research activity, I kept in mind all these critical points, and I elaborated
an accurate, logic and reproducible approach to engage the problem. An essential part of my
procedure was the division of patients in clinically defined groups: Control (control subjects),
MGUS, Complete (stringent complete responders), Therapy (VGPR, PR and SD patients), New
(newly diagnosed subjects), and Progressive (patients presenting progression of disease). As it may
be seen in chapter 3, I started my investigation exploring the utility of classical (CD19, CD45,
CD117, CD27, CD56, CD20 and CD200) and less analyzed markers (CD30, CD11a, CD49d and
CD58) in definition of the “normal” immunophenotype. I clearly demonstrated that normal/reactive
plasma cells are not equal among patients, showing a great variability in terms of percentage of
positive cells and levels of expression of many antigens. These differences should be carefully
considered in elaborating MRD assessment specific panels. In addition, immunophenotypic
changes in normal plasma cells showed a degree of association with type of response/relapsing
disease, even in the multivariate analysis, thus opening the debate about the introduction of normal
plasma cell study in clinical routine both for multiple myeloma and MGUS patients. As regards
ranges of expression on normal plasma cells, it can be easily noted that for CD19, CD45 and CD27
percentages of positive polyclonal cells reflect the ranges found in precedent studies (Table 3 of the
Introduction) [141]. For CD56, detected percentages essentially did not depart from those described
elsewhere, except for an outlier identified in Therapy [141]. However expression close or
corresponding to 100% for this antigen has occasionally been reported [87, 91], recalling the
hypothesis that CD56+ plasma cells may be artificially low in MFC analysis, acting as an anchor
and making plasma cells more resistant to bone marrow aspiration [90]. CD20 was never expressed
on plasma cells in Control group, but the range of expression was broad on polyclonal plasma cells
in all other groups [141], thus opening the way to a discussion about the role of bone marrow
microenvironment (and eventually inflammatory cytokines) on CD20 expression. CD200 was
expressed variably on normal plasma cells [141], and my data match with both papers reporting its
absence [59, 87] and those indicating positivity [77, 93]. CD58, CD49d and CD11a were never
completely absent on polyclonal plasma cells, but a common pattern of expression did not emerged
comparing all groups of patients [141]. In turn, frequency of CD30+ cells was modest in both
clonal and normal plasmacellular compartments in all groups [141], accordingly to a previous
report on myeloma cells [138], so I suggest that CD30 should not be considered for further
investigation. Comparing results obtained for normal plasma cells in all groups, significant
differences emerged for CD56, CD45, CD27, CD20, CD200, CD11a and CD58 [141]. These data
put the accent on the lack of appropriateness of experimental approach considering polyclonal
plasma cells as homogeneous in treated and untreated subjects. In addition, described differences
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underlie the opportunity of using normal plasma cell analysis in order to determine how changes in
bone marrow microenvironment influence surface antigen expression. This approach is particularly
important in the look of factors which may be associated with risk of progression or the ability to
reach a response to therapy. Deviation from normality in immunophenotype of clonal plasma cells
emerged in comparison with plasma cells from non-myeloma and non-MGUS groups, especially
for some antigens like CD19 (for MGUS and Progressive), CD56 (for Therapy, New and
Progressive), CD117 (for all groups), CD20 (for MGUS and Therapy), CD200 (for Therapy, New
and Progressive), CD11a (for New and Progressive) and CD49d (for Progressive) [141]. These
alterations always emerged clonal plasma cells vs Control plasma cells, but only in the case of
CD19, CD56, CD49d and CD117 the differences with pathological groups interested also
Complete group. Therefore, in respect to plasma cells of healthy subjects, plasma cells of stringent
complete responders -although polyclonal- present fewer significant immunophenotypic
differences from the immunophenotype of clonal plasma cells. Also in distinguishing clonal
plasma cells from their normal counterpart, markers showed not to be equivalent; some surface
antigens might be successfully employed in all -or almost all- groups (CD45, CD56, CD19,
CD117, CD49d), while others reveled their utility in less than three groups (CD27, CD58, CD20
and CD200) [141]. Putting all evidences together, I suggest the use of stage specific MFC panels,
with the addition of appropriate MFC markers to the backbone ones (CD38, CD138, CD19, CD45,
CD56) [77]; the evaluation of the disease should involve polyclonal plasma cells, in order to follow
progressions and explore the opportunity to obtain predictive information. CD49d should be
universally present in order to distinguish clonal plasma cells from normal cells; for MGUS
diagnosis and monitoring, CD20 and CD200 are suggested to be added; newly diagnosed patients
should benefit the addition of CD11a; assessment of disease progression or response to therapy
may be made more accurate by the introduction of CD27, CD58, CD11a and CD20 [141]. It is well
accepted that in assessing the predictive/prognostic values of MFC markers and their utility in
following disease steps, immunological-biochemical-hematological profile must not be ignored,
given that it represents the “mirror” of the altered bone marrow microenvironment
influencing/being influenced by plasmacellular phenotype [3, 15, 34, 60, 103]. In accordance with
this assumption, I elaborated two different statistical models (multinomial logistic regression
analysis, and subsequent multivariate regression approach). The objectives were to see whether a
correlation exists between the expression of each marker and the attribution of the patients to their
own groups, and to determine the effect of other clinical variables on such an eventual correlation.
A considerable quantity of significant associations interested polyclonal plasma cells: percentage of
cells positive for CD200 and CD56, and levels of expression of CD45, CD19, CD58, CD11a and
CD200. In addition, fractions of aberrant plasma cells positive for CD19 and CD200, and intensity
of expression of CD19, CD49d, CD117 and CD200 on clonal plasma cells exhibited significance
[141]. When the model was elaborated again including significant prognostic variables, I noticed
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that percentage of CD200+ normal plasma cells and levels of expression of CD117 on clonal
plasma cells and CD19 on normal plasma cells loosed their association, as happened for levels of
expression of CD11a in comparing Control vs Complete and MGUS normal plasma cells, MFI
ratio for CD200 analyzing Control vs Complete, and percentage of CD200+ clonal plasma cells
comparing MGUS vs Progressive [141]. In turn CD19 and CD49d on clonal plasma cells, and
CD45, CD58 and CD56 on normal plasma cells maintained their explicative power, so they are
good candidates for deeper studies, i.e. analysis of a prospective cohort to examine time and
progression dependent fluctuations in levels of MFC markers, in order to define a threshold of
expression for each antigen that allows attributing clearly each subject to the relative group [141].
Extending the study with a focus on MGUS and SMM patients and their risk of progression [20]
may also be an interesting advancement. The purpose should be the detection of a correlation
between the immunophenotypic characteristics of normal and clonal MGUS and SMM plasma cells
and the currently used models to estimate the risk of progression in these patients [20, 149].
Assumed this, the look for new markers on both normal and clonal plasma cells is also undelayable
in order to ensure the widest applicability of MFC analysis, including samples in which plasma cell
detection may be hampered by therapeutic interventions or time and apoptosis dependent loss of
antigens [97-98, 101-102]. Their reported medullary patterns of expression, with the actual data
about their presence on myeloma plasma cells, constitute the reasons which induced me to select
CD229, CD319 and CD54, as possible candidates for suitable alternatives to classical plasma cell
selection markers CD38 and CD138. In my experiments, CD229 was persistently positive on both
bone marrow and peripheral blood plasma cells. Full positivity is preserved in bone marrow
samples stained with APC conjugated antibodies, whereas in 1.1% of samples analyzed through
PerCP-Cy5.5 conjugate in combination with fixation/permeabilization technique causes an
impairment in staining. In turn, CD319 and CD54 were uniformly positive only on bone marrow
plasma cells. When used together with CD38 in the initial gate, the three markers allow an efficient
identification of plasma cells, and thus may be considered as potent alternatives to CD38 vs
CD138, especially in cases particularly prone to loss or downregulation of CD138 [97-98], or in
case anti-CD138 therapy [100]. In turn, when CD229, CD319 and CD54 were used in combination
with CD138 or SSC, the scenario changed drastically. With CD54/CD319 vs SSC or CD138 gate,
the major problem is detection of all clonal plasma cells, since their levels of expression are
partially overlapping with other non-plasmacellular populations. On the contrary, although initial
plasma cell identification gate was contaminated with lymphocytes and plasmacytoid dendritic
cells, exclusion of non-plasmacellular events was more efficient using CD229 vs SSC and CD138
as initial gate when compared with CD54/CD319 vs SSC and CD54/CD319 vs CD138. Given
these results, I propose that CD229 should be considered in further studies on patients undergoing
to anti-CD38 therapies in order to assess its possible use in clinical settings. In order to deeply
dissect CD229 expression in bone marrow, I included some additional antibody panels in my
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experimental routine. I noticed that CD229 was absent on monocytes, eosinophils and neutrophils,
whereas T, NK and B lymphocytes were positive in both peripheral blood and bone marrow
specimens, in line with previous reports [144].
The study of immunophenotypes or distribution of other cell types in multiple myeloma and
MGUS samples, with the simultaneous assessment of surface/intracellular marker expression on
plasma cells, is an undiscussed advantage of MFC. Besides the look for other markers in plasma
cell detection, the immunophenotypic characterization of other cellular populations in bone marrow
samples is fundamental in order to define the actors involved in immune disfunction and
unsuccessful eradication of the neoplastic clone. In myeloma patients, many factors concur to
determine the general immunosuppression: influence of neoplastic cells on bone marrow
microenvironment and immune cells, effect of therapy and normal age-related decline of immune
functions [119-120, 150]. Considered that B cells share the same ontological bone marrow path of
plasma cells and a number of markers -CD229 for example-, it would sound logic to explore
deficiencies affecting this compartment. In spite of this, the great majority of efforts focused on the
dysfunctions in T cell compartment, DCs and myeloid derived suppressor cells (MDSCs). So I
decided to start an investigation concentrating my analysis on different distribution of
naïve/transitional and memory B cells in myeloma patients, looking for a possible relationship with
the depth of response. Once again, I recurred to the division of patients in distinct clinical groups,
as I exposed some lines above in this discussion. In healthy subjects I found a higher percentage of
IgD+CD27+ memory cells compared to Therapy and Complete groups. IgD+IgM−CD27+ memory 
cells appear to play an important role in respiratory mucosal defense via, whereas
CD27+IgM+IgD+ memory cells are involved in the response to encapsulated bacteria [151]. My
data open the route to speculations about therapy related mechanisms responsible for increased
susceptibility to infections, which could be specific of responding patients. Naïve/Transitional
cells were expanded in Complete compared to Therapy patients, showing a possible reorganization
of B cell compartment in patients who do not show signs of neoplastic clone, or a superior ability
of stringent complete responders to modulate inflammation and its resolution, given the
documented cytokine and interleukin profiles documented in the elderly naïve/transitional B cells
[130]. As regards DN B cells, an increase of this subset in Therapy patients compared to Complete
was recorded. This is not surprising, since DN B cells are described as exhausted B lymphocyte
population filling the immunological space especially in elderly subjects [127-130]. Differences in
percentage of DN B cells may reflect the ability of various categories of patients to reach deep
responses. Considering these results, monitoring fluctuations in percentage of Naïve/Transitional
and DN B cells may reveal a useful tool in predicting the type of response, although larger cohort
studies are necessary to identify a cut-off value in order to distinguish stringent complete from
other responding patients. In addition, the study of immunophenotypic profiles of these
lymphocytes as regards chemokine receptor would put some light in definition of their role (or
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defects) in myeloma. Another interesting finding is that none of the studied patients showed signs
of expansion of a clonal B population. This result must be confirmed by deeper molecular studies,
however it represents an interesting start point to explore the presence of a relation between B cells
and neoplastic clone. My approach was extremely innovative, since studies about alterations of B
compartment in bone marrow of myeloma patients classically target variations in B cell
progenitors/precursors [121-123] . Although MFC makes possible the simultaneous study of clonal
plasma cells and hematopoietic progenitor bone marrow compartment, rarely these data are used to
make a connection between immunophenotypic plasma cell characteristics and modifications in
bone marrow populations. An exception to this strategy is the report from Schmidt-Hieber et al.,
demonstrating that differences in CD34+CD19-CD38+/CD34+CD19+CD38+ ratio in newly
diagnosed patients accordingly to CD117 plasmacellular positivity and negativity [136]. On the
basis of these preliminary data, I chose to explore the relationship between presence/absence of
CD117 on clonal plasma cell surface and distribution of HPCs into CD34+CD19- and Pro-B
subsets in MGUS and treated/untreated myeloma subjects. CD117+ clonal plasma cells exhibited a
trend, with the highest percentages recorded in MGUS, decreasing through Therapy and New, to
the most reduced fraction observed in Progressive. In addition, in New, only CD117- were
classified as stage ISS III. These results strongly recalls the association of CD117 negativity with
features of a more aggressive disease in multiple myeloma [60], and supports the hypothesis that
CD117+ clones might be deleted during progression [103]. In New CD117+ patients normal
plasma cells were significantly higher and clonal plasma cells were significantly lower vs New
CD117- subjects, accordingly to precedent reports [136]. As regards distribution of CD34+ HPCs, I
did not record general variations in percentage of CD34+ HPC, and CD34+CD19- and Pro-B cell
subsets comparing all groups among them, conflicting with precedent papers [121-123]. Of note, in
the cited works, patients were not divided in groups according to the immunophenotype of clonal
plasma cells, so evaluate the exact weight of previously reported data is not possible. Carrying on
the analysis, I noticed that CD117 has a strong influence on CD34+ HPC distribution both in New
and Progressive groups, but with different outcomes. In New my findings are completely coherent
with those described by Schmidt-Hieber et al. [136], with a significant inverse correlation between
CD117 positivity and CD34+CD19-/CD34+CD19+ ratio. The opposite situation was recorded in
Progressive, with a significant direct correlation between CD117 and CD34+CD19-
/CD34+CD19+ ratio. The most surprising results emerged from analysis of Control and Complete
data with measured values for CD117- cases. Total CD34+ HPCs were less expanded in CD117-
New vs both Complete and CD117- Therapy subjects, reflecting a possible reorganization of BM
niches in patients able to respond to treatment. Significant differences in CD34+CD19- and
CD34+CD19+ distributions in CD117- New and Therapy patients produced a more elevated
CD34+CD19-/CD34+CD19+ in CD117- New subjects vs CD117- Therapy cases. When the
analysis involved Control, Complete and CD117+ cases, no differences were detected. My report
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clearly demonstrates that response to treatment take place through different forms in CD117- and
CD117+ patients. Specifically, it implies a different regulation of CD34+ HPC subsets which
clearly rises comparing untreated and treated CD117- patients, but it is impossible to detect in
CD117+ cases. Given that alterations in distribution of CD34+ HPC subsets exclusively regards
patients unable to reach complete response, I reasonably suppose that other clonal plasma cell
immunophenotypes (not described in this study) may exert an influence on the ability of CD117-
patients to achieve a deeper response. One future step will surely be a profound exam of other
CD34+ HPC subsets, and the research of eventual connection of CD34+ HPC distribution with
immunophenotypic profiles (other than CD117 positivity) on both clonal and normal plasma cells.
Moreover, it will be intriguing to verify how differences in bone marrow HPC subsets influences
graft content. In conclusion, I put together many pieces of the same puzzle, describing a serious
impact of well designed MFC studies on the understanding of biology of MGUS and multiple
myeloma. Clearly the sample sizes are small, and prospective evaluations are recommendable for
every aspect dissected in my experimental activity, but the importance of the listed findings is
evident. The added value of this investigation is the continue effort in the direction of
individualized/personalized medicine, with the adoption of a method which took constantly into
account clinical variables and depth of response. The extremely ordered approach and careful data
analysis provided new fundamental insights in some myeloma hot points, i.e. definition of normal
plasmacellular immunophenotype, identification of new markers useful in diagnosis/MRD
assessment, elaboration of responding/relapsing patients specific MFC panels, exploration of
response/progression related distribution of the least investigated immune cells, i.e. B lymphocytes,
and description of possible mechanism of immunophenotype dependent response to therapy. I
confidentially believe that these data may represent the basis for innovative and productive
directions of research in future, and may give a strong impulse to development of MFC
translational applications to MGUS and multiple myeloma diagnosis and management.
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